Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2186899,maximum concentration (Cmax),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[ng] / [ml],285,748,DB00608,Chloroquine
,2186899,maximum concentration (Cmax),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[ng] / [ml],151,749,DB00608,Chloroquine
,2186899,minimum concentration (Cmin),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[ng] / [ml],125,750,DB00608,Chloroquine
,2186899,minimum concentration (Cmin),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[ng] / [ml],31,751,DB00608,Chloroquine
,2186899,elimination half-life (t1/2),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),h,23.3,752,DB00608,Chloroquine
,2186899,elimination half-life (t1/2),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),h,18.3,753,DB00608,Chloroquine
,2186899,plasma clearance (Cl),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[l] / [h·kg],0.032,754,DB00608,Chloroquine
,2186899,plasma clearance (Cl),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[l] / [h·kg],1.27,755,DB00608,Chloroquine
,2186899,apparent volume of distribution (Vss),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[l] / [kg],1.05,756,DB00608,Chloroquine
,2186899,apparent volume of distribution (Vss),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[l] / [kg],33.32,757,DB00608,Chloroquine
,2186899,Cmax,"The Cmax, Cmin and t1/2 of CYCLO were 56 ng/ml, 17 ng/ml and 15.0 h, respectively.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[ng] / [ml],56,758,DB00608,Chloroquine
,2186899,Cmin,"The Cmax, Cmin and t1/2 of CYCLO were 56 ng/ml, 17 ng/ml and 15.0 h, respectively.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[ng] / [ml],17,759,DB00608,Chloroquine
,2186899,t1/2,"The Cmax, Cmin and t1/2 of CYCLO were 56 ng/ml, 17 ng/ml and 15.0 h, respectively.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),h,15.0,760,DB00608,Chloroquine
,2575156,time to peak whole blood concentration,The rate of absorption was over three times slower with the viscous solution; median time to peak whole blood concentration with the commercial aqueous solution was 10 (range 5-20) min compared with 30 (range 10-60) min for the more viscous formulation (P less than 0.05).,An improved formulation of chloroquine for intramuscular administration: absorption kinetics in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575156/),min,10,1615,DB00608,Chloroquine
,2575156,time to peak whole blood concentration,The rate of absorption was over three times slower with the viscous solution; median time to peak whole blood concentration with the commercial aqueous solution was 10 (range 5-20) min compared with 30 (range 10-60) min for the more viscous formulation (P less than 0.05).,An improved formulation of chloroquine for intramuscular administration: absorption kinetics in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575156/),min,30,1616,DB00608,Chloroquine
,2575156,Peak whole blood concentrations,"Peak whole blood concentrations were 66% (95% CI 50-82%) of those with the commercial preparation, but the acute bioavailability of the two solutions was similar.",An improved formulation of chloroquine for intramuscular administration: absorption kinetics in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575156/),%,66,1617,DB00608,Chloroquine
,15204721,C(max),AQ-13 achieved C(max) after oral administration at approximately 3 to 4 h and could be detected in blood for 2 to 5 days after oral administration.,"Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15204721/),h,3,1842,DB00608,Chloroquine
,15204721,Oral bioavailability,"Oral bioavailability of AQ-13 was good, approximately 70%.","Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15204721/),%,70,1843,DB00608,Chloroquine
,15204721,bioavailability,The bioavailability of AQ-13 in cynomolgus macaques following oral administration was 23.8% for the 20-mg/kg group and 47.6% for the 100-mg/kg group.,"Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15204721/),%,23.8,1844,DB00608,Chloroquine
,15204721,bioavailability,The bioavailability of AQ-13 in cynomolgus macaques following oral administration was 23.8% for the 20-mg/kg group and 47.6% for the 100-mg/kg group.,"Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15204721/),%,47.6,1845,DB00608,Chloroquine
<,31325302,EC50,"TSC3 showed potent in vitro activity against atovaquone-, dihydroartemisinin-, chloroquine- and mefloquine-resistant P. falciparum lines (EC50 <15 nM).",Development of pyridyl thiosemicarbazones as highly potent agents for the treatment of malaria after oral administration. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325302/),nM,15,2172,DB00608,Chloroquine
>,31325302,selectivity index,The selectivity index (EC50 cells/EC50Pf W2 line) of TSC3 was >500 in two of three mammalian cell lines.,Development of pyridyl thiosemicarbazones as highly potent agents for the treatment of malaria after oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325302/),,500,2173,DB00608,Chloroquine
,31325302,maximum blood concentration,A single oral dose of TSC3 at 16 mg/kg in healthy mice achieved a mean maximum blood concentration of 1883 ng/mL at 1 h after dosing and an elimination half-life of 48.7 h in groups of five mice.,Development of pyridyl thiosemicarbazones as highly potent agents for the treatment of malaria after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325302/),[ng] / [ml],1883,2174,DB00608,Chloroquine
,31325302,elimination half-life,A single oral dose of TSC3 at 16 mg/kg in healthy mice achieved a mean maximum blood concentration of 1883 ng/mL at 1 h after dosing and an elimination half-life of 48.7 h in groups of five mice.,Development of pyridyl thiosemicarbazones as highly potent agents for the treatment of malaria after oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325302/),h,48.7,2175,DB00608,Chloroquine
,15508779,EC50,"The mean EC50 values for quinine, quinidine, cinchonine and cinchonidine were 144 nM, 80 nM, 104 nM and 225 nM, respectively, and the EC99 values 8040 nM, 861 nM, 1176 nM and 6531 nM.",In-vitro response of Plasmodium falciparum to the main alkaloids of Cinchona in northwestern Thailand. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15508779/),nM,144,2241,DB00608,Chloroquine
,15508779,EC50,"The mean EC50 values for quinine, quinidine, cinchonine and cinchonidine were 144 nM, 80 nM, 104 nM and 225 nM, respectively, and the EC99 values 8040 nM, 861 nM, 1176 nM and 6531 nM.",In-vitro response of Plasmodium falciparum to the main alkaloids of Cinchona in northwestern Thailand. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15508779/),nM,80,2242,DB00608,Chloroquine
,15508779,EC50,"The mean EC50 values for quinine, quinidine, cinchonine and cinchonidine were 144 nM, 80 nM, 104 nM and 225 nM, respectively, and the EC99 values 8040 nM, 861 nM, 1176 nM and 6531 nM.",In-vitro response of Plasmodium falciparum to the main alkaloids of Cinchona in northwestern Thailand. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15508779/),nM,104,2243,DB00608,Chloroquine
,15508779,EC50,"The mean EC50 values for quinine, quinidine, cinchonine and cinchonidine were 144 nM, 80 nM, 104 nM and 225 nM, respectively, and the EC99 values 8040 nM, 861 nM, 1176 nM and 6531 nM.",In-vitro response of Plasmodium falciparum to the main alkaloids of Cinchona in northwestern Thailand. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15508779/),nM,225,2244,DB00608,Chloroquine
,15508779,EC99,"The mean EC50 values for quinine, quinidine, cinchonine and cinchonidine were 144 nM, 80 nM, 104 nM and 225 nM, respectively, and the EC99 values 8040 nM, 861 nM, 1176 nM and 6531 nM.",In-vitro response of Plasmodium falciparum to the main alkaloids of Cinchona in northwestern Thailand. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15508779/),nM,8040,2245,DB00608,Chloroquine
,15508779,EC99,"The mean EC50 values for quinine, quinidine, cinchonine and cinchonidine were 144 nM, 80 nM, 104 nM and 225 nM, respectively, and the EC99 values 8040 nM, 861 nM, 1176 nM and 6531 nM.",In-vitro response of Plasmodium falciparum to the main alkaloids of Cinchona in northwestern Thailand. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15508779/),nM,861,2246,DB00608,Chloroquine
,15508779,EC99,"The mean EC50 values for quinine, quinidine, cinchonine and cinchonidine were 144 nM, 80 nM, 104 nM and 225 nM, respectively, and the EC99 values 8040 nM, 861 nM, 1176 nM and 6531 nM.",In-vitro response of Plasmodium falciparum to the main alkaloids of Cinchona in northwestern Thailand. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15508779/),nM,1176,2247,DB00608,Chloroquine
,15508779,EC99,"The mean EC50 values for quinine, quinidine, cinchonine and cinchonidine were 144 nM, 80 nM, 104 nM and 225 nM, respectively, and the EC99 values 8040 nM, 861 nM, 1176 nM and 6531 nM.",In-vitro response of Plasmodium falciparum to the main alkaloids of Cinchona in northwestern Thailand. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15508779/),nM,6531,2248,DB00608,Chloroquine
,21080867,maximal rate,"Management included mechanical ventilation (80%), 8.4% sodium bicarbonate (66%), epinephrine [73%, maximal rate: 2.8 mg/h (0.8-5.0)], and extracorporeal life support (16%).",Blood concentrations are better predictors of chioroquine poisoning severity than plasma concentrations: a prospective study with modeling of the concentration/effect relationships. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21080867/),[mg] / [h],2.8,5449,DB00608,Chloroquine
,20166428,AUC,"The main disposition parameters to AS+AQ were: for DHA, AUC = 632 +/- 475 ng h/ml and Cmax = 432 +/- 325 ng/ml, and for MdAQ = 14268 +/- 4114 ng h/ml and Cmax = 336 +/- 225 ng/ml (mean +/- standard deviation).",Pharmacokinetics and pharmacodynamics of a new ACT formulation: Artesunate/Amodiaquine (TRIMALACT) following oral administration in African malaria patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166428/),[h·ng] / [ml],632,6017,DB00608,Chloroquine
,20166428,Cmax,"The main disposition parameters to AS+AQ were: for DHA, AUC = 632 +/- 475 ng h/ml and Cmax = 432 +/- 325 ng/ml, and for MdAQ = 14268 +/- 4114 ng h/ml and Cmax = 336 +/- 225 ng/ml (mean +/- standard deviation).",Pharmacokinetics and pharmacodynamics of a new ACT formulation: Artesunate/Amodiaquine (TRIMALACT) following oral administration in African malaria patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166428/),[ng] / [ml],432,6018,DB00608,Chloroquine
,20166428,Cmax,"The main disposition parameters to AS+AQ were: for DHA, AUC = 632 +/- 475 ng h/ml and Cmax = 432 +/- 325 ng/ml, and for MdAQ = 14268 +/- 4114 ng h/ml and Cmax = 336 +/- 225 ng/ml (mean +/- standard deviation).",Pharmacokinetics and pharmacodynamics of a new ACT formulation: Artesunate/Amodiaquine (TRIMALACT) following oral administration in African malaria patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166428/),[ng] / [ml],336,6019,DB00608,Chloroquine
,32558210,plasma clearance,Median [IQR] plasma clearance of the Seraph for chloroquine/hydroxychloroquine was 1.71 [0.51-4.38] mL/min/1.79 [0.21-3.68] mL/min respectively.,Clearance of chloroquine and hydroxychloroquine by the Seraph® 100 Microbinda Affinity Blood Filter -a device approved for the treatment of COVID-19 patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32558210/),[ml] / [min],1.71,6935,DB00608,Chloroquine
,32558210,plasma clearance,Median [IQR] plasma clearance of the Seraph for chloroquine/hydroxychloroquine was 1.71 [0.51-4.38] mL/min/1.79 [0.21-3.68] mL/min respectively.,Clearance of chloroquine and hydroxychloroquine by the Seraph® 100 Microbinda Affinity Blood Filter -a device approved for the treatment of COVID-19 patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32558210/),[ml] / [min],1.79,6936,DB00608,Chloroquine
,24991836,overall response rate (ORR),"The overall response rate (ORR) for dogs with lymphoma was 93.3%, with median progression-free interval (PFI) of 5 mo.",Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24991836/),%,93.3,8456,DB00608,Chloroquine
,8866337,volume of distribution (Vd),"Halofantrine parameter estimates (mean +/- s.d.) were: volume of distribution (Vd), 7.53 +/- 1.45 mL (g liver)-1; clearance (CL), 0.11 +/- 0.07 mL min-1 (g liver)-1; initial distribution half-life (initial t1/2), 14.62 +/- 2.38 min; terminal half-life (terminal t1/2), 138.7 +/- 178.8 min; AUC 606 +/- 194 mg mL-1 min-1 (g liver)-1; elimination rate constant (Ke), 0.0135 +/- 0.012 min-1.",Mefloquine effect on disposition of halofantrine in the isolated perfused rat liver. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866337/),ml,7.53,8764,DB00608,Chloroquine
,8866337,clearance (CL),"Halofantrine parameter estimates (mean +/- s.d.) were: volume of distribution (Vd), 7.53 +/- 1.45 mL (g liver)-1; clearance (CL), 0.11 +/- 0.07 mL min-1 (g liver)-1; initial distribution half-life (initial t1/2), 14.62 +/- 2.38 min; terminal half-life (terminal t1/2), 138.7 +/- 178.8 min; AUC 606 +/- 194 mg mL-1 min-1 (g liver)-1; elimination rate constant (Ke), 0.0135 +/- 0.012 min-1.",Mefloquine effect on disposition of halofantrine in the isolated perfused rat liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866337/),[ml] / [min],0.11,8765,DB00608,Chloroquine
,8866337,initial distribution half-life (initial t1/2),"Halofantrine parameter estimates (mean +/- s.d.) were: volume of distribution (Vd), 7.53 +/- 1.45 mL (g liver)-1; clearance (CL), 0.11 +/- 0.07 mL min-1 (g liver)-1; initial distribution half-life (initial t1/2), 14.62 +/- 2.38 min; terminal half-life (terminal t1/2), 138.7 +/- 178.8 min; AUC 606 +/- 194 mg mL-1 min-1 (g liver)-1; elimination rate constant (Ke), 0.0135 +/- 0.012 min-1.",Mefloquine effect on disposition of halofantrine in the isolated perfused rat liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866337/),min,14.62,8766,DB00608,Chloroquine
,8866337,terminal half-life (terminal t1/2),"Halofantrine parameter estimates (mean +/- s.d.) were: volume of distribution (Vd), 7.53 +/- 1.45 mL (g liver)-1; clearance (CL), 0.11 +/- 0.07 mL min-1 (g liver)-1; initial distribution half-life (initial t1/2), 14.62 +/- 2.38 min; terminal half-life (terminal t1/2), 138.7 +/- 178.8 min; AUC 606 +/- 194 mg mL-1 min-1 (g liver)-1; elimination rate constant (Ke), 0.0135 +/- 0.012 min-1.",Mefloquine effect on disposition of halofantrine in the isolated perfused rat liver. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866337/),min,138.7,8767,DB00608,Chloroquine
,8866337,AUC,"Halofantrine parameter estimates (mean +/- s.d.) were: volume of distribution (Vd), 7.53 +/- 1.45 mL (g liver)-1; clearance (CL), 0.11 +/- 0.07 mL min-1 (g liver)-1; initial distribution half-life (initial t1/2), 14.62 +/- 2.38 min; terminal half-life (terminal t1/2), 138.7 +/- 178.8 min; AUC 606 +/- 194 mg mL-1 min-1 (g liver)-1; elimination rate constant (Ke), 0.0135 +/- 0.012 min-1.",Mefloquine effect on disposition of halofantrine in the isolated perfused rat liver. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866337/),[mg] / [min·ml],606,8768,DB00608,Chloroquine
,8866337,elimination rate constant (Ke),"Halofantrine parameter estimates (mean +/- s.d.) were: volume of distribution (Vd), 7.53 +/- 1.45 mL (g liver)-1; clearance (CL), 0.11 +/- 0.07 mL min-1 (g liver)-1; initial distribution half-life (initial t1/2), 14.62 +/- 2.38 min; terminal half-life (terminal t1/2), 138.7 +/- 178.8 min; AUC 606 +/- 194 mg mL-1 min-1 (g liver)-1; elimination rate constant (Ke), 0.0135 +/- 0.012 min-1.",Mefloquine effect on disposition of halofantrine in the isolated perfused rat liver. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866337/),1/[min],0.0135,8769,DB00608,Chloroquine
,30399360,plasma window,"Model validation used 13 nonpregnancy and 3 pregnancy clinical studies, and a therapeutic CQ plasma window of 0.3-2 μM was derived.",Dose Optimization of Chloroquine by Pharmacokinetic Modeling During Pregnancy for the Treatment of Zika Virus Infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399360/),μM,0.3-2,9303,DB00608,Chloroquine
,32415986,half-lives,"The relationship between plasma and whole blood concentrations of chloroquine and P. vivax parasitemia was characterized by a PK/PD delayed response model, where the equilibration half-lives were 32.7 hours (95% confidence interval (CI) 27.4-40.5) for plasma data and 24.1 hours (95% CI 19.0-32.7) for whole blood data.",Population Pharmacokinetics and Pharmacodynamics of Chloroquine in a Plasmodium vivax Volunteer Infection Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32415986/),h,32.7,11182,DB00608,Chloroquine
,32415986,half-lives,"The relationship between plasma and whole blood concentrations of chloroquine and P. vivax parasitemia was characterized by a PK/PD delayed response model, where the equilibration half-lives were 32.7 hours (95% confidence interval (CI) 27.4-40.5) for plasma data and 24.1 hours (95% CI 19.0-32.7) for whole blood data.",Population Pharmacokinetics and Pharmacodynamics of Chloroquine in a Plasmodium vivax Volunteer Infection Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32415986/),h,24.1,11183,DB00608,Chloroquine
,32415986,maximum parasite killing rate,"The estimated parasite multiplication rate was 17 folds per 48 hours (95% CI 14-20) and maximum parasite killing rate by chloroquine was 0.213 hour-1 (95% CI 0.196-0.230), translating to a parasite clearance half-life of 4.5 hours (95% CI 4.1-5.0) and a parasite reduction ratio of 400 every 48 hours (95% CI 320-500).",Population Pharmacokinetics and Pharmacodynamics of Chloroquine in a Plasmodium vivax Volunteer Infection Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32415986/),1/[h],0.213,11184,DB00608,Chloroquine
,32415986,parasite clearance half-life,"The estimated parasite multiplication rate was 17 folds per 48 hours (95% CI 14-20) and maximum parasite killing rate by chloroquine was 0.213 hour-1 (95% CI 0.196-0.230), translating to a parasite clearance half-life of 4.5 hours (95% CI 4.1-5.0) and a parasite reduction ratio of 400 every 48 hours (95% CI 320-500).",Population Pharmacokinetics and Pharmacodynamics of Chloroquine in a Plasmodium vivax Volunteer Infection Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32415986/),h,4.5,11185,DB00608,Chloroquine
,32415986,parasite reduction ratio,"The estimated parasite multiplication rate was 17 folds per 48 hours (95% CI 14-20) and maximum parasite killing rate by chloroquine was 0.213 hour-1 (95% CI 0.196-0.230), translating to a parasite clearance half-life of 4.5 hours (95% CI 4.1-5.0) and a parasite reduction ratio of 400 every 48 hours (95% CI 320-500).",Population Pharmacokinetics and Pharmacodynamics of Chloroquine in a Plasmodium vivax Volunteer Infection Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32415986/),,400,11186,DB00608,Chloroquine
,8036681,maximum plasma concentration,"Mean values (SD in parentheses) of maximum plasma concentration of 57.7 (7.7) vs. 55.7 (7.4) ng/mL were reached at 2.2 (0.6) vs. 2.2 (0.6) h, for the G6PD deficient and G6PD normal groups, respectively.",Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8036681/),[ng] / [ml],57.7,11359,DB00608,Chloroquine
,8036681,maximum plasma concentration,"Mean values (SD in parentheses) of maximum plasma concentration of 57.7 (7.7) vs. 55.7 (7.4) ng/mL were reached at 2.2 (0.6) vs. 2.2 (0.6) h, for the G6PD deficient and G6PD normal groups, respectively.",Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8036681/),[ng] / [ml],55.7,11360,DB00608,Chloroquine
,8036681,t1/2 lambda,"Thereafter, drug levels declined rapidly and monoexponentially with a t1/2 lambda of 6.4 (1.9) vs. 6.3 (2.7) h.",Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8036681/),h,6.4,11361,DB00608,Chloroquine
,8036681,t1/2 lambda,"Thereafter, drug levels declined rapidly and monoexponentially with a t1/2 lambda of 6.4 (1.9) vs. 6.3 (2.7) h.",Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8036681/),h,6.3,11362,DB00608,Chloroquine
,8036681,MRT,"The respective mean values (SD in parentheses) for MRT, AUC0-varies; is directly proportional to Cl/f, and Vz/f were 6.8 (0.4) vs. 6.8 (0.5) h, 0.547 (0.070) vs. 0.521 (0.090) micrograms/h/mL, 8.54 (0.37) vs. 8.97 (1.46) mL/min/kg and 4.8 (1.7) vs. 5.1 (1.2) L/kg.",Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8036681/),h,6.8,11363,DB00608,Chloroquine
,8036681,Vz/f,"The respective mean values (SD in parentheses) for MRT, AUC0-varies; is directly proportional to Cl/f, and Vz/f were 6.8 (0.4) vs. 6.8 (0.5) h, 0.547 (0.070) vs. 0.521 (0.090) micrograms/h/mL, 8.54 (0.37) vs. 8.97 (1.46) mL/min/kg and 4.8 (1.7) vs. 5.1 (1.2) L/kg.",Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8036681/),[ml] / [kg·min],8.54,11364,DB00608,Chloroquine
,8036681,Vz/f,"The respective mean values (SD in parentheses) for MRT, AUC0-varies; is directly proportional to Cl/f, and Vz/f were 6.8 (0.4) vs. 6.8 (0.5) h, 0.547 (0.070) vs. 0.521 (0.090) micrograms/h/mL, 8.54 (0.37) vs. 8.97 (1.46) mL/min/kg and 4.8 (1.7) vs. 5.1 (1.2) L/kg.",Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8036681/),[ml] / [kg·min],8.97,11365,DB00608,Chloroquine
,8036681,Vz/f,"The respective mean values (SD in parentheses) for MRT, AUC0-varies; is directly proportional to Cl/f, and Vz/f were 6.8 (0.4) vs. 6.8 (0.5) h, 0.547 (0.070) vs. 0.521 (0.090) micrograms/h/mL, 8.54 (0.37) vs. 8.97 (1.46) mL/min/kg and 4.8 (1.7) vs. 5.1 (1.2) L/kg.",Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8036681/),[l] / [kg],4.8,11366,DB00608,Chloroquine
,8036681,Vz/f,"The respective mean values (SD in parentheses) for MRT, AUC0-varies; is directly proportional to Cl/f, and Vz/f were 6.8 (0.4) vs. 6.8 (0.5) h, 0.547 (0.070) vs. 0.521 (0.090) micrograms/h/mL, 8.54 (0.37) vs. 8.97 (1.46) mL/min/kg and 4.8 (1.7) vs. 5.1 (1.2) L/kg.",Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8036681/),[l] / [kg],5.1,11367,DB00608,Chloroquine
,10604820,plasma concentrations,"The mean and SEM plasma concentrations (g/mL) of TMP, SMX, and AcSMX 2 hours after the first treatment dose were 2.0 +/- 1.0 (range 0.5-6), 53 +/- 22 (range 24-146), and 13.5 +/- 12 (range 0-65), respectively.",A reversed-phase high-performance liquid chromatography method for the determination of cotrimoxazole (trimethoprim/ sulphamethoxazole) in children treated for malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604820/),[g] / [ml],2.0,12682,DB00608,Chloroquine
,10604820,plasma concentrations,"The mean and SEM plasma concentrations (g/mL) of TMP, SMX, and AcSMX 2 hours after the first treatment dose were 2.0 +/- 1.0 (range 0.5-6), 53 +/- 22 (range 24-146), and 13.5 +/- 12 (range 0-65), respectively.",A reversed-phase high-performance liquid chromatography method for the determination of cotrimoxazole (trimethoprim/ sulphamethoxazole) in children treated for malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604820/),[g] / [ml],53,12683,DB00608,Chloroquine
,10604820,plasma concentrations,"The mean and SEM plasma concentrations (g/mL) of TMP, SMX, and AcSMX 2 hours after the first treatment dose were 2.0 +/- 1.0 (range 0.5-6), 53 +/- 22 (range 24-146), and 13.5 +/- 12 (range 0-65), respectively.",A reversed-phase high-performance liquid chromatography method for the determination of cotrimoxazole (trimethoprim/ sulphamethoxazole) in children treated for malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604820/),[g] / [ml],13.5,12684,DB00608,Chloroquine
,32306288,apparent,"Chloroquine is well absorbed and distributes extensively resulting in a large volume of distribution with an apparent and terminal half-life of 1.6 days and 2 weeks, respectively.",Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32306288/),d,1.6,13783,DB00608,Chloroquine
,32306288,terminal half-life,"Chloroquine is well absorbed and distributes extensively resulting in a large volume of distribution with an apparent and terminal half-life of 1.6 days and 2 weeks, respectively.",Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32306288/),weeks,2,13784,DB00608,Chloroquine
,8169835,apparent first-order distribution (lambda 1),"The apparent first-order distribution (lambda 1) and elimination (lambda z) rate constants were 0.043 +/- 0.014 min-1 and 0.020 +/- 0.007 min-1, respectively.",Mefloquine transfer during in vitro human placenta perfusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169835/),1/[min],0.043,14426,DB00608,Chloroquine
,8169835,elimination (lambda z),"The apparent first-order distribution (lambda 1) and elimination (lambda z) rate constants were 0.043 +/- 0.014 min-1 and 0.020 +/- 0.007 min-1, respectively.",Mefloquine transfer during in vitro human placenta perfusion. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169835/),1/[min],0.043,14427,DB00608,Chloroquine
,8169835,rate constants,"The apparent first-order distribution (lambda 1) and elimination (lambda z) rate constants were 0.043 +/- 0.014 min-1 and 0.020 +/- 0.007 min-1, respectively.",Mefloquine transfer during in vitro human placenta perfusion. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169835/),1/[min],0.020,14428,DB00608,Chloroquine
,8169835,mass ratio,The fetomaternal mass ratio became constant (0.46 +/- 0.07) after 120 min of perfusion and the time needed to achieve equal concentrations on both sides of the placenta was 178 +/- 31 min.,Mefloquine transfer during in vitro human placenta perfusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169835/),,0.46,14429,DB00608,Chloroquine
,8169835,time needed to achieve,The fetomaternal mass ratio became constant (0.46 +/- 0.07) after 120 min of perfusion and the time needed to achieve equal concentrations on both sides of the placenta was 178 +/- 31 min.,Mefloquine transfer during in vitro human placenta perfusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169835/),min,178,14430,DB00608,Chloroquine
,8169835,clearance,MQ clearance was 3.36 +/- 0.38 ml/min.,Mefloquine transfer during in vitro human placenta perfusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169835/),[ml] / [min],3.36,14431,DB00608,Chloroquine
more,2757893,terminal elimination half-life,"2. The terminal elimination half-life of hydroxychloroquine is more than 40 days, thus blood and urine samples were collected for 5 months following each dose to characterise adequately the terminal elimination phase and obtain accurate estimates of the areas under the concentration-time curves.",Bioavailability of hydroxychloroquine tablets in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2757893/),d,40,15632,DB00608,Chloroquine
,2757893,fraction of the oral dose absorbed,"3. The mean (+/- s.d.) fraction of the oral dose absorbed, estimated from the blood and urine data, was 0.74 (+/- 0.13).",Bioavailability of hydroxychloroquine tablets in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2757893/),,0.74,15633,DB00608,Chloroquine
up to,1841837,maximal concentrations,"Peak concentrations in the fetus reached up to +/- 280 ng/ml within 2-4 h after administration while maximal concentrations in the mother reached up to 2,850 ng/ml.",Transplacental distribution of chloroquine in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1841837/),[ng] / [ml],"2,850",20338,DB00608,Chloroquine
,1841837,terminal half-life,"The terminal half-life of chloroquine in pregnant sheep was very long, amounting to 65.1 +/- 34.9 h (range 27.4-119 h).",Transplacental distribution of chloroquine in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1841837/),h,65.1,20339,DB00608,Chloroquine
,1841837,volume of distribution (V(area),"Tissue binding was high, as reflected by the extensive volume of distribution (V(area): 19.0 +/- 11.0 l/kg).",Transplacental distribution of chloroquine in sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1841837/),[l] / [kg],19.0,20340,DB00608,Chloroquine
,1841837,Total clearance,Total clearance was equal to 3.42 +/- 0.60 ml/min/kg.,Transplacental distribution of chloroquine in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1841837/),[ml] / [kg·min],3.42,20341,DB00608,Chloroquine
,24914738,ED90,Compound 23 was found to be efficacious (ED90 of 28.6 mg·kg(-1)) in the humanized P. falciparum mouse model of malaria (Pf/SCID model).,"Aminoazabenzimidazoles, a novel class of orally active antimalarial agents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24914738/),[mg] / [kg],28.6,21003,DB00608,Chloroquine
,3323258,apparent oral clearance rate,"The apparent oral clearance rate of chloroquine was reduced from 0.49 +/- 0.04 L/d/kg in the control group to 0.23 +/- 0.02 L/d/kg in the test group, and the elimination half-life was prolonged from 3.11 days in the control group to 4.62 days in the test group.",Chloroquine elimination in humans: effect of low-dose cimetidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323258/),[l] / [d·kg],0.49,24302,DB00608,Chloroquine
,3323258,apparent oral clearance rate,"The apparent oral clearance rate of chloroquine was reduced from 0.49 +/- 0.04 L/d/kg in the control group to 0.23 +/- 0.02 L/d/kg in the test group, and the elimination half-life was prolonged from 3.11 days in the control group to 4.62 days in the test group.",Chloroquine elimination in humans: effect of low-dose cimetidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323258/),[l] / [d·kg],0.23,24303,DB00608,Chloroquine
,3323258,elimination half-life,"The apparent oral clearance rate of chloroquine was reduced from 0.49 +/- 0.04 L/d/kg in the control group to 0.23 +/- 0.02 L/d/kg in the test group, and the elimination half-life was prolonged from 3.11 days in the control group to 4.62 days in the test group.",Chloroquine elimination in humans: effect of low-dose cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323258/),d,3.11,24304,DB00608,Chloroquine
,3323258,elimination half-life,"The apparent oral clearance rate of chloroquine was reduced from 0.49 +/- 0.04 L/d/kg in the control group to 0.23 +/- 0.02 L/d/kg in the test group, and the elimination half-life was prolonged from 3.11 days in the control group to 4.62 days in the test group.",Chloroquine elimination in humans: effect of low-dose cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323258/),d,4.62,24305,DB00608,Chloroquine
,3323258,apparent volume of distribution at steady state,The apparent volume of distribution at steady state was increased from 0.46 +/- 0.07 L/kg in the control group to 0.72 +/- 0.10 L/kg in the test group.,Chloroquine elimination in humans: effect of low-dose cimetidine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323258/),[l] / [kg],0.46,24306,DB00608,Chloroquine
,3323258,apparent volume of distribution at steady state,The apparent volume of distribution at steady state was increased from 0.46 +/- 0.07 L/kg in the control group to 0.72 +/- 0.10 L/kg in the test group.,Chloroquine elimination in humans: effect of low-dose cimetidine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323258/),[l] / [kg],0.72,24307,DB00608,Chloroquine
,3915449,half-life,"The results showed that: amodiaquine was no more detected in the blood, a main metabolite (monodesethyl derivative) appeared as the active form of the drug in vivo, metabolite's half-life had a mean value of 15.6 +/- 5.4 days.",[Pharmacokinetics of amodiaquine and prevention of Plasmodium falciparum malaria]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3915449/),d,15.6,27803,DB00608,Chloroquine
,25563929,oral bioavailability,"The PK evaluation of NP046 showed low oral bioavailability (3.2% and 6% at 50 mg/kg and 10 mg/kg dose, respectively and a moderate mean half-life ranging from 3.1 to 4.4 hours.",Efficacy and pharmacokinetic evaluation of a novel anti-malarial compound (NP046) in a mouse model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25563929/),%,3.2,29021,DB00608,Chloroquine
,25563929,oral bioavailability,"The PK evaluation of NP046 showed low oral bioavailability (3.2% and 6% at 50 mg/kg and 10 mg/kg dose, respectively and a moderate mean half-life ranging from 3.1 to 4.4 hours.",Efficacy and pharmacokinetic evaluation of a novel anti-malarial compound (NP046) in a mouse model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25563929/),%,6,29022,DB00608,Chloroquine
,25563929,half-life,"The PK evaluation of NP046 showed low oral bioavailability (3.2% and 6% at 50 mg/kg and 10 mg/kg dose, respectively and a moderate mean half-life ranging from 3.1 to 4.4 hours.",Efficacy and pharmacokinetic evaluation of a novel anti-malarial compound (NP046) in a mouse model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25563929/),h,3.1 to 4.4,29023,DB00608,Chloroquine
,8003056,AUC ratios,The median value of individual AUC ratios (MTX/MTX + CQ) was 1.6 (95% confidence interval 1.2-3.6).,Chloroquine reduces the bioavailability of methotrexate in patients with rheumatoid arthritis. A possible mechanism of reduced hepatotoxicity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8003056/),,1.6,30552,DB00608,Chloroquine
,3179169,Half-life,"3. Half-life and mean residence time were long (around 40 days) and large volumes of distribution were calculated (5,522 l from blood, 44,257 l from plasma).",A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179169/),d,40,31464,DB00608,Chloroquine
,3179169,mean residence time,"3. Half-life and mean residence time were long (around 40 days) and large volumes of distribution were calculated (5,522 l from blood, 44,257 l from plasma).",A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179169/),d,40,31465,DB00608,Chloroquine
,3179169,volumes of distribution,"3. Half-life and mean residence time were long (around 40 days) and large volumes of distribution were calculated (5,522 l from blood, 44,257 l from plasma).",A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179169/),l,"5,522",31466,DB00608,Chloroquine
,3179169,volumes of distribution,"3. Half-life and mean residence time were long (around 40 days) and large volumes of distribution were calculated (5,522 l from blood, 44,257 l from plasma).",A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179169/),l,"44,257",31467,DB00608,Chloroquine
,3179169,clearance,"The persistence of hydroxychloroquine in the body is due primarily to this extensive tissue distribution, rather than to low clearance (667 ml min-1 based on plasma data, 96 ml min-1 based on blood data).",A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179169/),[ml] / [min],667,31468,DB00608,Chloroquine
,3179169,clearance,"The persistence of hydroxychloroquine in the body is due primarily to this extensive tissue distribution, rather than to low clearance (667 ml min-1 based on plasma data, 96 ml min-1 based on blood data).",A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179169/),[ml] / [min],96,31469,DB00608,Chloroquine
,3179169,Blood to plasma concentration ratios,Blood to plasma concentration ratios were not constant (mean +/- s.d.: 7.2 +/- 4.2).,A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179169/),,7.2,31470,DB00608,Chloroquine
,14738591,terminal half life,The uveal tract concentrations reached the maximum value of 158.42 +/- 7.86 micrograms equiv g-1 (mean+/-s.e.) at 1 week and decreased very slowly with a terminal half life of 4476 h (187 day).,"Absorption, distribution and excretion of 14C-chloroquine after single oral administration in albino and pigmented rats: binding characteristics of chloroquine-related radioactivity to melanin in-vivo. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14738591/),h,4476,32091,DB00608,Chloroquine
,14738591,uveal tract concentrations,The uveal tract concentrations at 24 weeks were still high (67.75 +/- 6.19 micrograms equiv g-1).,"Absorption, distribution and excretion of 14C-chloroquine after single oral administration in albino and pigmented rats: binding characteristics of chloroquine-related radioactivity to melanin in-vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14738591/),[equiv·μg] / [g],67.75,32092,DB00608,Chloroquine
,14738591,AUC,The AUC for uveal tract was 842.3 mg.h g-1.,"Absorption, distribution and excretion of 14C-chloroquine after single oral administration in albino and pigmented rats: binding characteristics of chloroquine-related radioactivity to melanin in-vivo. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14738591/),[h·mg] / [g],842.3,32093,DB00608,Chloroquine
,8373715,(R)/(S) ratio,"In all patients, the blood concentration of (R)-hydroxychloroquine exceeded that of the (S)-enantiomer, the mean (R)/(S) ratio being 2.2 (range 1.6-2.9).",Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8373715/),,2.2,32342,DB00608,Chloroquine
,8373715,(R)/(S) ratio,"A similar excess of (R)-hydroxychloroquine was found in the plasma, the mean (R)/(S) ratio being 1.6 (range 1.2-1.9).",Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8373715/),,1.6,32343,DB00608,Chloroquine
,8373715,blood concentration ratio (R)/(S),The mean enantiomer blood concentration ratio (R)/(S) for the metabolite desethylhydroxychloroquine was 0.45 (range 0.34-0.58) and for desethylchloroquine it was 0.56 (range 0.35-0.86) suggesting stereoselective metabolism of hydroxychloroquine.,Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8373715/),,0.45,32344,DB00608,Chloroquine
,8373715,blood concentration ratio (R)/(S),The mean enantiomer blood concentration ratio (R)/(S) for the metabolite desethylhydroxychloroquine was 0.45 (range 0.34-0.58) and for desethylchloroquine it was 0.56 (range 0.35-0.86) suggesting stereoselective metabolism of hydroxychloroquine.,Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8373715/),,0.56,32345,DB00608,Chloroquine
,8373715,renal clearance from blood,"(S)-hydroxychloroquine had a mean (+/- s.d.) renal clearance from blood of 41 +/- 11 ml min-1, approximately twice that of (R)-hydroxychloroquine.",Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8373715/),[ml] / [min],41,32346,DB00608,Chloroquine
,19858250,areas under the plasma concentration-time curve (AUC(0-infinity)),"The areas under the plasma concentration-time curve (AUC(0-infinity)) (28.7 and 31.8 mg.h liter(-1) for pregnant and nonpregnant subjects, respectively) were consistent with the results of previous studies, but the estimated terminal elimination half-lives (78 and 77 h, respectively) were generally longer.",Pharmacokinetic properties of azithromycin in pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19858250/),[h·mg] / [liter],28.7,32896,DB00608,Chloroquine
,19858250,areas under the plasma concentration-time curve (AUC(0-infinity)),"The areas under the plasma concentration-time curve (AUC(0-infinity)) (28.7 and 31.8 mg.h liter(-1) for pregnant and nonpregnant subjects, respectively) were consistent with the results of previous studies, but the estimated terminal elimination half-lives (78 and 77 h, respectively) were generally longer.",Pharmacokinetic properties of azithromycin in pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19858250/),[h·mg] / [liter],31.8,32897,DB00608,Chloroquine
,19858250,terminal elimination half-lives,"The areas under the plasma concentration-time curve (AUC(0-infinity)) (28.7 and 31.8 mg.h liter(-1) for pregnant and nonpregnant subjects, respectively) were consistent with the results of previous studies, but the estimated terminal elimination half-lives (78 and 77 h, respectively) were generally longer.",Pharmacokinetic properties of azithromycin in pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19858250/),h,78,32898,DB00608,Chloroquine
,19858250,terminal elimination half-lives,"The areas under the plasma concentration-time curve (AUC(0-infinity)) (28.7 and 31.8 mg.h liter(-1) for pregnant and nonpregnant subjects, respectively) were consistent with the results of previous studies, but the estimated terminal elimination half-lives (78 and 77 h, respectively) were generally longer.",Pharmacokinetic properties of azithromycin in pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19858250/),h,77,32899,DB00608,Chloroquine
,32660993,50% inhibitory concentration [IC50],"Here, ivermectin showed inhibition of the in vitro development of Plasmodium cynomolgi schizonts (50% inhibitory concentration [IC50], 10.42 μM) and hypnozoites (IC50, 29.24 μM) in primary macaque hepatocytes when administered as a high dose prophylactically but not when administered in radical cure mode.","Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32660993/),μM,10.42,33911,DB00608,Chloroquine
,32660993,IC50,"Here, ivermectin showed inhibition of the in vitro development of Plasmodium cynomolgi schizonts (50% inhibitory concentration [IC50], 10.42 μM) and hypnozoites (IC50, 29.24 μM) in primary macaque hepatocytes when administered as a high dose prophylactically but not when administered in radical cure mode.","Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32660993/),μM,29.24,33912,DB00608,Chloroquine
,21966980,IC(50),"An aminomethylthiazole pyrazole carboxamide lead 3 with good in vitro antiplasmodial activity [IC(50): 0.08 μM (K1, chloroquine and multidrug resistant strain) and 0.07 μM (NF54, chloroquine sensitive strain)] and microsomal metabolic stability was identified from whole cell screening of a SoftFocus kinase library.",Novel orally active antimalarial thiazoles. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21966980/),μM,0.08,34183,DB00608,Chloroquine
,21966980,IC(50),"An aminomethylthiazole pyrazole carboxamide lead 3 with good in vitro antiplasmodial activity [IC(50): 0.08 μM (K1, chloroquine and multidrug resistant strain) and 0.07 μM (NF54, chloroquine sensitive strain)] and microsomal metabolic stability was identified from whole cell screening of a SoftFocus kinase library.",Novel orally active antimalarial thiazoles. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21966980/),μM,0.07,34184,DB00608,Chloroquine
,21966980,oral bioavailability,"Pharmacokinetic studies in rats revealed good oral bioavailability (51% at 22 mg/kg) with a moderate rate of absorption, reasonable half-life (t(1/2) 3 h), and high volume of distribution with moderately high plasma and blood clearance after IV administration.",Novel orally active antimalarial thiazoles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21966980/),%,51,34185,DB00608,Chloroquine
,21966980,half-life (t(1/2),"Pharmacokinetic studies in rats revealed good oral bioavailability (51% at 22 mg/kg) with a moderate rate of absorption, reasonable half-life (t(1/2) 3 h), and high volume of distribution with moderately high plasma and blood clearance after IV administration.",Novel orally active antimalarial thiazoles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21966980/),h,3,34186,DB00608,Chloroquine
,21966980,IC(50),"Toward toxicity profiling, 3 exhibited moderate potential to inhibit CYP1A2 (IC(50) = 1.5 μM) and 2D6 (IC(50) = 0.4 μM) as well as having a potential hERG liability (IC(50) = 3.7 μM).",Novel orally active antimalarial thiazoles. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21966980/),μM,1.5,34187,DB00608,Chloroquine
,21966980,IC(50),"Toward toxicity profiling, 3 exhibited moderate potential to inhibit CYP1A2 (IC(50) = 1.5 μM) and 2D6 (IC(50) = 0.4 μM) as well as having a potential hERG liability (IC(50) = 3.7 μM).",Novel orally active antimalarial thiazoles. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21966980/),μM,0.4,34188,DB00608,Chloroquine
,21966980,IC(50),"Toward toxicity profiling, 3 exhibited moderate potential to inhibit CYP1A2 (IC(50) = 1.5 μM) and 2D6 (IC(50) = 0.4 μM) as well as having a potential hERG liability (IC(50) = 3.7 μM).",Novel orally active antimalarial thiazoles. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21966980/),μM,3.7,34189,DB00608,Chloroquine
,20361799,IC(50),"Both 18 and 4 are highly potent antimalarial compounds, with IC(50) values of 5.6 and 17.3 nM, respectively, against the W2 (CQ-resistant) strain of Plasmodium falciparum (for CQ, IC(50) = 382 nM).",Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20361799/),nM,5.6,35798,DB00608,Chloroquine
,20361799,IC(50),"Both 18 and 4 are highly potent antimalarial compounds, with IC(50) values of 5.6 and 17.3 nM, respectively, against the W2 (CQ-resistant) strain of Plasmodium falciparum (for CQ, IC(50) = 382 nM).",Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20361799/),nM,17.3,35799,DB00608,Chloroquine
,20361799,IC(50),"Both 18 and 4 are highly potent antimalarial compounds, with IC(50) values of 5.6 and 17.3 nM, respectively, against the W2 (CQ-resistant) strain of Plasmodium falciparum (for CQ, IC(50) = 382 nM).",Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20361799/),nM,382,35800,DB00608,Chloroquine
,2875158,tmax in saliva,The results showed the drug to be rapidly absorbed with a tmax in saliva of 3.9 +/- 1.6 h.,Saliva secretion of chloroquine in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875158/),h,3.9,38993,DB00608,Chloroquine
,2875158,elimination half-life,"A long elimination half-life of 7-20 days, calculated from the saliva concentration-time profile, is in agreement with values previously reported for the drug using plasma level data.",Saliva secretion of chloroquine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875158/),d,7-20,38994,DB00608,Chloroquine
,2875158,Cs/Cp,"In three of the volunteers from whom simultaneous blood samples were obtained, the mean Cs/Cp value was 1.20 +/- 0.27.",Saliva secretion of chloroquine in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875158/),,1.20,38995,DB00608,Chloroquine
,25759576,oral bioavailability,"A microemulsion formulation of TQ (MTQ) with sizes <20 nm improved the solubility of TQ and enhanced the oral bioavailability from 55% to 99% in healthy mice (area under the curve 0 to infinity: 11,368±1,232 and 23,842±872 min·μmol/L) for reference TQ and MTQ, respectively.",Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25759576/),%,55,42852,DB00608,Chloroquine
,25759576,oral bioavailability,"A microemulsion formulation of TQ (MTQ) with sizes <20 nm improved the solubility of TQ and enhanced the oral bioavailability from 55% to 99% in healthy mice (area under the curve 0 to infinity: 11,368±1,232 and 23,842±872 min·μmol/L) for reference TQ and MTQ, respectively.",Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25759576/),%,99,42853,DB00608,Chloroquine
,25759576,area under the curve 0 to infinity,"A microemulsion formulation of TQ (MTQ) with sizes <20 nm improved the solubility of TQ and enhanced the oral bioavailability from 55% to 99% in healthy mice (area under the curve 0 to infinity: 11,368±1,232 and 23,842±872 min·μmol/L) for reference TQ and MTQ, respectively.",Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25759576/),[min·μM] / [l],"11,368",42854,DB00608,Chloroquine
,25759576,area under the curve 0 to infinity,"A microemulsion formulation of TQ (MTQ) with sizes <20 nm improved the solubility of TQ and enhanced the oral bioavailability from 55% to 99% in healthy mice (area under the curve 0 to infinity: 11,368±1,232 and 23,842±872 min·μmol/L) for reference TQ and MTQ, respectively.",Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25759576/),[min·μM] / [l],"23,842",42855,DB00608,Chloroquine
greater,1763797,peak concentrations,The low-dose intravenous quinine regimen resulted in mean peak concentrations greater than 6 mg/l and mean low concentrations greater than 3.5 mg/l.,Quinine treatment of severe falciparum malaria in African children: a randomized comparison of three regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763797/),[mg] / [l],6,43035,DB00608,Chloroquine
greater,1763797,low concentrations,The low-dose intravenous quinine regimen resulted in mean peak concentrations greater than 6 mg/l and mean low concentrations greater than 3.5 mg/l.,Quinine treatment of severe falciparum malaria in African children: a randomized comparison of three regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763797/),[mg] / [l],3.5,43036,DB00608,Chloroquine
,1763797,99% in vitro inhibitory concentration (EC99),"All blood concentrations exceeded the 99% in vitro inhibitory concentration (EC99) of 0.89 mg/l or less of quinine for 60 isolates of Plasmodium falciparum, which were taken from children with malaria during the same period.",Quinine treatment of severe falciparum malaria in African children: a randomized comparison of three regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763797/),[mg] / [l],0.89,43037,DB00608,Chloroquine
,32838422,Plasma concentrations,"Plasma concentrations of chloroquine in older children ranged from 67 to 1112 ng/ml, and in adults the value ranged from 74 to 1147 ng/ml.",Exposure to chloroquine in male adults and children aged 9-11 years with malaria due to Plasmodium vivax. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32838422/),[ng] / [ml],67 to 1112,43354,DB00608,Chloroquine
,32838422,Plasma concentrations,"Plasma concentrations of chloroquine in older children ranged from 67 to 1112 ng/ml, and in adults the value ranged from 74 to 1147 ng/ml.",Exposure to chloroquine in male adults and children aged 9-11 years with malaria due to Plasmodium vivax. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32838422/),[ng] / [ml],74 to 1147,43355,DB00608,Chloroquine
,32639233,Whole blood concentrations,Whole blood concentrations of 13.5 µmol/L (95% credible interval 10.1-17.7) were associated with 1% mortality.,Concentration-dependent mortality of chloroquine in overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32639233/),[μM] / [l],13.5,43719,DB00608,Chloroquine
,8462231,Terminal half-life (t1/2 lambda z),"Terminal half-life (t1/2 lambda z) and mean residence time (MRT) were longer for (R)-chloroquine (294h and 388h, respectively) than for (S)-chloroquine (236h and 272h, respectively).",Stereoselective pharmacokinetic properties of chloroquine and de-ethyl-chloroquine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462231/),h,294,46505,DB00608,Chloroquine
,8462231,Terminal half-life (t1/2 lambda z),"Terminal half-life (t1/2 lambda z) and mean residence time (MRT) were longer for (R)-chloroquine (294h and 388h, respectively) than for (S)-chloroquine (236h and 272h, respectively).",Stereoselective pharmacokinetic properties of chloroquine and de-ethyl-chloroquine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462231/),h,236,46506,DB00608,Chloroquine
,8462231,mean residence time (MRT),"Terminal half-life (t1/2 lambda z) and mean residence time (MRT) were longer for (R)-chloroquine (294h and 388h, respectively) than for (S)-chloroquine (236h and 272h, respectively).",Stereoselective pharmacokinetic properties of chloroquine and de-ethyl-chloroquine in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462231/),h,388,46507,DB00608,Chloroquine
,8462231,mean residence time (MRT),"Terminal half-life (t1/2 lambda z) and mean residence time (MRT) were longer for (R)-chloroquine (294h and 388h, respectively) than for (S)-chloroquine (236h and 272h, respectively).",Stereoselective pharmacokinetic properties of chloroquine and de-ethyl-chloroquine in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462231/),h,272,46508,DB00608,Chloroquine
,8462231,total body clearance,The total body clearance was lower for the (R)-enantiomer [136 +/- 38 ml/min (8.16 +/- 2.28 L/h)] than for the (S)-enantiomer [237 +/- 71 ml/min (14.22 +/- 4.26 L/h)].,Stereoselective pharmacokinetic properties of chloroquine and de-ethyl-chloroquine in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462231/),[ml] / [min],136,46509,DB00608,Chloroquine
,8462231,total body clearance,The total body clearance was lower for the (R)-enantiomer [136 +/- 38 ml/min (8.16 +/- 2.28 L/h)] than for the (S)-enantiomer [237 +/- 71 ml/min (14.22 +/- 4.26 L/h)].,Stereoselective pharmacokinetic properties of chloroquine and de-ethyl-chloroquine in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462231/),[l] / [h],8.16,46510,DB00608,Chloroquine
,8462231,total body clearance,The total body clearance was lower for the (R)-enantiomer [136 +/- 38 ml/min (8.16 +/- 2.28 L/h)] than for the (S)-enantiomer [237 +/- 71 ml/min (14.22 +/- 4.26 L/h)].,Stereoselective pharmacokinetic properties of chloroquine and de-ethyl-chloroquine in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462231/),[ml] / [min],237,46511,DB00608,Chloroquine
,8462231,total body clearance,The total body clearance was lower for the (R)-enantiomer [136 +/- 38 ml/min (8.16 +/- 2.28 L/h)] than for the (S)-enantiomer [237 +/- 71 ml/min (14.22 +/- 4.26 L/h)].,Stereoselective pharmacokinetic properties of chloroquine and de-ethyl-chloroquine in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462231/),[l] / [h],14.22,46512,DB00608,Chloroquine
,8462231,volume of distribution,"Although the (R)-stereoisomer remained longer in the body, its volume of distribution (3410 +/- 720L) was lower than than that of (S)-chloroquine (4830 +/- 1490L).",Stereoselective pharmacokinetic properties of chloroquine and de-ethyl-chloroquine in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462231/),l,3410,46513,DB00608,Chloroquine
,8462231,volume of distribution,"Although the (R)-stereoisomer remained longer in the body, its volume of distribution (3410 +/- 720L) was lower than than that of (S)-chloroquine (4830 +/- 1490L).",Stereoselective pharmacokinetic properties of chloroquine and de-ethyl-chloroquine in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462231/),l,4830,46514,DB00608,Chloroquine
,8462231,Binding,Binding to total human plasma amounted to 66.6 +/- 3.3% for (S)-chloroquine and to 42.7 +/- 2.1% for the (R)-enantiomer.,Stereoselective pharmacokinetic properties of chloroquine and de-ethyl-chloroquine in humans. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462231/),%,66.6,46515,DB00608,Chloroquine
,8462231,Binding,Binding to total human plasma amounted to 66.6 +/- 3.3% for (S)-chloroquine and to 42.7 +/- 2.1% for the (R)-enantiomer.,Stereoselective pharmacokinetic properties of chloroquine and de-ethyl-chloroquine in humans. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462231/),%,42.7,46516,DB00608,Chloroquine
,8462231,AUC,"De-ethyl-chloroquine concentrations were also different for both enantiomers, resulting in a statistically significant increase in the AUC of (S)-de-ethyl-chloroquine (12.9 +/- 7.4 mg/L.h) compared with (R)-de-ethyl-chloroquine (6.29 +/- 2.18 mg/L.h).",Stereoselective pharmacokinetic properties of chloroquine and de-ethyl-chloroquine in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462231/),[mg] / [h·l],12.9,46517,DB00608,Chloroquine
,8462231,AUC,"De-ethyl-chloroquine concentrations were also different for both enantiomers, resulting in a statistically significant increase in the AUC of (S)-de-ethyl-chloroquine (12.9 +/- 7.4 mg/L.h) compared with (R)-de-ethyl-chloroquine (6.29 +/- 2.18 mg/L.h).",Stereoselective pharmacokinetic properties of chloroquine and de-ethyl-chloroquine in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462231/),[mg] / [h·l],6.29,46518,DB00608,Chloroquine
,8462231,R:S ratio,"With a daily dosage regimen, the divergent pharmacokinetic behaviour of chloroquine enantiomers generates a calculated R:S ratio of blood concentrations amounting to 1:0.7 at steady-state.",Stereoselective pharmacokinetic properties of chloroquine and de-ethyl-chloroquine in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462231/),,1,46519,DB00608,Chloroquine
,8462231,R:S ratio,"With a daily dosage regimen, the divergent pharmacokinetic behaviour of chloroquine enantiomers generates a calculated R:S ratio of blood concentrations amounting to 1:0.7 at steady-state.",Stereoselective pharmacokinetic properties of chloroquine and de-ethyl-chloroquine in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462231/),,0.7,46520,DB00608,Chloroquine
,10630270,elimination half-life,Plasma hydroxychloroquine level was 29.40 mumol/L (9.87 mg/L) 2 hours after ingestion and the elimination half-life of hydroxychloroquine was 22 hours.,Hydroxychloroquine overdose: toxicokinetics and management. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630270/),h,22,46844,DB00608,Chloroquine
,22580781,half-life,PK results showed that VN/12-1 has a half-life of 6 h.,"Murine toxicology and pharmacokinetics evaluation of retinoic acid metabolism blocking agent (RAMBA), VN/12-1. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22580781/),h,6,47431,DB00608,Chloroquine
,22580781,area under the curve (AUC),The area under the curve (AUC) for VN/12-1 was 83.78 h μg/ml.,"Murine toxicology and pharmacokinetics evaluation of retinoic acid metabolism blocking agent (RAMBA), VN/12-1. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22580781/),[h·μg] / [ml],83.78,47432,DB00608,Chloroquine
,9217701,exposure time,The exposure time for artemisinin was 3 hours twice daily and for mefloquine 24 hours.,Efficacy of artemisinin and mefloquine combinations against Plasmodium falciparum. In vitro simulation of in vivo pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9217701/),h,3,49175,DB00608,Chloroquine
,9217701,exposure time,The exposure time for artemisinin was 3 hours twice daily and for mefloquine 24 hours.,Efficacy of artemisinin and mefloquine combinations against Plasmodium falciparum. In vitro simulation of in vivo pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9217701/),,24,49176,DB00608,Chloroquine
,19188392,clearance,"The clearance and the central and peripheral volumes of distribution were 15.5 liters/h, 733 liters, and 1,630 liters, respectively.",Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19188392/),[l] / [h],15.5,51102,DB00608,Chloroquine
,19188392,central,"The clearance and the central and peripheral volumes of distribution were 15.5 liters/h, 733 liters, and 1,630 liters, respectively.",Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19188392/),[l] / [h],15.5,51103,DB00608,Chloroquine
,19188392,central,"The clearance and the central and peripheral volumes of distribution were 15.5 liters/h, 733 liters, and 1,630 liters, respectively.",Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19188392/),l,733,51104,DB00608,Chloroquine
,19188392,peripheral volumes of distribution,"The clearance and the central and peripheral volumes of distribution were 15.5 liters/h, 733 liters, and 1,630 liters, respectively.",Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19188392/),l,"1,630",51105,DB00608,Chloroquine
,32915766,flow rate,"HCQ, DCQ and DDCQ were chromatographically separated on a biphenyl column with gradient elution, at a flow rate of 500 μL/min.",Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915766/),[μl] / [min],500,51311,DB00608,Chloroquine
,32915766,analysis time,The analysis time was 8 min.,Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915766/),min,8,51312,DB00608,Chloroquine
,32915766,recoveries,"For each analyte linear calibration curves were obtained over the concentration range 50-2000 μg/L, the lower limit of quantification (LLOQ) was 13 μg/L, the inter-assay relative standard deviation (RSD) was <10% at 25, 800 and 1750 μg/L and mean recoveries were 80, 81, 78 and 62% for HCQ, d4-HCQ, DCQ and DDCQ, respectively.",Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915766/),%,80,51313,DB00608,Chloroquine
,32915766,recoveries,"For each analyte linear calibration curves were obtained over the concentration range 50-2000 μg/L, the lower limit of quantification (LLOQ) was 13 μg/L, the inter-assay relative standard deviation (RSD) was <10% at 25, 800 and 1750 μg/L and mean recoveries were 80, 81, 78 and 62% for HCQ, d4-HCQ, DCQ and DDCQ, respectively.",Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915766/),%,81,51314,DB00608,Chloroquine
,32915766,recoveries,"For each analyte linear calibration curves were obtained over the concentration range 50-2000 μg/L, the lower limit of quantification (LLOQ) was 13 μg/L, the inter-assay relative standard deviation (RSD) was <10% at 25, 800 and 1750 μg/L and mean recoveries were 80, 81, 78 and 62% for HCQ, d4-HCQ, DCQ and DDCQ, respectively.",Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915766/),%,78,51315,DB00608,Chloroquine
,32915766,recoveries,"For each analyte linear calibration curves were obtained over the concentration range 50-2000 μg/L, the lower limit of quantification (LLOQ) was 13 μg/L, the inter-assay relative standard deviation (RSD) was <10% at 25, 800 and 1750 μg/L and mean recoveries were 80, 81, 78 and 62% for HCQ, d4-HCQ, DCQ and DDCQ, respectively.",Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915766/),%,62,51316,DB00608,Chloroquine
,32054478,t1/2,"However, a significant (P < 0.05) longer t1/2 was found for NQ in male rats (192.1 ± 47.7), compared with female rats (143.9 ± 27.1).",The gender-related variability in the pharmacokinetics and antiplasmodial activity of naphthoquine in rodents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32054478/),,192.1,54822,DB00608,Chloroquine
,32054478,t1/2,"However, a significant (P < 0.05) longer t1/2 was found for NQ in male rats (192.1 ± 47.7), compared with female rats (143.9 ± 27.1).",The gender-related variability in the pharmacokinetics and antiplasmodial activity of naphthoquine in rodents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32054478/),,143.9,54823,DB00608,Chloroquine
,21801400,total MCD,The total MCD of tafenoquine required in combination regimens for radical cure was ten-fold lower (1.8 mg/kg versus 18 mg/kg) than for monotherapy.,Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21801400/),,1,55856,DB00608,Chloroquine
,21801400,maximum observed plasma concentrations,"At its MCD in combination with blood schizonticidal drugs (1.8 mg/kg), the maximum observed plasma concentrations were substantially lower than (20-84 versus 550-1,100 ng/ml) after administration of 1, 200 mg in clinical studies.",Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21801400/),[ng] / [ml],20-84,55857,DB00608,Chloroquine
,21801400,maximum observed plasma concentrations,"At its MCD in combination with blood schizonticidal drugs (1.8 mg/kg), the maximum observed plasma concentrations were substantially lower than (20-84 versus 550-1,100 ng/ml) after administration of 1, 200 mg in clinical studies.",Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21801400/),[ng] / [ml],"550-1,100",55858,DB00608,Chloroquine
,3567044,half-life,"After i.v. dosage, the half-life ranged between 144 and 298 h; the total plasma clearance was between 282 and 1130 ml min-1 and the volume of distribution between 142 and 398 1 kg-1.",The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3567044/),h,144 and 298,57663,DB00608,Chloroquine
,3567044,total plasma clearance,"After i.v. dosage, the half-life ranged between 144 and 298 h; the total plasma clearance was between 282 and 1130 ml min-1 and the volume of distribution between 142 and 398 1 kg-1.",The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3567044/),[ml] / [min],282 and 1130,57664,DB00608,Chloroquine
,3567044,volume of distribution,"After i.v. dosage, the half-life ranged between 144 and 298 h; the total plasma clearance was between 282 and 1130 ml min-1 and the volume of distribution between 142 and 398 1 kg-1.",The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3567044/),[1] / [kg],142 and 398,57665,DB00608,Chloroquine
,3567044,total urinary recovery,The estimated total urinary recovery of chloroquine and desethylchloroquine was 77% of the oral dose.,The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3567044/),%,77,57666,DB00608,Chloroquine
up to,2662478,apparent volumes of distribution,"Bioavailability is essentially complete, apparent volumes of distribution range up to 800 L/kg, and the pharmacokinetic data are generally accomodated by three compartment models.",Recent developments in the understanding of the pharmacokinetics and mechanism of action of chloroquine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2662478/),[l] / [kg],800,58765,DB00608,Chloroquine
,2662478,Half-lives,"Half-lives for the terminal component are 1 to 2 months, but the terminal phases may be of minor importance in effectiveness.",Recent developments in the understanding of the pharmacokinetics and mechanism of action of chloroquine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2662478/),month,1 to 2,58766,DB00608,Chloroquine
,17213921,oral clearance,"However, AQ-13 was cleared more rapidly than CQ (respectively, median oral clearance 14.0-14.7 l/h versus 9.5-11.3 l/h; p < or = 0.03).","Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213921/),[l] / [h],14.0-14.7,59164,DB00608,Chloroquine
,17213921,oral clearance,"However, AQ-13 was cleared more rapidly than CQ (respectively, median oral clearance 14.0-14.7 l/h versus 9.5-11.3 l/h; p < or = 0.03).","Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17213921/),[l] / [h],9.5-11.3,59165,DB00608,Chloroquine
,2386369,50% inhibitory concentration,"Recently, chloroquine-susceptible and chloroquine-resistant clones of Plasmodium falciparum were shown to be inhibited by 5-fluoroorotate, with a 50% inhibitory concentration of 6 nM in vitro.",Antimalarial activity of a combination of 5-fluoroorotate and uridine in mice. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2386369/),nM,6,61614,DB00608,Chloroquine
,33277347,plasma half-life,"The PBPK model in rat featured plasma and red blood cell (RBC) concentrations, extensive and apparent nonlinear tissue distribution, fitted hepatic and renal intrinsic clearances, and a plasma half-life of about 1 day.",Physiologically Based Pharmacokinetics of Lysosomotropic Chloroquine in Rat and Human. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33277347/),d,1,62178,DB00608,Chloroquine
,33277347,RBC-to-plasma ratio,The RBC-to-plasma ratio of 11.6 was assumed to reflect cell lipid partitioning.,Physiologically Based Pharmacokinetics of Lysosomotropic Chloroquine in Rat and Human. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33277347/),,11.6,62179,DB00608,Chloroquine
,33277347,volume of distribution (Vss) ratio,The human-to-rat volume of distribution (Vss) ratio of 7 used to scale rat tissue partitioning to human along with estimation of hepatic clearance allowed excellent fitting of oral-dose PK (150-600 mg) of CQ with a 50-day half-life in humans.,Physiologically Based Pharmacokinetics of Lysosomotropic Chloroquine in Rat and Human. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33277347/),,7,62180,DB00608,Chloroquine
,33277347,half-life,The human-to-rat volume of distribution (Vss) ratio of 7 used to scale rat tissue partitioning to human along with estimation of hepatic clearance allowed excellent fitting of oral-dose PK (150-600 mg) of CQ with a 50-day half-life in humans.,Physiologically Based Pharmacokinetics of Lysosomotropic Chloroquine in Rat and Human. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33277347/),d,50,62181,DB00608,Chloroquine
,33134609,tmax,"Additionally, pharmacokinetics demonstrated rapid absorption of compound 3 (tmax = 5.0 min) after intragastric administration of 3-encapsulated nanoemulsion at a dose of 0.02 mg/kg in mice, with penetration of compound 3 to deep compartments.",Azacarbazole n-3 and n-6 polyunsaturated fatty acids ethyl esters nanoemulsion with enhanced efficacy against Plasmodium falciparum. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33134609/),min,5.0,64263,DB00608,Chloroquine
,21466937,flow rate,"Both were separated from the internal standard quinine on a reversed phase C18 column, with the mobile phase consisting of a mixture of 1% diethylamine, acetonitrile and methanol (20:55:25, v:v:v) running at a flow rate of 1.0ml/min.",HPLC with ultraviolet detection for the determination of chloroquine and desethylchloroquine in whole blood and finger-prick capillary blood dried on filter paper. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466937/),[ml] / [min],1.0,66829,DB00608,Chloroquine
,21466937,Retention times,"Retention times of QN, DECQ and CQ were 4.5, 5.7 and 6.4min, respectively.",HPLC with ultraviolet detection for the determination of chloroquine and desethylchloroquine in whole blood and finger-prick capillary blood dried on filter paper. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466937/),min,4.5,66830,DB00608,Chloroquine
,21466937,Retention times,"Retention times of QN, DECQ and CQ were 4.5, 5.7 and 6.4min, respectively.",HPLC with ultraviolet detection for the determination of chloroquine and desethylchloroquine in whole blood and finger-prick capillary blood dried on filter paper. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466937/),min,5.7,66831,DB00608,Chloroquine
,21466937,Retention times,"Retention times of QN, DECQ and CQ were 4.5, 5.7 and 6.4min, respectively.",HPLC with ultraviolet detection for the determination of chloroquine and desethylchloroquine in whole blood and finger-prick capillary blood dried on filter paper. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466937/),min,6.4,66832,DB00608,Chloroquine
,21466937,Limit of quantification (LOQ),Limit of quantification (LOQ) for both CQ and DECQ was accepted as 50ng/ml using 80μl DBS sample and 25ng/ml using 150μl whole blood sample.,HPLC with ultraviolet detection for the determination of chloroquine and desethylchloroquine in whole blood and finger-prick capillary blood dried on filter paper. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466937/),[ng] / [ml],50,66833,DB00608,Chloroquine
,21466937,Limit of quantification (LOQ),Limit of quantification (LOQ) for both CQ and DECQ was accepted as 50ng/ml using 80μl DBS sample and 25ng/ml using 150μl whole blood sample.,HPLC with ultraviolet detection for the determination of chloroquine and desethylchloroquine in whole blood and finger-prick capillary blood dried on filter paper. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466937/),[ng] / [ml],25,66834,DB00608,Chloroquine
,21466937,recoveries,"The mean recoveries for CQ, DECQ and internal standard for both whole blood and DBS were between 74 and 87%.",HPLC with ultraviolet detection for the determination of chloroquine and desethylchloroquine in whole blood and finger-prick capillary blood dried on filter paper. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466937/),%,74 and 87,66835,DB00608,Chloroquine
,2055762,maximum daily dosage,Retinopathy can be avoided by observing a maximum daily dosage of 3.5-4 mg/kg ideal body weight for chloroquine and 6-6.5 mg/kg for hydroxychloroquine.,[Chloroquine and hydroxychloroquine: side effect profile of important therapeutic drugs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2055762/),,3,67745,DB00608,Chloroquine
,32968954,absorption rate constant,"The estimated parameter values were 9.3/h, 860.8 L, and 15.7 L/h for the absorption rate constant, the central compartment volume, and the clearance, respectively.",Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32968954/),1/[h],9.3,68470,DB00608,Chloroquine
,32968954,absorption rate constant,"The estimated parameter values were 9.3/h, 860.8 L, and 15.7 L/h for the absorption rate constant, the central compartment volume, and the clearance, respectively.",Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32968954/),l,860.8,68471,DB00608,Chloroquine
,32968954,central compartment volume,"The estimated parameter values were 9.3/h, 860.8 L, and 15.7 L/h for the absorption rate constant, the central compartment volume, and the clearance, respectively.",Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32968954/),l,860.8,68472,DB00608,Chloroquine
,32968954,absorption rate constant,"The estimated parameter values were 9.3/h, 860.8 L, and 15.7 L/h for the absorption rate constant, the central compartment volume, and the clearance, respectively.",Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32968954/),[l] / [h],15.7,68473,DB00608,Chloroquine
,32968954,central compartment volume,"The estimated parameter values were 9.3/h, 860.8 L, and 15.7 L/h for the absorption rate constant, the central compartment volume, and the clearance, respectively.",Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32968954/),[l] / [h],15.7,68474,DB00608,Chloroquine
,32968954,clearance,"The estimated parameter values were 9.3/h, 860.8 L, and 15.7 L/h for the absorption rate constant, the central compartment volume, and the clearance, respectively.",Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32968954/),[l] / [h],15.7,68475,DB00608,Chloroquine
,32968954,bioavailability factor,The bioavailability factor was fixed to 0.74 based on previously published models.,Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32968954/),,0.74,68476,DB00608,Chloroquine
,18186973,bio-availability,"The bio-availability of CQ was also significantly increased in the presence of CP, with the mean value for the area under the curve, of erythrocytic concentration v. time, increasing from 99,921 to 214,516 ng/ml.h (P=0.001).",Comparative study of interactions between chloroquine and chlorpheniramine or promethazine in healthy volunteers: a potential combination-therapy phenomenon for resuscitating chloroquine for malaria treatment in Africa. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18186973/),[ng] / [h·ml],"99,921",69764,DB00608,Chloroquine
,18186973,bio-availability,"The bio-availability of CQ was also significantly increased in the presence of CP, with the mean value for the area under the curve, of erythrocytic concentration v. time, increasing from 99,921 to 214,516 ng/ml.h (P=0.001).",Comparative study of interactions between chloroquine and chlorpheniramine or promethazine in healthy volunteers: a potential combination-therapy phenomenon for resuscitating chloroquine for malaria treatment in Africa. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18186973/),[ng] / [h·ml],"214,516",69765,DB00608,Chloroquine
,18186973,area under the curve,"The bio-availability of CQ was also significantly increased in the presence of CP, with the mean value for the area under the curve, of erythrocytic concentration v. time, increasing from 99,921 to 214,516 ng/ml.h (P=0.001).",Comparative study of interactions between chloroquine and chlorpheniramine or promethazine in healthy volunteers: a potential combination-therapy phenomenon for resuscitating chloroquine for malaria treatment in Africa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18186973/),[ng] / [h·ml],"99,921",69766,DB00608,Chloroquine
,18186973,area under the curve,"The bio-availability of CQ was also significantly increased in the presence of CP, with the mean value for the area under the curve, of erythrocytic concentration v. time, increasing from 99,921 to 214,516 ng/ml.h (P=0.001).",Comparative study of interactions between chloroquine and chlorpheniramine or promethazine in healthy volunteers: a potential combination-therapy phenomenon for resuscitating chloroquine for malaria treatment in Africa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18186973/),[ng] / [h·ml],"214,516",69767,DB00608,Chloroquine
,18186973,half-life,"The mean half-life of CQ in the erythrocytes also increased when CP was used, from 51 to 100 h, but this change was not statistically significant (P=0.83).",Comparative study of interactions between chloroquine and chlorpheniramine or promethazine in healthy volunteers: a potential combination-therapy phenomenon for resuscitating chloroquine for malaria treatment in Africa. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18186973/),h,51,69768,DB00608,Chloroquine
,18186973,half-life,"The mean half-life of CQ in the erythrocytes also increased when CP was used, from 51 to 100 h, but this change was not statistically significant (P=0.83).",Comparative study of interactions between chloroquine and chlorpheniramine or promethazine in healthy volunteers: a potential combination-therapy phenomenon for resuscitating chloroquine for malaria treatment in Africa. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18186973/),h,100,69769,DB00608,Chloroquine
,3208546,maximum plasma chlorproguanil concentration,The mean maximum plasma chlorproguanil concentration was 36.7 +/- (SD) 7.9 ng/ml and was reached at 3.8 +/- 1.3 h.,Pharmacokinetics of chlorproguanil in man after a single oral dose of Lapudrine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3208546/),[ng] / [ml],36.7,76147,DB00608,Chloroquine
,3208546,elimination half-life,The chlorproguanil elimination half-life was 17.5 +/- 6.7 h and its plasma clearance was 1.28 +/- 0.12 l/h/kg.,Pharmacokinetics of chlorproguanil in man after a single oral dose of Lapudrine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3208546/),h,17.5,76148,DB00608,Chloroquine
,3208546,plasma clearance,The chlorproguanil elimination half-life was 17.5 +/- 6.7 h and its plasma clearance was 1.28 +/- 0.12 l/h/kg.,Pharmacokinetics of chlorproguanil in man after a single oral dose of Lapudrine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3208546/),[l] / [h·kg],1.28,76149,DB00608,Chloroquine
,3208546,whole blood to plasma ratio,The mean whole blood to plasma ratio was 3.1 at 4 h after dosing.,Pharmacokinetics of chlorproguanil in man after a single oral dose of Lapudrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3208546/),,3.1,76150,DB00608,Chloroquine
,3208546,t1/2,An excretion rate-time plot from urine data shows a rapid (t1/2 = 20 h) and a slow phase (t1/2 = 51 h) in the elimination of chlorcycloguanil.,Pharmacokinetics of chlorproguanil in man after a single oral dose of Lapudrine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3208546/),h,20,76151,DB00608,Chloroquine
,3208546,t1/2,An excretion rate-time plot from urine data shows a rapid (t1/2 = 20 h) and a slow phase (t1/2 = 51 h) in the elimination of chlorcycloguanil.,Pharmacokinetics of chlorproguanil in man after a single oral dose of Lapudrine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3208546/),h,51,76152,DB00608,Chloroquine
,12665265,"time of peak plasma concentration, (t(max))","The time of peak plasma concentration, (t(max)) after the first dose was found to be 3.5 hours while peak plasma concentrations, (Cp(max)) were obtained at 2, 28, and 52 hours with values of 204.",Therapeutic monitoring of chloroquine in pregnant women with malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12665265/),h,3.5,76258,DB00608,Chloroquine
,12665265,"peak plasma concentrations, (Cp(max))","The time of peak plasma concentration, (t(max)) after the first dose was found to be 3.5 hours while peak plasma concentrations, (Cp(max)) were obtained at 2, 28, and 52 hours with values of 204.",Therapeutic monitoring of chloroquine in pregnant women with malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12665265/),h,2,76259,DB00608,Chloroquine
,12665265,"peak plasma concentrations, (Cp(max))","The time of peak plasma concentration, (t(max)) after the first dose was found to be 3.5 hours while peak plasma concentrations, (Cp(max)) were obtained at 2, 28, and 52 hours with values of 204.",Therapeutic monitoring of chloroquine in pregnant women with malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12665265/),h,28,76260,DB00608,Chloroquine
,12665265,"peak plasma concentrations, (Cp(max))","The time of peak plasma concentration, (t(max)) after the first dose was found to be 3.5 hours while peak plasma concentrations, (Cp(max)) were obtained at 2, 28, and 52 hours with values of 204.",Therapeutic monitoring of chloroquine in pregnant women with malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12665265/),h,52,76261,DB00608,Chloroquine
,12665265,"peak plasma concentrations, (Cp(max))","The time of peak plasma concentration, (t(max)) after the first dose was found to be 3.5 hours while peak plasma concentrations, (Cp(max)) were obtained at 2, 28, and 52 hours with values of 204.",Therapeutic monitoring of chloroquine in pregnant women with malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12665265/),h,204,76262,DB00608,Chloroquine
,1545355,fraction absorbed,"The mean fraction absorbed (+/- SD) was 0.67 +/- 0.12, which was not significantly different from that reported previously in a conventional bioavailability study (p = 0.22).",Bioavailability of hydroxychloroquine tablets assessed with deconvolution techniques. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545355/),,0.67,84587,DB00608,Chloroquine
,1545355,absorption half-life,The mean absorption half-life was calculated to be 4.0 +/- 1.3 h.,Bioavailability of hydroxychloroquine tablets assessed with deconvolution techniques. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545355/),h,4.0,84588,DB00608,Chloroquine
,1545355,lag time before absorption commenced,The mean lag time before absorption commenced was 0.57 +/- 0.30 h.,Bioavailability of hydroxychloroquine tablets assessed with deconvolution techniques. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545355/),h,0.57,84589,DB00608,Chloroquine
,1545355,fraction of the dose absorbed,The fraction of the dose absorbed ranged from 0.44 to 0.86.,Bioavailability of hydroxychloroquine tablets assessed with deconvolution techniques. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545355/),,0.44 to 0.86,84590,DB00608,Chloroquine
,8983859,t1/2z,"There is increased plasma protein binding, predominantly to alpha 1-acid glycoprotein, and elimination half-lives (in healthy adults quinine t1/2z = 11 hours, quinidine t1/2z = 8 hours) are prolonged by 50%.","Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983859/),h,11,87263,DB00608,Chloroquine
,8983859,t1/2z,"There is increased plasma protein binding, predominantly to alpha 1-acid glycoprotein, and elimination half-lives (in healthy adults quinine t1/2z = 11 hours, quinidine t1/2z = 8 hours) are prolonged by 50%.","Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983859/),h,8,87264,DB00608,Chloroquine
more,8983859,bioavailability,Quinine is well absorbed by mouth or following intramuscular injection even in severe cases of malaria (estimated bioavailability more than 85%).,"Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983859/),%,85,87265,DB00608,Chloroquine
more,8983859,total apparent volume of distribution (Vd),"Chloroquine is extensively distributed with an enormous total apparent volume of distribution (Vd) more than 100 L/kg, and a terminal elimination half-life of 1 to 2 months.","Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983859/),[l] / [kg],100,87266,DB00608,Chloroquine
,8983859,terminal elimination half-life,"Chloroquine is extensively distributed with an enormous total apparent volume of distribution (Vd) more than 100 L/kg, and a terminal elimination half-life of 1 to 2 months.","Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983859/),month,1 to 2,87267,DB00608,Chloroquine
exceeds,8983859,Oral bioavailability,Oral bioavailability exceeds 75%.,"Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983859/),%,75,87268,DB00608,Chloroquine
,8983859,Vd,Its pharmacokinetic properties are similar to these of chloroquine although the Vd is smaller (17 to 34 L/kg) and the terminal elimination half-life is 1 to 3 weeks.,"Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983859/),[l] / [kg],17 to 34,87269,DB00608,Chloroquine
,8983859,terminal elimination half-life,Its pharmacokinetic properties are similar to these of chloroquine although the Vd is smaller (17 to 34 L/kg) and the terminal elimination half-life is 1 to 3 weeks.,"Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983859/),weeks,1 to 3,87270,DB00608,Chloroquine
,3555581,fever,"All patients responded to treatment with fever and parasite clearance times of 61 +/- 29 h (mean +/- s.d.) and 52 +/- 24 h, respectively.",Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555581/),h,61,87380,DB00608,Chloroquine
,3555581,parasite clearance times,"All patients responded to treatment with fever and parasite clearance times of 61 +/- 29 h (mean +/- s.d.) and 52 +/- 24 h, respectively.",Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555581/),h,61,87381,DB00608,Chloroquine
,3555581,parasite clearance times,"All patients responded to treatment with fever and parasite clearance times of 61 +/- 29 h (mean +/- s.d.) and 52 +/- 24 h, respectively.",Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555581/),h,52,87382,DB00608,Chloroquine
,3555581,apparent absorption half-time (t1/2abs),The mean apparent absorption half-time (t1/2abs) of mefloquine was 4.89 h (range 2.25-9.72) and mean peak plasma concentration was 1815 ng ml-1 (range 725-3368).,Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555581/),h,4.89,87383,DB00608,Chloroquine
,3555581,peak plasma concentration,The mean apparent absorption half-time (t1/2abs) of mefloquine was 4.89 h (range 2.25-9.72) and mean peak plasma concentration was 1815 ng ml-1 (range 725-3368).,Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555581/),[ng] / [ml],1815,87384,DB00608,Chloroquine
,3555581,Peak plasma mefloquine concentrations,"Peak plasma mefloquine concentrations in three patients who vomited within 2 h of treatment were 725, 956 and 1972 ng ml-1.",Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555581/),[ng] / [ml],725,87385,DB00608,Chloroquine
,3555581,Peak plasma mefloquine concentrations,"Peak plasma mefloquine concentrations in three patients who vomited within 2 h of treatment were 725, 956 and 1972 ng ml-1.",Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555581/),[ng] / [ml],956,87386,DB00608,Chloroquine
,3555581,Peak plasma mefloquine concentrations,"Peak plasma mefloquine concentrations in three patients who vomited within 2 h of treatment were 725, 956 and 1972 ng ml-1.",Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555581/),[ng] / [ml],1972,87387,DB00608,Chloroquine
,15273091,rates of clearance,"The rates of clearance of oritavancin and latex beads were comparable (150 and 120 microl x mg of protein(-1) x h(-1), respectively) and were approximately 200 times higher than that of horseradish peroxidase.",Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15273091/),[-1·mg·μl] / [h],150,89144,DB00608,Chloroquine
,15273091,rates of clearance,"The rates of clearance of oritavancin and latex beads were comparable (150 and 120 microl x mg of protein(-1) x h(-1), respectively) and were approximately 200 times higher than that of horseradish peroxidase.",Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15273091/),[-1·mg·μl] / [h],120,89145,DB00608,Chloroquine
,15273091,MIC,"Oritavancin was bactericidal against intracellular Staphylococcus aureus (phagolysosomal infection) but was unable to control the intracellular growth of Listeria monocytogenes (cytosolic infection), even though its cellular concentration largely exceeded the MIC (0.02 mg/liter) and minimal bactericidal concentration (2 mg/liter).",Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15273091/),[mg] / [l],0.02,89146,DB00608,Chloroquine
,15273091,minimal bactericidal concentration,"Oritavancin was bactericidal against intracellular Staphylococcus aureus (phagolysosomal infection) but was unable to control the intracellular growth of Listeria monocytogenes (cytosolic infection), even though its cellular concentration largely exceeded the MIC (0.02 mg/liter) and minimal bactericidal concentration (2 mg/liter).",Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15273091/),[mg] / [l],2,89147,DB00608,Chloroquine
,6976848,plasma elimination half-life,The plasma elimination half-life was about 4 h.,Studies on the pharmacokinetics of primaquine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6976848/),h,4,91171,DB00608,Chloroquine
,2891831,urinary excretion,"The total estimated urinary excretion of desethylchloroquine and bisdesethylchloroquine was 25 and 64% respectively of the administered dose, with the maximum urinary excretion occurring on the first day.",Distribution and urinary excretion of the desethylmetabolites of chloroquine in the rat. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891831/),%,25,94058,DB00608,Chloroquine
,2891831,urinary excretion,"The total estimated urinary excretion of desethylchloroquine and bisdesethylchloroquine was 25 and 64% respectively of the administered dose, with the maximum urinary excretion occurring on the first day.",Distribution and urinary excretion of the desethylmetabolites of chloroquine in the rat. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891831/),%,64,94059,DB00608,Chloroquine
,7826832,fever,"All patients showed a rapid initial response to the treatment with median (range) values of fever and parasite clearance times of 13.7 (2-47) and 58 (33-38) h, respectively.",The pharmacokinetics of chloroquine in healthy Thai subjects and patients with Plasmodium vivax malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826832/),h,13.7,94153,DB00608,Chloroquine
,7826832,parasite clearance times,"All patients showed a rapid initial response to the treatment with median (range) values of fever and parasite clearance times of 13.7 (2-47) and 58 (33-38) h, respectively.",The pharmacokinetics of chloroquine in healthy Thai subjects and patients with Plasmodium vivax malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826832/),h,58,94154,DB00608,Chloroquine
,7826832,Cmax,"In the patients, the median range Cmax value was significantly higher (1547 (996-2446) vs 838 (656-1587) ng ml-1), and AUC(0,28d) was greater (281 (250-515) vs 122 (103-182) micrograms ml-1 h).",The pharmacokinetics of chloroquine in healthy Thai subjects and patients with Plasmodium vivax malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826832/),[ng] / [ml],1547,94155,DB00608,Chloroquine
,7826832,Cmax,"In the patients, the median range Cmax value was significantly higher (1547 (996-2446) vs 838 (656-1587) ng ml-1), and AUC(0,28d) was greater (281 (250-515) vs 122 (103-182) micrograms ml-1 h).",The pharmacokinetics of chloroquine in healthy Thai subjects and patients with Plasmodium vivax malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826832/),[ng] / [ml],838,94156,DB00608,Chloroquine
,7826832,"AUC(0,28d)","In the patients, the median range Cmax value was significantly higher (1547 (996-2446) vs 838 (656-1587) ng ml-1), and AUC(0,28d) was greater (281 (250-515) vs 122 (103-182) micrograms ml-1 h).",The pharmacokinetics of chloroquine in healthy Thai subjects and patients with Plasmodium vivax malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826832/),[h·μg] / [ml],281,94157,DB00608,Chloroquine
,7826832,"AUC(0,28d)","In the patients, the median range Cmax value was significantly higher (1547 (996-2446) vs 838 (656-1587) ng ml-1), and AUC(0,28d) was greater (281 (250-515) vs 122 (103-182) micrograms ml-1 h).",The pharmacokinetics of chloroquine in healthy Thai subjects and patients with Plasmodium vivax malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826832/),[h·μg] / [ml],122,94158,DB00608,Chloroquine
,7826832,"(AUC(0,28d)","In addition, the median (AUC(0,28d) of DECQ was significantly greater (170 (72-265) vs 77 (49-140) micrograms ml-1 h).",The pharmacokinetics of chloroquine in healthy Thai subjects and patients with Plasmodium vivax malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826832/),[h·μg] / [ml],170,94159,DB00608,Chloroquine
,7826832,"(AUC(0,28d)","In addition, the median (AUC(0,28d) of DECQ was significantly greater (170 (72-265) vs 77 (49-140) micrograms ml-1 h).",The pharmacokinetics of chloroquine in healthy Thai subjects and patients with Plasmodium vivax malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826832/),[h·μg] / [ml],77,94160,DB00608,Chloroquine
,20086162,area under the plasma concentration-time curve,"Pregnant subjects had significantly lower area under the plasma concentration-time curve for both CQ (35,750 versus 47,892 microg.h/liter, P < 0.001) and DECQ (23,073 versus 41,584 microg.h/liter, P < 0.001), reflecting significant differences in elimination half-lives and in volumes of distribution and clearances relative to bioavailability.",Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086162/),[h·μg] / [l],"35,750",96813,DB00608,Chloroquine
,20086162,area under the plasma concentration-time curve,"Pregnant subjects had significantly lower area under the plasma concentration-time curve for both CQ (35,750 versus 47,892 microg.h/liter, P < 0.001) and DECQ (23,073 versus 41,584 microg.h/liter, P < 0.001), reflecting significant differences in elimination half-lives and in volumes of distribution and clearances relative to bioavailability.",Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086162/),[h·μg] / [l],"47,892",96814,DB00608,Chloroquine
,20086162,area under the plasma concentration-time curve,"Pregnant subjects had significantly lower area under the plasma concentration-time curve for both CQ (35,750 versus 47,892 microg.h/liter, P < 0.001) and DECQ (23,073 versus 41,584 microg.h/liter, P < 0.001), reflecting significant differences in elimination half-lives and in volumes of distribution and clearances relative to bioavailability.",Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086162/),[h·μg] / [l],"23,073",96815,DB00608,Chloroquine
,20086162,area under the plasma concentration-time curve,"Pregnant subjects had significantly lower area under the plasma concentration-time curve for both CQ (35,750 versus 47,892 microg.h/liter, P < 0.001) and DECQ (23,073 versus 41,584 microg.h/liter, P < 0.001), reflecting significant differences in elimination half-lives and in volumes of distribution and clearances relative to bioavailability.",Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086162/),[h·μg] / [l],"41,584",96816,DB00608,Chloroquine
,8156285,fraction absorbed,The mean fraction absorbed from the tablet was 0.79 (range 0.39 to 1.27).,Bioavailability of hydroxychloroquine tablets in patients with rheumatoid arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8156285/),,0.79,96933,DB00608,Chloroquine
,8156285,absorption lag-time,The mean absorption lag-time was 1.3 h (range 0.5 to 3.7 h) and the mean time for 50% absorption was 4.3 h (range 1.9 to 10.3 h).,Bioavailability of hydroxychloroquine tablets in patients with rheumatoid arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8156285/),h,1.3,96934,DB00608,Chloroquine
,8156285,time for 50% absorption,The mean absorption lag-time was 1.3 h (range 0.5 to 3.7 h) and the mean time for 50% absorption was 4.3 h (range 1.9 to 10.3 h).,Bioavailability of hydroxychloroquine tablets in patients with rheumatoid arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8156285/),h,4.3,96935,DB00608,Chloroquine
,27226909,area under the concentration-time curve (AUC),"The mean area under the concentration-time curve (AUC) was 2,108.9 versus 2,797.4 ng/hour/mL, mean peak plasma concentration (Cmax) was 415.6 versus 508.7 ng/mL and mean time to reach Cmax was 3.8 versus 3.6 hours for controls in phase one versus phase two, respectively; both AUC and Cmax levels were significantly reduced by khat-chewing (P <0.050).","Effect of Khat (Catha edulis) Use on the Bioavailability, Plasma Levels and Antimalarial Activity of Chloroquine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27226909/),[ng] / [h·ml],"2,108.9",98670,DB00608,Chloroquine
,27226909,area under the concentration-time curve (AUC),"The mean area under the concentration-time curve (AUC) was 2,108.9 versus 2,797.4 ng/hour/mL, mean peak plasma concentration (Cmax) was 415.6 versus 508.7 ng/mL and mean time to reach Cmax was 3.8 versus 3.6 hours for controls in phase one versus phase two, respectively; both AUC and Cmax levels were significantly reduced by khat-chewing (P <0.050).","Effect of Khat (Catha edulis) Use on the Bioavailability, Plasma Levels and Antimalarial Activity of Chloroquine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27226909/),[ng] / [h·ml],"2,797.4",98671,DB00608,Chloroquine
,27226909,peak plasma concentration (Cmax),"The mean area under the concentration-time curve (AUC) was 2,108.9 versus 2,797.4 ng/hour/mL, mean peak plasma concentration (Cmax) was 415.6 versus 508.7 ng/mL and mean time to reach Cmax was 3.8 versus 3.6 hours for controls in phase one versus phase two, respectively; both AUC and Cmax levels were significantly reduced by khat-chewing (P <0.050).","Effect of Khat (Catha edulis) Use on the Bioavailability, Plasma Levels and Antimalarial Activity of Chloroquine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27226909/),[ng] / [ml],415.6,98672,DB00608,Chloroquine
,27226909,peak plasma concentration (Cmax),"The mean area under the concentration-time curve (AUC) was 2,108.9 versus 2,797.4 ng/hour/mL, mean peak plasma concentration (Cmax) was 415.6 versus 508.7 ng/mL and mean time to reach Cmax was 3.8 versus 3.6 hours for controls in phase one versus phase two, respectively; both AUC and Cmax levels were significantly reduced by khat-chewing (P <0.050).","Effect of Khat (Catha edulis) Use on the Bioavailability, Plasma Levels and Antimalarial Activity of Chloroquine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27226909/),[ng] / [ml],508.7,98673,DB00608,Chloroquine
,27226909,time to reach Cmax,"The mean area under the concentration-time curve (AUC) was 2,108.9 versus 2,797.4 ng/hour/mL, mean peak plasma concentration (Cmax) was 415.6 versus 508.7 ng/mL and mean time to reach Cmax was 3.8 versus 3.6 hours for controls in phase one versus phase two, respectively; both AUC and Cmax levels were significantly reduced by khat-chewing (P <0.050).","Effect of Khat (Catha edulis) Use on the Bioavailability, Plasma Levels and Antimalarial Activity of Chloroquine. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27226909/),h,3.8,98674,DB00608,Chloroquine
,27226909,time to reach Cmax,"The mean area under the concentration-time curve (AUC) was 2,108.9 versus 2,797.4 ng/hour/mL, mean peak plasma concentration (Cmax) was 415.6 versus 508.7 ng/mL and mean time to reach Cmax was 3.8 versus 3.6 hours for controls in phase one versus phase two, respectively; both AUC and Cmax levels were significantly reduced by khat-chewing (P <0.050).","Effect of Khat (Catha edulis) Use on the Bioavailability, Plasma Levels and Antimalarial Activity of Chloroquine. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27226909/),h,3.6,98675,DB00608,Chloroquine
,27226909,concentrations,"For khat- versus non-khat-chewing malaria patients, mean plasma CQ concentrations were 266.4 ng/mL versus 427.5 ng/mL (P <0.001).","Effect of Khat (Catha edulis) Use on the Bioavailability, Plasma Levels and Antimalarial Activity of Chloroquine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27226909/),[ng] / [ml],266.4,98676,DB00608,Chloroquine
,27226909,concentrations,"For khat- versus non-khat-chewing malaria patients, mean plasma CQ concentrations were 266.4 ng/mL versus 427.5 ng/mL (P <0.001).","Effect of Khat (Catha edulis) Use on the Bioavailability, Plasma Levels and Antimalarial Activity of Chloroquine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27226909/),[ng] / [ml],427.5,98677,DB00608,Chloroquine
,15202566,maximum concentration,The maximum concentration of CPMQ was 0.32+/-0.13 microg/mL at 4 h.,Pharmacokinetics of primaquine and carboxyprimaquine in Korean patients with vivax malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15202566/),[μg] / [ml],0.32,99015,DB00608,Chloroquine
,15202566,elimination half-life,"The elimination half-life was 3.76+/-1.8 h and 15.7+/-12.2 h, for PMQ and CPMQ, respectively.",Pharmacokinetics of primaquine and carboxyprimaquine in Korean patients with vivax malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15202566/),h,3.76,99016,DB00608,Chloroquine
,15202566,elimination half-life,"The elimination half-life was 3.76+/-1.8 h and 15.7+/-12.2 h, for PMQ and CPMQ, respectively.",Pharmacokinetics of primaquine and carboxyprimaquine in Korean patients with vivax malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15202566/),h,15.7,99017,DB00608,Chloroquine
,26928448,parasitaemia,"Blood samples were collected from a total of 75 (8 Thais and 67 Burmeses; 36 males and 39 females; aged 17-52 years) patients with mono-infection with P. vivax malaria [median (95 % CI) admission parasitaemia 4898 (1206-29,480)/µL] following treatment with a three-day course of chloroquine (25 mg/kg body weight chloroquine phosphate over 3 days).",Population pharmacokinetics of a three-day chloroquine treatment in patients with Plasmodium vivax infection on the Thai-Myanmar border. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26928448/),,4898,99603,DB00608,Chloroquine
,29207305,flow rate,"The chromatographic separation and detection of analytes were achieved on a reversed phase Thermo Aquasil C18 (50×4.6mm, 3μ) column, with gradient elution using 0.2% formic acid and 0.1% formic acid in methanol as mobile phase at a flow rate of 0.5mL/min.",Simultaneous quantitation of hydroxychloroquine and its metabolites in mouse blood and tissues using LC-ESI-MS/MS: An application for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29207305/),[ml] / [min],0.5,101802,DB00608,Chloroquine
,3580252,Peak plasma chloroquine concentrations,Peak plasma chloroquine concentrations in the children with kwashiorkor varied from 9 ng ml-1 to 95 ng ml-1 (mean 40 +/- 34 ng ml-1).,Single dose disposition of chloroquine in kwashiorkor and normal children--evidence for decreased absorption in kwashiorkor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580252/),[ng] / [ml],95,105336,DB00608,Chloroquine
,3580252,Peak plasma chloroquine concentrations,Peak plasma chloroquine concentrations in the children with kwashiorkor varied from 9 ng ml-1 to 95 ng ml-1 (mean 40 +/- 34 ng ml-1).,Single dose disposition of chloroquine in kwashiorkor and normal children--evidence for decreased absorption in kwashiorkor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580252/),[ng] / [ml],40,105337,DB00608,Chloroquine
,3580252,Peak chloroquine concentrations,Peak chloroquine concentrations in the controls varied between 69 ng ml-1 and 330 ng ml-1 (mean 134 +/- 99 ng ml-1).,Single dose disposition of chloroquine in kwashiorkor and normal children--evidence for decreased absorption in kwashiorkor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580252/),[ng] / [ml],330,105338,DB00608,Chloroquine
,3580252,Peak chloroquine concentrations,Peak chloroquine concentrations in the controls varied between 69 ng ml-1 and 330 ng ml-1 (mean 134 +/- 99 ng ml-1).,Single dose disposition of chloroquine in kwashiorkor and normal children--evidence for decreased absorption in kwashiorkor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580252/),[ng] / [ml],134,105339,DB00608,Chloroquine
,3580252,Peak plasma desethylchloroquine concentrations,Peak plasma desethylchloroquine concentrations in the children with kwashiorkor varied between 3 and 13 ng ml-1 (mean 6 +/- 9 ng ml-1) while in the controls the concentrations varied between 14 and 170 ng ml-1 (mean 50 +/- 61 ng ml-1).,Single dose disposition of chloroquine in kwashiorkor and normal children--evidence for decreased absorption in kwashiorkor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580252/),[ng] / [ml],6,105340,DB00608,Chloroquine
,3580252,Peak plasma desethylchloroquine concentrations,Peak plasma desethylchloroquine concentrations in the children with kwashiorkor varied between 3 and 13 ng ml-1 (mean 6 +/- 9 ng ml-1) while in the controls the concentrations varied between 14 and 170 ng ml-1 (mean 50 +/- 61 ng ml-1).,Single dose disposition of chloroquine in kwashiorkor and normal children--evidence for decreased absorption in kwashiorkor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580252/),[ng] / [ml],50,105341,DB00608,Chloroquine
,7654492,Volume of distribution,"Volume of distribution, elimination half-life and clearance were not different for the three regimens, ranging from 250-302 l kg-1, 374-479 h and 0.44-0.58 l h-1 kg-1 respectively.",The pharmacokinetics of three multiple dose regimens of chloroquine: implications for malaria chemoprophylaxis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654492/),[l] / [kg],250-302,106188,DB00608,Chloroquine
,7654492,elimination half-life,"Volume of distribution, elimination half-life and clearance were not different for the three regimens, ranging from 250-302 l kg-1, 374-479 h and 0.44-0.58 l h-1 kg-1 respectively.",The pharmacokinetics of three multiple dose regimens of chloroquine: implications for malaria chemoprophylaxis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654492/),h,374-479,106189,DB00608,Chloroquine
,7654492,clearance,"Volume of distribution, elimination half-life and clearance were not different for the three regimens, ranging from 250-302 l kg-1, 374-479 h and 0.44-0.58 l h-1 kg-1 respectively.",The pharmacokinetics of three multiple dose regimens of chloroquine: implications for malaria chemoprophylaxis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654492/),[l] / [h·kg],0.44-0.58,106190,DB00608,Chloroquine
above,7654492,peak,"After the first week of all dosage regimens, peak and trough concentrations of chloroquine were above 16 micrograms l-1, sufficiently suppressive for chloroquine-sensitive P. falciparum strains.",The pharmacokinetics of three multiple dose regimens of chloroquine: implications for malaria chemoprophylaxis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654492/),[μg] / [l],16,106191,DB00608,Chloroquine
above,7654492,trough concentrations,"After the first week of all dosage regimens, peak and trough concentrations of chloroquine were above 16 micrograms l-1, sufficiently suppressive for chloroquine-sensitive P. falciparum strains.",The pharmacokinetics of three multiple dose regimens of chloroquine: implications for malaria chemoprophylaxis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654492/),[μg] / [l],16,106192,DB00608,Chloroquine
,11158748,relative bioavailability,"The median relative bioavailability of dihydroartemisinin (DHA), the active antimalarial metabolite of ARS, was higher in the low-dose i.r. group (10 mg/kg) than in the high-dose i.r. group (20 mg/kg) (58 versus 23%; P = 0.018).",Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11158748/),%,58,106298,DB00608,Chloroquine
,11158748,relative bioavailability,"The median relative bioavailability of dihydroartemisinin (DHA), the active antimalarial metabolite of ARS, was higher in the low-dose i.r. group (10 mg/kg) than in the high-dose i.r. group (20 mg/kg) (58 versus 23%; P = 0.018).",Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11158748/),%,23,106299,DB00608,Chloroquine
,11158748,absorption half-lives,"i.r. administered ARS was more rapidly absorbed in the low-dose group than the high-dose group (median [range] absorption half-lives, 0.7 h [0.3 to 1.24 h] versus 1.1 h [0.6 to 2.7 h] [P = 0.023].",Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11158748/),h,0.7,106300,DB00608,Chloroquine
,11158748,absorption half-lives,"i.r. administered ARS was more rapidly absorbed in the low-dose group than the high-dose group (median [range] absorption half-lives, 0.7 h [0.3 to 1.24 h] versus 1.1 h [0.6 to 2.7 h] [P = 0.023].",Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11158748/),h,1.1,106301,DB00608,Chloroquine
,11158748,half-life,i.r. administered ARS was eliminated with a median (range) half-life of 0.8 h (0.4 to 2.7 h) (low-dose group and 0.9 h (0.1 to 2.5 h) (high-dose group) (P = 1).,Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11158748/),h,0.8,106302,DB00608,Chloroquine
,11158748,half-life,i.r. administered ARS was eliminated with a median (range) half-life of 0.8 h (0.4 to 2.7 h) (low-dose group and 0.9 h (0.1 to 2.5 h) (high-dose group) (P = 1).,Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11158748/),h,0.9,106303,DB00608,Chloroquine
,11158748,fractional clearances,"The fractional clearances of DHA were 3.9, 2.6, and 1.5 liters/kg/h for the 20-mg/kg, 10-mg/kg and i.v. groups, respectively (P = 0.001 and P = 0.06 for the high-and low-dose i.r. groups compared with the i.v. groups, respectively).",Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11158748/),[l] / [h·kg],3.9,106304,DB00608,Chloroquine
,11158748,fractional clearances,"The fractional clearances of DHA were 3.9, 2.6, and 1.5 liters/kg/h for the 20-mg/kg, 10-mg/kg and i.v. groups, respectively (P = 0.001 and P = 0.06 for the high-and low-dose i.r. groups compared with the i.v. groups, respectively).",Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11158748/),[l] / [h·kg],2.6,106305,DB00608,Chloroquine
,11158748,fractional clearances,"The fractional clearances of DHA were 3.9, 2.6, and 1.5 liters/kg/h for the 20-mg/kg, 10-mg/kg and i.v. groups, respectively (P = 0.001 and P = 0.06 for the high-and low-dose i.r. groups compared with the i.v. groups, respectively).",Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11158748/),[l] / [h·kg],1.5,106306,DB00608,Chloroquine
,11158748,volumes of distribution,"The median volumes of distribution for DHA were 1.5 liters kg (20 mg/kg, i.r. group), 1.8 liters/kg (10 mg/kg, i.r. group), and 0.6 liters/kg (i.v. group) (P < 0.05 for both i.r. groups compared with the i.v. group).",Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11158748/),kg·l,1.5,106307,DB00608,Chloroquine
,11158748,volumes of distribution,"The median volumes of distribution for DHA were 1.5 liters kg (20 mg/kg, i.r. group), 1.8 liters/kg (10 mg/kg, i.r. group), and 0.6 liters/kg (i.v. group) (P < 0.05 for both i.r. groups compared with the i.v. group).",Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11158748/),[l] / [kg],1.8,106308,DB00608,Chloroquine
,11158748,volumes of distribution,"The median volumes of distribution for DHA were 1.5 liters kg (20 mg/kg, i.r. group), 1.8 liters/kg (10 mg/kg, i.r. group), and 0.6 liters/kg (i.v. group) (P < 0.05 for both i.r. groups compared with the i.v. group).",Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11158748/),[l] / [kg],0.6,106309,DB00608,Chloroquine
,30255310,apparent volume of distribution,The population estimated apparent volume of distribution was 1850 L/70 kg and estimated apparent clearance was 51 L/h.,Pharmacokinetics of Hydroxychloroquine in Pregnancies with Rheumatic Diseases. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30255310/),[l] / [70·kg],1850,107257,DB00608,Chloroquine
,30255310,apparent clearance,The population estimated apparent volume of distribution was 1850 L/70 kg and estimated apparent clearance was 51 L/h.,Pharmacokinetics of Hydroxychloroquine in Pregnancies with Rheumatic Diseases. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30255310/),[l] / [h],51,107258,DB00608,Chloroquine
,1796043,dissociation constant (Kd),Kinetic analysis of 111In-Lac-BSA binding with isolated parenchymal cells at 4 degrees C yielded a dissociation constant (Kd) of 2.5 x 10(-8) M and a value of 3.5 x 10(5) maximal binding sites/cell (Bmax).,Hepatic disposition characteristics of 111In-labeled lactosaminated bovine serum albumin in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1796043/),M,2.5 x 10(-8),107677,DB00608,Chloroquine
,1796043,internalization rate constant (kint),The internalization rate constant (kint) for 111In-Lac-BSA was calculated to be 0.46 min-1 in liver perfusion experiments using the EDTA-wash method.,Hepatic disposition characteristics of 111In-labeled lactosaminated bovine serum albumin in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1796043/),1/[min],0.46,107678,DB00608,Chloroquine
,16988539,50% inhibition,Another study stated that 50% inhibition of parasite growth in vitro required 6.6 microg/mL after a high dose of ciprofloxacin was used.,Effect of chloroquine on the bioavailability of ciprofloxacin in humans. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988539/),[μg] / [ml],6.6,107990,DB00608,Chloroquine
,16988539,peak serum concentration Cmax,"The peak serum concentration Cmax of ciprofloxacin was 3.42 +/- 0.32 microg/mL, which dropped to 2.8 +/- 0.18 microg/mL when chloroquine was taken together with ciprofloxacin.",Effect of chloroquine on the bioavailability of ciprofloxacin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988539/),[μg] / [ml],3.42,107991,DB00608,Chloroquine
,16988539,peak serum concentration Cmax,"The peak serum concentration Cmax of ciprofloxacin was 3.42 +/- 0.32 microg/mL, which dropped to 2.8 +/- 0.18 microg/mL when chloroquine was taken together with ciprofloxacin.",Effect of chloroquine on the bioavailability of ciprofloxacin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988539/),[μg] / [ml],2.8,107992,DB00608,Chloroquine
,3289601,Peak plasma concentrations,"3. Peak plasma concentrations at the end of the infusion ranged from 979 to 2,900 ng ml-1 in the malaria patients.",Pharmacokinetics of chloroquine in Thais: plasma and red-cell concentrations following an intravenous infusion to healthy subjects and patients with Plasmodium vivax malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3289601/),[ng] / [ml],"979 to 2,900",108107,DB00608,Chloroquine
,3289601,lambda z,"For the healthy subjects, mean estimates of these parameters were lambda z = 0.062 +/- 0.030 day-1, CL = 597 +/- 238 ml min-1, V1 = 0.66 +/- 0.71 l kg-1 and Vss = 132 +/- 50 l.kg-1 For the group of malaria patients, the corresponding values were lambda z = 0.055 +/- 0.032 day-1, CL = 535 +/- 246 ml min-1, V1 = 0.74 +/- 0.75 l kg-1 and Vss = 136 +/- 64 l kg-1 There was no statistically significant difference in the estimates for any parameter between groups (P less than or equal to 0.05).",Pharmacokinetics of chloroquine in Thais: plasma and red-cell concentrations following an intravenous infusion to healthy subjects and patients with Plasmodium vivax malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3289601/),1/[d],0.062,108108,DB00608,Chloroquine
,3289601,CL,"For the healthy subjects, mean estimates of these parameters were lambda z = 0.062 +/- 0.030 day-1, CL = 597 +/- 238 ml min-1, V1 = 0.66 +/- 0.71 l kg-1 and Vss = 132 +/- 50 l.kg-1 For the group of malaria patients, the corresponding values were lambda z = 0.055 +/- 0.032 day-1, CL = 535 +/- 246 ml min-1, V1 = 0.74 +/- 0.75 l kg-1 and Vss = 136 +/- 64 l kg-1 There was no statistically significant difference in the estimates for any parameter between groups (P less than or equal to 0.05).",Pharmacokinetics of chloroquine in Thais: plasma and red-cell concentrations following an intravenous infusion to healthy subjects and patients with Plasmodium vivax malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3289601/),[ml] / [min],597,108109,DB00608,Chloroquine
,3289601,V1,"For the healthy subjects, mean estimates of these parameters were lambda z = 0.062 +/- 0.030 day-1, CL = 597 +/- 238 ml min-1, V1 = 0.66 +/- 0.71 l kg-1 and Vss = 132 +/- 50 l.kg-1 For the group of malaria patients, the corresponding values were lambda z = 0.055 +/- 0.032 day-1, CL = 535 +/- 246 ml min-1, V1 = 0.74 +/- 0.75 l kg-1 and Vss = 136 +/- 64 l kg-1 There was no statistically significant difference in the estimates for any parameter between groups (P less than or equal to 0.05).",Pharmacokinetics of chloroquine in Thais: plasma and red-cell concentrations following an intravenous infusion to healthy subjects and patients with Plasmodium vivax malaria. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3289601/),[l] / [kg],0.66,108110,DB00608,Chloroquine
,3289601,Vss,"For the healthy subjects, mean estimates of these parameters were lambda z = 0.062 +/- 0.030 day-1, CL = 597 +/- 238 ml min-1, V1 = 0.66 +/- 0.71 l kg-1 and Vss = 132 +/- 50 l.kg-1 For the group of malaria patients, the corresponding values were lambda z = 0.055 +/- 0.032 day-1, CL = 535 +/- 246 ml min-1, V1 = 0.74 +/- 0.75 l kg-1 and Vss = 136 +/- 64 l kg-1 There was no statistically significant difference in the estimates for any parameter between groups (P less than or equal to 0.05).",Pharmacokinetics of chloroquine in Thais: plasma and red-cell concentrations following an intravenous infusion to healthy subjects and patients with Plasmodium vivax malaria. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3289601/),[l] / [kg],132,108111,DB00608,Chloroquine
,3289601,lambda z,"For the healthy subjects, mean estimates of these parameters were lambda z = 0.062 +/- 0.030 day-1, CL = 597 +/- 238 ml min-1, V1 = 0.66 +/- 0.71 l kg-1 and Vss = 132 +/- 50 l.kg-1 For the group of malaria patients, the corresponding values were lambda z = 0.055 +/- 0.032 day-1, CL = 535 +/- 246 ml min-1, V1 = 0.74 +/- 0.75 l kg-1 and Vss = 136 +/- 64 l kg-1 There was no statistically significant difference in the estimates for any parameter between groups (P less than or equal to 0.05).",Pharmacokinetics of chloroquine in Thais: plasma and red-cell concentrations following an intravenous infusion to healthy subjects and patients with Plasmodium vivax malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3289601/),1/[d],0.055,108112,DB00608,Chloroquine
,3289601,CL,"For the healthy subjects, mean estimates of these parameters were lambda z = 0.062 +/- 0.030 day-1, CL = 597 +/- 238 ml min-1, V1 = 0.66 +/- 0.71 l kg-1 and Vss = 132 +/- 50 l.kg-1 For the group of malaria patients, the corresponding values were lambda z = 0.055 +/- 0.032 day-1, CL = 535 +/- 246 ml min-1, V1 = 0.74 +/- 0.75 l kg-1 and Vss = 136 +/- 64 l kg-1 There was no statistically significant difference in the estimates for any parameter between groups (P less than or equal to 0.05).",Pharmacokinetics of chloroquine in Thais: plasma and red-cell concentrations following an intravenous infusion to healthy subjects and patients with Plasmodium vivax malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3289601/),[ml] / [min],535,108113,DB00608,Chloroquine
,3289601,V1,"For the healthy subjects, mean estimates of these parameters were lambda z = 0.062 +/- 0.030 day-1, CL = 597 +/- 238 ml min-1, V1 = 0.66 +/- 0.71 l kg-1 and Vss = 132 +/- 50 l.kg-1 For the group of malaria patients, the corresponding values were lambda z = 0.055 +/- 0.032 day-1, CL = 535 +/- 246 ml min-1, V1 = 0.74 +/- 0.75 l kg-1 and Vss = 136 +/- 64 l kg-1 There was no statistically significant difference in the estimates for any parameter between groups (P less than or equal to 0.05).",Pharmacokinetics of chloroquine in Thais: plasma and red-cell concentrations following an intravenous infusion to healthy subjects and patients with Plasmodium vivax malaria. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3289601/),[l] / [kg],0.74,108114,DB00608,Chloroquine
,3289601,Vss,"For the healthy subjects, mean estimates of these parameters were lambda z = 0.062 +/- 0.030 day-1, CL = 597 +/- 238 ml min-1, V1 = 0.66 +/- 0.71 l kg-1 and Vss = 132 +/- 50 l.kg-1 For the group of malaria patients, the corresponding values were lambda z = 0.055 +/- 0.032 day-1, CL = 535 +/- 246 ml min-1, V1 = 0.74 +/- 0.75 l kg-1 and Vss = 136 +/- 64 l kg-1 There was no statistically significant difference in the estimates for any parameter between groups (P less than or equal to 0.05).",Pharmacokinetics of chloroquine in Thais: plasma and red-cell concentrations following an intravenous infusion to healthy subjects and patients with Plasmodium vivax malaria. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3289601/),[l] / [kg],136,108115,DB00608,Chloroquine
,3289601,red cell to plasma ratio,The median value for the red cell to plasma ratio was between 3 and 4 in each group.,Pharmacokinetics of chloroquine in Thais: plasma and red-cell concentrations following an intravenous infusion to healthy subjects and patients with Plasmodium vivax malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3289601/),,3 and 4,108116,DB00608,Chloroquine
,10492767,parasite clearance time,Treatment with CQ-CP combination resulted in a shorter parasite clearance time (2.0 +/- 0.5 days) and a higher cure rate (87.5%) compared to treatment with CQ alone (3.5 +/- 0.5 days; 66.7%).,Effect of chlorpheniramine on the pharmacokinetics of and response to chloroquine of Nigerian children with falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492767/),d,2.0,109541,DB00608,Chloroquine
,10492767,cure rate,Treatment with CQ-CP combination resulted in a shorter parasite clearance time (2.0 +/- 0.5 days) and a higher cure rate (87.5%) compared to treatment with CQ alone (3.5 +/- 0.5 days; 66.7%).,Effect of chlorpheniramine on the pharmacokinetics of and response to chloroquine of Nigerian children with falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492767/),d,3.5,109542,DB00608,Chloroquine
,8329010,concentration ratio,"Blood AQm1 concentrations were higher than plasma levels, with an AQm1/AQ concentration ratio of 5 to 10.",Pharmacokinetic and pharmacodynamic study of amodiaquine and its two metabolites after a single oral dose in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8329010/),,5 to 10,110447,DB00608,Chloroquine
,8161714,Ki,"We found that CHQ inhibits non-competitively the metabolism of PZQ to its major metabolite, 4-hydroxy-praziquantel, with a Ki of 1.65 mM in rat hepatic microsomes.",The effect of chloroquine on the pharmacokinetics and metabolism of praziquantel in rats and in humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8161714/),mM,1.65,115507,DB00608,Chloroquine
,29096443,encapsulation efficiency,"With optimized process parameters including liquid flow rates and applied electric voltages, experiments are systematically carried out to generate a stable cone-jet mode to produce artemether-loaded PLGA-MPs with an average size of 2 μm, an encapsulation efficiency of 78 ± 5.6%, and a loading efficiency of 11.7%.",Characteristics of Artemether-Loaded Poly(lactic-co-glycolic) Acid Microparticles Fabricated by Coaxial Electrospray: Validation of Enhanced Encapsulation Efficiency and Bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29096443/),%,78,117523,DB00608,Chloroquine
,33188451,Absorption rate (ka),"Absorption rate (ka) was estimated to be 0.559 h-1, and a lag time of absorption (ALAG) was estimated to be 0.149 h.",Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33188451/),1/[h],0.559,118858,DB00608,Chloroquine
,33188451,lag time of absorption (ALAG),"Absorption rate (ka) was estimated to be 0.559 h-1, and a lag time of absorption (ALAG) was estimated to be 0.149 h.",Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33188451/),h,0.149,118859,DB00608,Chloroquine
,33188451,Apparent clearance (CL/F),Apparent clearance (CL/F) and apparent central volume of distribution (V2/F) was 33.3 l/h and 3630 l.,Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33188451/),[l] / [h],33.3,118860,DB00608,Chloroquine
,33188451,apparent central volume of distribution (V2/F),Apparent clearance (CL/F) and apparent central volume of distribution (V2/F) was 33.3 l/h and 3630 l.,Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33188451/),l,3630,118861,DB00608,Chloroquine
,33188451,Apparent distribution clearance (Q/F),Apparent distribution clearance (Q/F) and volume of distribution of peripheral compartment (Q3/F) were 58.7 l/h and 5120 l.,Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33188451/),[l] / [h],58.7,118862,DB00608,Chloroquine
,33188451,volume of distribution of peripheral compartment (Q3/F),Apparent distribution clearance (Q/F) and volume of distribution of peripheral compartment (Q3/F) were 58.7 l/h and 5120 l.,Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33188451/),l,5120,118863,DB00608,Chloroquine
,3524743,Fever,Fever and parasite clearance times (mean (SD) 60 (23) h and 53 (22) h respectively) were comparable with those obtained with intravenous quinine.,Intramuscular loading dose of quinine for falciparum malaria: pharmacokinetics and toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524743/),h,60,120593,DB00608,Chloroquine
,3524743,parasite clearance times,Fever and parasite clearance times (mean (SD) 60 (23) h and 53 (22) h respectively) were comparable with those obtained with intravenous quinine.,Intramuscular loading dose of quinine for falciparum malaria: pharmacokinetics and toxicity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524743/),h,53,120594,DB00608,Chloroquine
,3524743,peak plasma quinine concentration,The mean peak plasma quinine concentration of 11.0 mg/l (34.4 mu mol/l) [corrected] was reached a median of five hours after administration of the loading dose.,Intramuscular loading dose of quinine for falciparum malaria: pharmacokinetics and toxicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3524743/),[mg] / [l],11.0,120595,DB00608,Chloroquine
,24991838,progression-free survival,The median progression-free survival in 13 melanoma patients treated with HCQ 1200mg/d in combination with TEM was 3.5 mo.,Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24991838/),mo,3.5,123535,DB00608,Chloroquine
,22390538,K1,"One of these frontrunner compounds, 15, was equipotent across the two strains (K1 = 25.0 nM, NF54 = 28.0 nM) and superior to chloroquine in the K1 strain (chloroquine IC(50) K1 = 194.0 nM).","3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22390538/),nM,25.0,126117,DB00608,Chloroquine
,22390538,NF54,"One of these frontrunner compounds, 15, was equipotent across the two strains (K1 = 25.0 nM, NF54 = 28.0 nM) and superior to chloroquine in the K1 strain (chloroquine IC(50) K1 = 194.0 nM).","3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22390538/),nM,28.0,126118,DB00608,Chloroquine
,22390538,IC(50) K1,"One of these frontrunner compounds, 15, was equipotent across the two strains (K1 = 25.0 nM, NF54 = 28.0 nM) and superior to chloroquine in the K1 strain (chloroquine IC(50) K1 = 194.0 nM).","3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22390538/),nM,194.0,126119,DB00608,Chloroquine
,22390538,ED(50),Dose-response studies generated ED(50) and ED(90) values of 0.83 and 1.74 mg/kg for 15 in the standard four-dose Peters test.,"3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22390538/),[mg] / [kg],0.83,126120,DB00608,Chloroquine
,22390538,ED(90),Dose-response studies generated ED(50) and ED(90) values of 0.83 and 1.74 mg/kg for 15 in the standard four-dose Peters test.,"3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22390538/),[mg] / [kg],1.74,126121,DB00608,Chloroquine
,22390538,oral bioavailability,Pharmacokinetic studies in the rat indicated that this compound has good oral bioavailability (51% at 20 mg/kg) and a reasonable half-life (t(1/2) ∼ 7-8 h).,"3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22390538/),%,51,126122,DB00608,Chloroquine
,22390538,half-life (t(1/2),Pharmacokinetic studies in the rat indicated that this compound has good oral bioavailability (51% at 20 mg/kg) and a reasonable half-life (t(1/2) ∼ 7-8 h).,"3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22390538/),h,7-8,126123,DB00608,Chloroquine
,32866424,overall survival,Median overall survival was 16 months (range 2-32).,Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32866424/),month,16,126667,DB00608,Chloroquine
,32866424,Media,Median survival was 11.5 months for EGFRvIII- patients and 20 months for EGFRvIII+ patients.,Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32866424/),month,11.5,126668,DB00608,Chloroquine
,32866424,Media,Median survival was 11.5 months for EGFRvIII- patients and 20 months for EGFRvIII+ patients.,Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32866424/),month,20,126669,DB00608,Chloroquine
,32866424,survival,Median survival was 11.5 months for EGFRvIII- patients and 20 months for EGFRvIII+ patients.,Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32866424/),month,11.5,126670,DB00608,Chloroquine
,32866424,survival,Median survival was 11.5 months for EGFRvIII- patients and 20 months for EGFRvIII+ patients.,Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32866424/),month,20,126671,DB00608,Chloroquine
,12100003,area under the curve,"3. The mean (+/-SEM) of area under the curve values after administration of water +/- control) and GFJ were 5.34 +/- 0.38 and 7.01 +/- 0.66 mg.h/L, respectively.",Effect of grapefruit juice on plasma chloroquine kinetics in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100003/),[h·mg] / [l],5.34,130056,DB00608,Chloroquine
,12100003,area under the curve,"3. The mean (+/-SEM) of area under the curve values after administration of water +/- control) and GFJ were 5.34 +/- 0.38 and 7.01 +/- 0.66 mg.h/L, respectively.",Effect of grapefruit juice on plasma chloroquine kinetics in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100003/),[h·mg] / [l],7.01,130057,DB00608,Chloroquine
,12100003,C(max),The corresponding mean C(max) values were 763.4 +/- 39.1 and 859.2 +/- 45.2 mg/L and the corresponding T(max) values (median) were 2.65 and 2.95 h.,Effect of grapefruit juice on plasma chloroquine kinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100003/),[mg] / [l],763.4,130058,DB00608,Chloroquine
,12100003,C(max),The corresponding mean C(max) values were 763.4 +/- 39.1 and 859.2 +/- 45.2 mg/L and the corresponding T(max) values (median) were 2.65 and 2.95 h.,Effect of grapefruit juice on plasma chloroquine kinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100003/),[mg] / [l],859.2,130059,DB00608,Chloroquine
,12100003,T(max),The corresponding mean C(max) values were 763.4 +/- 39.1 and 859.2 +/- 45.2 mg/L and the corresponding T(max) values (median) were 2.65 and 2.95 h.,Effect of grapefruit juice on plasma chloroquine kinetics in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100003/),h,2.65,130060,DB00608,Chloroquine
,12100003,T(max),The corresponding mean C(max) values were 763.4 +/- 39.1 and 859.2 +/- 45.2 mg/L and the corresponding T(max) values (median) were 2.65 and 2.95 h.,Effect of grapefruit juice on plasma chloroquine kinetics in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100003/),h,2.95,130061,DB00608,Chloroquine
,1809245,peak concentrations,These amounts were markedly higher than peak concentrations in plasma (3.16 pmol microliters-1) and in host tissues (78 pmol mgm-1) and skin (up to 93 pmol mg-1).,Uptake of chloroquine by Onchocerca volvulus in vivo and in vitro. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1809245/),[pM] / [μl],3.16,130943,DB00608,Chloroquine
,1809245,peak concentrations,These amounts were markedly higher than peak concentrations in plasma (3.16 pmol microliters-1) and in host tissues (78 pmol mgm-1) and skin (up to 93 pmol mg-1).,Uptake of chloroquine by Onchocerca volvulus in vivo and in vitro. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1809245/),[pM] / [mgm],78,130944,DB00608,Chloroquine
up to,1809245,peak concentrations,These amounts were markedly higher than peak concentrations in plasma (3.16 pmol microliters-1) and in host tissues (78 pmol mgm-1) and skin (up to 93 pmol mg-1).,Uptake of chloroquine by Onchocerca volvulus in vivo and in vitro. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1809245/),[pM] / [mg],93,130945,DB00608,Chloroquine
,2189012,Plasma,Plasma quinine concentrations (mean +/- SE) were 8.7 +/- 1.2 mg/l at 30 min and 11.0 +/- 1.8 mg/l at 4.5 h.,A safe and effective consecutive-infusion regimen for rapid quinine loading in severe falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2189012/),[mg] / [l],8.7,131268,DB00608,Chloroquine
,2189012,Plasma,Plasma quinine concentrations (mean +/- SE) were 8.7 +/- 1.2 mg/l at 30 min and 11.0 +/- 1.8 mg/l at 4.5 h.,A safe and effective consecutive-infusion regimen for rapid quinine loading in severe falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2189012/),[mg] / [l],11.0,131269,DB00608,Chloroquine
,2189012,concentrations,Plasma quinine concentrations (mean +/- SE) were 8.7 +/- 1.2 mg/l at 30 min and 11.0 +/- 1.8 mg/l at 4.5 h.,A safe and effective consecutive-infusion regimen for rapid quinine loading in severe falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2189012/),[mg] / [l],8.7,131270,DB00608,Chloroquine
,2189012,concentrations,Plasma quinine concentrations (mean +/- SE) were 8.7 +/- 1.2 mg/l at 30 min and 11.0 +/- 1.8 mg/l at 4.5 h.,A safe and effective consecutive-infusion regimen for rapid quinine loading in severe falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2189012/),[mg] / [l],11.0,131271,DB00608,Chloroquine
,11299036,times to fever clearance,"Mean times to fever clearance, symptoms clearance and asexual parasites clearance were longer in the uncoated tablets group: 36 h (range 24-48 h, SD = 16.8) vs. 60 h (range 24-96 h, SD = 31.2, P = 0.001) for fever clearance, 36 h (24-48 h, SD = 16.8) vs. 48 h (24-72, SD = 24, P = 0.001) for symptoms clearance and 48 h (24-72, SD = 1) vs. 72 h (48-96, SD = 24, P = 0.001) for parasitaemia clearance.",Rapid therapeutic response onset of a new pharmaceutical form of chloroquine phosphate 300 mg: effervescent tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11299036/),h,36,132394,DB00608,Chloroquine
,11299036,times to fever clearance,"Mean times to fever clearance, symptoms clearance and asexual parasites clearance were longer in the uncoated tablets group: 36 h (range 24-48 h, SD = 16.8) vs. 60 h (range 24-96 h, SD = 31.2, P = 0.001) for fever clearance, 36 h (24-48 h, SD = 16.8) vs. 48 h (24-72, SD = 24, P = 0.001) for symptoms clearance and 48 h (24-72, SD = 1) vs. 72 h (48-96, SD = 24, P = 0.001) for parasitaemia clearance.",Rapid therapeutic response onset of a new pharmaceutical form of chloroquine phosphate 300 mg: effervescent tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11299036/),h,60,132395,DB00608,Chloroquine
,3893840,half-lives (t1/2 beta),"In healthy subjects, the cinchona alkaloids (quinine and quinidine), primaquine and proguanil (chloroguanide) are all rapidly eliminated with half-lives (t1/2 beta) of between 6 and 12 hours.",Clinical pharmacokinetics of antimalarial drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),h,6 and 12,134980,DB00608,Chloroquine
,3893840,t1/2 beta,Chloroquine (t1/2 beta 6 to 50 days) and mefloquine (t1/2 beta 6.5 to 33 days) have extensive tissue distribution and prolonged activity after a single dose.,Clinical pharmacokinetics of antimalarial drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),d,6 to 50,134981,DB00608,Chloroquine
,3893840,t1/2 beta,Chloroquine (t1/2 beta 6 to 50 days) and mefloquine (t1/2 beta 6.5 to 33 days) have extensive tissue distribution and prolonged activity after a single dose.,Clinical pharmacokinetics of antimalarial drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),d,6.5 to 33,134982,DB00608,Chloroquine
,3893840,t1/2,"Pyrimethamine (t1/2 35 to 175 hours) has more limited tissue distribution, plasma and erythrocyte concentrations are similar, and 85% of the drug in plasma is bound to plasma proteins.",Clinical pharmacokinetics of antimalarial drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),h,35 to 175,134983,DB00608,Chloroquine
,20334568,concentrations,"Mean concentrations of HCQ in adenoid tissue of subjects treated with 400 and 800 mg were 87,210 +/- 17,817 and 167,472 +/- 93,793 ng/g, respectively.",Short communication: preferential concentration of hydroxychloroquine in adenoid tissue of HIV-infected subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20334568/),,"87,210",135795,DB00608,Chloroquine
,20334568,concentrations,"Mean concentrations of HCQ in adenoid tissue of subjects treated with 400 and 800 mg were 87,210 +/- 17,817 and 167,472 +/- 93,793 ng/g, respectively.",Short communication: preferential concentration of hydroxychloroquine in adenoid tissue of HIV-infected subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20334568/),,"167,472",135796,DB00608,Chloroquine
,3887162,Times,"Times required for parasite clearance and elimination of fever (49.4 +/- 17.8 and 69.5 +/- 18.7 hours, respectively) were comparable to those in earlier studies with a loading dose of quinine.",Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3887162/),h,49.4,136289,DB00608,Chloroquine
,3887162,Times,"Times required for parasite clearance and elimination of fever (49.4 +/- 17.8 and 69.5 +/- 18.7 hours, respectively) were comparable to those in earlier studies with a loading dose of quinine.",Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3887162/),h,69.5,136290,DB00608,Chloroquine
,3887162,elimination half-life,"The elimination half-life was 12.8 hours, the volume of distribution was 1.68 liters per kilogram, total clearance was 1.75 ml per kilogram per minute, and urinary clearance was 0.62 ml per kilogram per minute.",Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3887162/),h,12.8,136291,DB00608,Chloroquine
,3887162,volume of distribution,"The elimination half-life was 12.8 hours, the volume of distribution was 1.68 liters per kilogram, total clearance was 1.75 ml per kilogram per minute, and urinary clearance was 0.62 ml per kilogram per minute.",Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3887162/),[l] / [kg],1.68,136292,DB00608,Chloroquine
,3887162,total clearance,"The elimination half-life was 12.8 hours, the volume of distribution was 1.68 liters per kilogram, total clearance was 1.75 ml per kilogram per minute, and urinary clearance was 0.62 ml per kilogram per minute.",Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3887162/),[ml] / [kg·min],1.75,136293,DB00608,Chloroquine
,3887162,urinary clearance,"The elimination half-life was 12.8 hours, the volume of distribution was 1.68 liters per kilogram, total clearance was 1.75 ml per kilogram per minute, and urinary clearance was 0.62 ml per kilogram per minute.",Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3887162/),[ml] / [kg·min],0.62,136294,DB00608,Chloroquine
,14639053,bioavailability,"The population estimate of bioavailability of 0.75 (0.07), n = 9, was consistent with literature values.",Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639053/),,0.75,137772,DB00608,Chloroquine
,14639053,Cl,"The parameter values from the final model were: Cl = 9.9 +/- 0.4 L/h, V = 605 +/- 91 L, ka = 0.77 +/- 0.22 hours(-1), t(tag) = 0.44 +/- 0.02 hours.",Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639053/),[l] / [h],9.9,137773,DB00608,Chloroquine
,14639053,V,"The parameter values from the final model were: Cl = 9.9 +/- 0.4 L/h, V = 605 +/- 91 L, ka = 0.77 +/- 0.22 hours(-1), t(tag) = 0.44 +/- 0.02 hours.",Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639053/),l,605,137774,DB00608,Chloroquine
,14639053,ka,"The parameter values from the final model were: Cl = 9.9 +/- 0.4 L/h, V = 605 +/- 91 L, ka = 0.77 +/- 0.22 hours(-1), t(tag) = 0.44 +/- 0.02 hours.",Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639053/),1/[hours],0.77,137775,DB00608,Chloroquine
,14639053,t(tag),"The parameter values from the final model were: Cl = 9.9 +/- 0.4 L/h, V = 605 +/- 91 L, ka = 0.77 +/- 0.22 hours(-1), t(tag) = 0.44 +/- 0.02 hours.",Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639053/),h,0.44,137776,DB00608,Chloroquine
,10750517,parasite clearance time (PCT),The parasite clearance time (PCT) of these drugs ranged between two days and a week and the fever clearance time (FCT) was within 48 hours.,Comparative efficacy and safety of chloroquine and alternative antimalarial drugs: a meta-analysis from six African countries. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10750517/),d,two,138310,DB00608,Chloroquine
,10750517,fever clearance time (FCT),The parasite clearance time (PCT) of these drugs ranged between two days and a week and the fever clearance time (FCT) was within 48 hours.,Comparative efficacy and safety of chloroquine and alternative antimalarial drugs: a meta-analysis from six African countries. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10750517/),h,48,138311,DB00608,Chloroquine
,26818020,parasite clearance time,"The median parasite clearance time was 24 h in FDC of arterolane maleate and PQP group and 26 h in chloroquine group (Log-rank, p = 0.2264).","Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26818020/),h,24,139831,DB00608,Chloroquine
,26818020,parasite clearance time,"The median parasite clearance time was 24 h in FDC of arterolane maleate and PQP group and 26 h in chloroquine group (Log-rank, p = 0.2264).","Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26818020/),h,26,139832,DB00608,Chloroquine
,26818020,fever clearance time,"Similarly, median fever clearance time was 24 h in both the groups (Log-rank, p = 0.7750).","Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26818020/),h,24,139833,DB00608,Chloroquine
,26818020,t1/2,The pharmacokinetic analysis indicates that arterolane maleate is well absorbed and has a relatively short t1/2 of 3.2 h.,"Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26818020/),h,3.2,139834,DB00608,Chloroquine
,26818020,t1/2,Piperaquine is also well absorbed after oral administration with a t1/2 of about 228.33 h.,"Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26818020/),h,228.33,139835,DB00608,Chloroquine
,17967917,volume of distribution at steady state,"For PQ, the median volume of distribution at steady state, allowing for bioavailability (Vss/F), was 431 liters/kg (interquartile range [IQR], 283 to 588 liters/kg), the median clearance (CL/F) was 0.85 liters/h/kg (IQR, 0.67 to 1.06 liters/h/kg), the median distribution half-life (t 1/2 alpha) was 0.12 h (IQR, 0.05 to 0.66 h), and the median elimination half-life (t 1/2 beta) was 413 h (IQR, 318 to 516 h).",Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17967917/),[l] / [kg],431,141186,DB00608,Chloroquine
,17967917,bioavailability (Vss/F),"For PQ, the median volume of distribution at steady state, allowing for bioavailability (Vss/F), was 431 liters/kg (interquartile range [IQR], 283 to 588 liters/kg), the median clearance (CL/F) was 0.85 liters/h/kg (IQR, 0.67 to 1.06 liters/h/kg), the median distribution half-life (t 1/2 alpha) was 0.12 h (IQR, 0.05 to 0.66 h), and the median elimination half-life (t 1/2 beta) was 413 h (IQR, 318 to 516 h).",Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17967917/),[l] / [kg],431,141187,DB00608,Chloroquine
,17967917,clearance (CL/F),"For PQ, the median volume of distribution at steady state, allowing for bioavailability (Vss/F), was 431 liters/kg (interquartile range [IQR], 283 to 588 liters/kg), the median clearance (CL/F) was 0.85 liters/h/kg (IQR, 0.67 to 1.06 liters/h/kg), the median distribution half-life (t 1/2 alpha) was 0.12 h (IQR, 0.05 to 0.66 h), and the median elimination half-life (t 1/2 beta) was 413 h (IQR, 318 to 516 h).",Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17967917/),[l] / [h·kg],0.85,141188,DB00608,Chloroquine
,17967917,distribution half-life (t 1/2 alpha),"For PQ, the median volume of distribution at steady state, allowing for bioavailability (Vss/F), was 431 liters/kg (interquartile range [IQR], 283 to 588 liters/kg), the median clearance (CL/F) was 0.85 liters/h/kg (IQR, 0.67 to 1.06 liters/h/kg), the median distribution half-life (t 1/2 alpha) was 0.12 h (IQR, 0.05 to 0.66 h), and the median elimination half-life (t 1/2 beta) was 413 h (IQR, 318 to 516 h).",Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17967917/),h,0.12,141189,DB00608,Chloroquine
,17967917,elimination half-life (t 1/2 beta),"For PQ, the median volume of distribution at steady state, allowing for bioavailability (Vss/F), was 431 liters/kg (interquartile range [IQR], 283 to 588 liters/kg), the median clearance (CL/F) was 0.85 liters/h/kg (IQR, 0.67 to 1.06 liters/h/kg), the median distribution half-life (t 1/2 alpha) was 0.12 h (IQR, 0.05 to 0.66 h), and the median elimination half-life (t 1/2 beta) was 413 h (IQR, 318 to 516 h).",Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17967917/),h,413,141190,DB00608,Chloroquine
,17967917,Vss/F,"For CQ, the median Vss/F was 154 liters/kg (IQR, 101 to 210 liters/kg), the median CL/F was 0.80 liters/h/kg (IQR, 0.52 to 0.96 liters/h/kg), the median t 1/2 alpha was 0.43 h (IQR, 0.05 to 1.82 h), and the median t 1/2 beta was 233 h (IQR, 206 to 298 h).",Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17967917/),[l] / [kg],154,141191,DB00608,Chloroquine
,17967917,CL/F,"For CQ, the median Vss/F was 154 liters/kg (IQR, 101 to 210 liters/kg), the median CL/F was 0.80 liters/h/kg (IQR, 0.52 to 0.96 liters/h/kg), the median t 1/2 alpha was 0.43 h (IQR, 0.05 to 1.82 h), and the median t 1/2 beta was 233 h (IQR, 206 to 298 h).",Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17967917/),[l] / [h·kg],0.80,141192,DB00608,Chloroquine
,17967917,t 1/2 alpha,"For CQ, the median Vss/F was 154 liters/kg (IQR, 101 to 210 liters/kg), the median CL/F was 0.80 liters/h/kg (IQR, 0.52 to 0.96 liters/h/kg), the median t 1/2 alpha was 0.43 h (IQR, 0.05 to 1.82 h), and the median t 1/2 beta was 233 h (IQR, 206 to 298 h).",Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17967917/),h,0.43,141193,DB00608,Chloroquine
,17967917,t 1/2 beta,"For CQ, the median Vss/F was 154 liters/kg (IQR, 101 to 210 liters/kg), the median CL/F was 0.80 liters/h/kg (IQR, 0.52 to 0.96 liters/h/kg), the median t 1/2 alpha was 0.43 h (IQR, 0.05 to 1.82 h), and the median t 1/2 beta was 233 h (IQR, 206 to 298 h).",Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17967917/),h,233,141194,DB00608,Chloroquine
,17967917,t 1/2 beta,"The noncompartmentally derived median DECQ t 1/2 beta was 290 h (IQR, 236 to 368 h).",Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17967917/),h,290,141195,DB00608,Chloroquine
,33259916,plasma concentrations,"Median (interquartile range) HCQ plasma concentrations were 0.09 (0.06-0.14) mg/L and 0.07 (0.05-0.08) mg/L for 400 mg × 1/day and 200 mg × 3/day, respectively.",Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33259916/),[mg] / [l],0.09,143519,DB00608,Chloroquine
,33259916,plasma concentrations,"Median (interquartile range) HCQ plasma concentrations were 0.09 (0.06-0.14) mg/L and 0.07 (0.05-0.08) mg/L for 400 mg × 1/day and 200 mg × 3/day, respectively.",Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33259916/),[mg] / [l],0.07,143520,DB00608,Chloroquine
,33259916,ELF,"Median HCQ ELF concentrations were 3.74 (1.10-7.26) mg/L and 1.81 (1.20-7.25) for 400 mg × 1/day and 200 mg × 3/day, respectively.",Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33259916/),[mg] / [l],3.74,143521,DB00608,Chloroquine
,33259916,ELF,"Median HCQ ELF concentrations were 3.74 (1.10-7.26) mg/L and 1.81 (1.20-7.25) for 400 mg × 1/day and 200 mg × 3/day, respectively.",Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33259916/),,1.81,143522,DB00608,Chloroquine
,33259916,concentrations,"Median HCQ ELF concentrations were 3.74 (1.10-7.26) mg/L and 1.81 (1.20-7.25) for 400 mg × 1/day and 200 mg × 3/day, respectively.",Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33259916/),[mg] / [l],3.74,143523,DB00608,Chloroquine
,33259916,concentrations,"Median HCQ ELF concentrations were 3.74 (1.10-7.26) mg/L and 1.81 (1.20-7.25) for 400 mg × 1/day and 200 mg × 3/day, respectively.",Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33259916/),,1.81,143524,DB00608,Chloroquine
,7974678,Peak mefloquine concentrations,"Peak mefloquine concentrations were significantly lower in the pregnant patients (median [range]; 1257 [650-1584] vs. 1617 [1051-3111] ng/mL) and the total apparent volume of distribution (Vd/f) was larger (10.8 [8.3-26.1] vs. 10.0 [4.8-13.9] L/kg; P < 0.05 in each case), consistent with an expanded circulating blood volume and increased tissue binding in pregnancy.",Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7974678/),[ng] / [ml],1257,143704,DB00608,Chloroquine
,7974678,Peak mefloquine concentrations,"Peak mefloquine concentrations were significantly lower in the pregnant patients (median [range]; 1257 [650-1584] vs. 1617 [1051-3111] ng/mL) and the total apparent volume of distribution (Vd/f) was larger (10.8 [8.3-26.1] vs. 10.0 [4.8-13.9] L/kg; P < 0.05 in each case), consistent with an expanded circulating blood volume and increased tissue binding in pregnancy.",Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7974678/),[ng] / [ml],1617,143705,DB00608,Chloroquine
,7974678,total apparent volume of distribution (Vd/f),"Peak mefloquine concentrations were significantly lower in the pregnant patients (median [range]; 1257 [650-1584] vs. 1617 [1051-3111] ng/mL) and the total apparent volume of distribution (Vd/f) was larger (10.8 [8.3-26.1] vs. 10.0 [4.8-13.9] L/kg; P < 0.05 in each case), consistent with an expanded circulating blood volume and increased tissue binding in pregnancy.",Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7974678/),[l] / [kg],10.8,143706,DB00608,Chloroquine
,7974678,total apparent volume of distribution (Vd/f),"Peak mefloquine concentrations were significantly lower in the pregnant patients (median [range]; 1257 [650-1584] vs. 1617 [1051-3111] ng/mL) and the total apparent volume of distribution (Vd/f) was larger (10.8 [8.3-26.1] vs. 10.0 [4.8-13.9] L/kg; P < 0.05 in each case), consistent with an expanded circulating blood volume and increased tissue binding in pregnancy.",Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7974678/),[l] / [kg],10.0,143707,DB00608,Chloroquine
,18021335,Cmax,"The pharmacokinetics of MTX were also similar with the Cmax and AUC values being 455.00 +/- 101.00 nm and 1469.92 +/- 299.77 nm/h for MTX group and 425.00 +/- 169.60 nm and 1560.73 +/- 615.49 nm/h for MTX plus CQ group, respectively.",Comparative study of the pharmacokinetics of MTX in juvenile idiopathic arthritis patients receiving long-term MTX monotherapy or MTX plus chloroquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021335/),nm,455.00,145177,DB00608,Chloroquine
,18021335,Cmax,"The pharmacokinetics of MTX were also similar with the Cmax and AUC values being 455.00 +/- 101.00 nm and 1469.92 +/- 299.77 nm/h for MTX group and 425.00 +/- 169.60 nm and 1560.73 +/- 615.49 nm/h for MTX plus CQ group, respectively.",Comparative study of the pharmacokinetics of MTX in juvenile idiopathic arthritis patients receiving long-term MTX monotherapy or MTX plus chloroquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021335/),nm,425.00,145178,DB00608,Chloroquine
,18021335,AUC,"The pharmacokinetics of MTX were also similar with the Cmax and AUC values being 455.00 +/- 101.00 nm and 1469.92 +/- 299.77 nm/h for MTX group and 425.00 +/- 169.60 nm and 1560.73 +/- 615.49 nm/h for MTX plus CQ group, respectively.",Comparative study of the pharmacokinetics of MTX in juvenile idiopathic arthritis patients receiving long-term MTX monotherapy or MTX plus chloroquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021335/),[nm] / [h],1469.92,145179,DB00608,Chloroquine
,18021335,AUC,"The pharmacokinetics of MTX were also similar with the Cmax and AUC values being 455.00 +/- 101.00 nm and 1469.92 +/- 299.77 nm/h for MTX group and 425.00 +/- 169.60 nm and 1560.73 +/- 615.49 nm/h for MTX plus CQ group, respectively.",Comparative study of the pharmacokinetics of MTX in juvenile idiopathic arthritis patients receiving long-term MTX monotherapy or MTX plus chloroquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021335/),[nm] / [h],1560.73,145180,DB00608,Chloroquine
,11991015,AUC,"The AUC and Cpmax for Shellyquine were 4396.3 +/- 833 ng mL(-1) h and 162 +/- 14 ng/mL, respectively.",Comparative bioavailability of oral sugar-coated and plain formulation of chloroquine phosphate marketed in Tanzania. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11991015/),[h·ng] / [ml],4396.3,145989,DB00608,Chloroquine
,11991015,Cpmax,"The AUC and Cpmax for Shellyquine were 4396.3 +/- 833 ng mL(-1) h and 162 +/- 14 ng/mL, respectively.",Comparative bioavailability of oral sugar-coated and plain formulation of chloroquine phosphate marketed in Tanzania. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11991015/),[ng] / [ml],162,145990,DB00608,Chloroquine
,11991015,AUC,"The AUC and Cpmax for Dawaquin were 2060 +/- 339 ng mL(-1) h and 56.6 +/- 5.2 ng/mL, respectively.",Comparative bioavailability of oral sugar-coated and plain formulation of chloroquine phosphate marketed in Tanzania. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11991015/),[h·ng] / [ml],2060,145991,DB00608,Chloroquine
,11991015,Cpmax,"The AUC and Cpmax for Dawaquin were 2060 +/- 339 ng mL(-1) h and 56.6 +/- 5.2 ng/mL, respectively.",Comparative bioavailability of oral sugar-coated and plain formulation of chloroquine phosphate marketed in Tanzania. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11991015/),[ng] / [ml],56.6,145992,DB00608,Chloroquine
,24282507,IC50,"It had IC50 values of 0.37 and 0.55 µg/mL, against 3D7 and Dd2 respectively.","New antimalarial hits from Dacryodes edulis (Burseraceae)--part I: isolation, in vitro activity, in silico ""drug-likeness"" and pharmacokinetic profiles. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24282507/),[μg] / [ml],0.37,147197,DB00608,Chloroquine
,24282507,IC50,"It had IC50 values of 0.37 and 0.55 µg/mL, against 3D7 and Dd2 respectively.","New antimalarial hits from Dacryodes edulis (Burseraceae)--part I: isolation, in vitro activity, in silico ""drug-likeness"" and pharmacokinetic profiles. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24282507/),[μg] / [ml],0.55,147198,DB00608,Chloroquine
,23138518,Cmax,"The mean values of Cmax and AUC0-24 for the test and reference formulations of HCQ (197.6 and 199.0 ng/mL, 2460.1 and 2468.3 ng/mL/h) were not significantly different.",A parallel design study to assess the bioequivalence of generic and branded hydroxychloroquine sulfate tablets in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23138518/),[ng] / [ml],197.6,150361,DB00608,Chloroquine
,23138518,Cmax,"The mean values of Cmax and AUC0-24 for the test and reference formulations of HCQ (197.6 and 199.0 ng/mL, 2460.1 and 2468.3 ng/mL/h) were not significantly different.",A parallel design study to assess the bioequivalence of generic and branded hydroxychloroquine sulfate tablets in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23138518/),[ng] / [ml],199.0,150362,DB00608,Chloroquine
,23138518,AUC0-24,"The mean values of Cmax and AUC0-24 for the test and reference formulations of HCQ (197.6 and 199.0 ng/mL, 2460.1 and 2468.3 ng/mL/h) were not significantly different.",A parallel design study to assess the bioequivalence of generic and branded hydroxychloroquine sulfate tablets in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23138518/),[ng] / [h·ml],2460.1,150363,DB00608,Chloroquine
,23138518,AUC0-24,"The mean values of Cmax and AUC0-24 for the test and reference formulations of HCQ (197.6 and 199.0 ng/mL, 2460.1 and 2468.3 ng/mL/h) were not significantly different.",A parallel design study to assess the bioequivalence of generic and branded hydroxychloroquine sulfate tablets in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23138518/),[ng] / [h·ml],2468.3,150364,DB00608,Chloroquine
,8089046,AUC,"The mean (+/- S.E.) AUC values after administration with water (control) and Aradaib, Karkadi and Lemon, respectively, were 7.52 +/- 0.87, 2.60 +/- 0.24, 2.16 +/- 0.30 and 2.41 +/- 0.29 mg.h/L.","Significant reduction in chloroquine bioavailability following coadministration with the Sudanese beverages Aradaib, Karkadi and Lemon. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8089046/),[h·mg] / [l],7.52,151803,DB00608,Chloroquine
,8089046,AUC,"The mean (+/- S.E.) AUC values after administration with water (control) and Aradaib, Karkadi and Lemon, respectively, were 7.52 +/- 0.87, 2.60 +/- 0.24, 2.16 +/- 0.30 and 2.41 +/- 0.29 mg.h/L.","Significant reduction in chloroquine bioavailability following coadministration with the Sudanese beverages Aradaib, Karkadi and Lemon. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8089046/),[h·mg] / [l],2.60,151804,DB00608,Chloroquine
,8089046,AUC,"The mean (+/- S.E.) AUC values after administration with water (control) and Aradaib, Karkadi and Lemon, respectively, were 7.52 +/- 0.87, 2.60 +/- 0.24, 2.16 +/- 0.30 and 2.41 +/- 0.29 mg.h/L.","Significant reduction in chloroquine bioavailability following coadministration with the Sudanese beverages Aradaib, Karkadi and Lemon. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8089046/),[h·mg] / [l],2.16,151805,DB00608,Chloroquine
,8089046,AUC,"The mean (+/- S.E.) AUC values after administration with water (control) and Aradaib, Karkadi and Lemon, respectively, were 7.52 +/- 0.87, 2.60 +/- 0.24, 2.16 +/- 0.30 and 2.41 +/- 0.29 mg.h/L.","Significant reduction in chloroquine bioavailability following coadministration with the Sudanese beverages Aradaib, Karkadi and Lemon. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8089046/),[h·mg] / [l],2.41,151806,DB00608,Chloroquine
,8089046,Cmax,"The corresponding mean Cmax values were 553 +/- 17.8, 184 +/- 21.3, 148 +/- 14.1 and 210 +/- 17.4 mg/L and the corresponding Tmax values were 3.0 +/- 1.0, 3.2 +/- 1.2, 2.6 +/- 0.8 and 2.5 +/- 1.0 h.","Significant reduction in chloroquine bioavailability following coadministration with the Sudanese beverages Aradaib, Karkadi and Lemon. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8089046/),[mg] / [l],553,151807,DB00608,Chloroquine
,8089046,Cmax,"The corresponding mean Cmax values were 553 +/- 17.8, 184 +/- 21.3, 148 +/- 14.1 and 210 +/- 17.4 mg/L and the corresponding Tmax values were 3.0 +/- 1.0, 3.2 +/- 1.2, 2.6 +/- 0.8 and 2.5 +/- 1.0 h.","Significant reduction in chloroquine bioavailability following coadministration with the Sudanese beverages Aradaib, Karkadi and Lemon. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8089046/),[mg] / [l],184,151808,DB00608,Chloroquine
,8089046,Cmax,"The corresponding mean Cmax values were 553 +/- 17.8, 184 +/- 21.3, 148 +/- 14.1 and 210 +/- 17.4 mg/L and the corresponding Tmax values were 3.0 +/- 1.0, 3.2 +/- 1.2, 2.6 +/- 0.8 and 2.5 +/- 1.0 h.","Significant reduction in chloroquine bioavailability following coadministration with the Sudanese beverages Aradaib, Karkadi and Lemon. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8089046/),[mg] / [l],148,151809,DB00608,Chloroquine
,8089046,Cmax,"The corresponding mean Cmax values were 553 +/- 17.8, 184 +/- 21.3, 148 +/- 14.1 and 210 +/- 17.4 mg/L and the corresponding Tmax values were 3.0 +/- 1.0, 3.2 +/- 1.2, 2.6 +/- 0.8 and 2.5 +/- 1.0 h.","Significant reduction in chloroquine bioavailability following coadministration with the Sudanese beverages Aradaib, Karkadi and Lemon. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8089046/),[mg] / [l],210,151810,DB00608,Chloroquine
,8089046,Tmax,"The corresponding mean Cmax values were 553 +/- 17.8, 184 +/- 21.3, 148 +/- 14.1 and 210 +/- 17.4 mg/L and the corresponding Tmax values were 3.0 +/- 1.0, 3.2 +/- 1.2, 2.6 +/- 0.8 and 2.5 +/- 1.0 h.","Significant reduction in chloroquine bioavailability following coadministration with the Sudanese beverages Aradaib, Karkadi and Lemon. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8089046/),h,3.0,151811,DB00608,Chloroquine
,8089046,Tmax,"The corresponding mean Cmax values were 553 +/- 17.8, 184 +/- 21.3, 148 +/- 14.1 and 210 +/- 17.4 mg/L and the corresponding Tmax values were 3.0 +/- 1.0, 3.2 +/- 1.2, 2.6 +/- 0.8 and 2.5 +/- 1.0 h.","Significant reduction in chloroquine bioavailability following coadministration with the Sudanese beverages Aradaib, Karkadi and Lemon. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8089046/),h,3.2,151812,DB00608,Chloroquine
,8089046,Tmax,"The corresponding mean Cmax values were 553 +/- 17.8, 184 +/- 21.3, 148 +/- 14.1 and 210 +/- 17.4 mg/L and the corresponding Tmax values were 3.0 +/- 1.0, 3.2 +/- 1.2, 2.6 +/- 0.8 and 2.5 +/- 1.0 h.","Significant reduction in chloroquine bioavailability following coadministration with the Sudanese beverages Aradaib, Karkadi and Lemon. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8089046/),h,2.6,151813,DB00608,Chloroquine
,8089046,Tmax,"The corresponding mean Cmax values were 553 +/- 17.8, 184 +/- 21.3, 148 +/- 14.1 and 210 +/- 17.4 mg/L and the corresponding Tmax values were 3.0 +/- 1.0, 3.2 +/- 1.2, 2.6 +/- 0.8 and 2.5 +/- 1.0 h.","Significant reduction in chloroquine bioavailability following coadministration with the Sudanese beverages Aradaib, Karkadi and Lemon. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8089046/),h,2.5,151814,DB00608,Chloroquine
above,32438446,Cmax /EC90 ratio,Only 14 of the 56 analyzed drugs achieved a Cmax /EC90 ratio above 1.,Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438446/),,1,152820,DB00608,Chloroquine
,8562294,elimination half-life,"The elimination half-life of S(+)-HCQ (457 +/- 122 h) was significantly shorter than that of R(-)-HCQ (526 +/- 140 h), partly due to its faster urinary excretion and hepatic metabolism.",Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562294/),h,457,153015,DB00608,Chloroquine
,8562294,elimination half-life,"The elimination half-life of S(+)-HCQ (457 +/- 122 h) was significantly shorter than that of R(-)-HCQ (526 +/- 140 h), partly due to its faster urinary excretion and hepatic metabolism.",Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562294/),h,526,153016,DB00608,Chloroquine
,8562294,renal clearance,"Its renal clearance was twice that of R(-)-HCQ (4.61 +/- 4.01 vs 1.79 +/- 1.30 1 h-1), and metabolites derived from the S-isomer represented 80-90% of the urinary recovery of the dose.",Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562294/),[1] / [h],4.61,153017,DB00608,Chloroquine
,8562294,renal clearance,"Its renal clearance was twice that of R(-)-HCQ (4.61 +/- 4.01 vs 1.79 +/- 1.30 1 h-1), and metabolites derived from the S-isomer represented 80-90% of the urinary recovery of the dose.",Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8562294/),[1] / [h],1.79,153018,DB00608,Chloroquine
,18810398,plasma area under the substrate concentration-time curve (AUC 0-infinity),"Mean MB plasma area under the substrate concentration-time curve (AUC 0-infinity) was 7,639 +/- 3,384 ng/mL*h and 51,171 +/- 17,147 ng/mL*h after i.v. and oral administration, respectively (dosage 1:10), and 76,897 +/- 46,037 ng/mL*h after MB combined with CQ.",High absolute bioavailability of methylene blue given as an aqueous oral formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18810398/),[ng] / [h·ml],"7,639",156062,DB00608,Chloroquine
,18810398,plasma area under the substrate concentration-time curve (AUC 0-infinity),"Mean MB plasma area under the substrate concentration-time curve (AUC 0-infinity) was 7,639 +/- 3,384 ng/mL*h and 51,171 +/- 17,147 ng/mL*h after i.v. and oral administration, respectively (dosage 1:10), and 76,897 +/- 46,037 ng/mL*h after MB combined with CQ.",High absolute bioavailability of methylene blue given as an aqueous oral formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18810398/),[ng] / [h·ml],"51,171",156063,DB00608,Chloroquine
,18810398,plasma area under the substrate concentration-time curve (AUC 0-infinity),"Mean MB plasma area under the substrate concentration-time curve (AUC 0-infinity) was 7,639 +/- 3,384 ng/mL*h and 51,171 +/- 17,147 ng/mL*h after i.v. and oral administration, respectively (dosage 1:10), and 76,897 +/- 46,037 ng/mL*h after MB combined with CQ.",High absolute bioavailability of methylene blue given as an aqueous oral formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18810398/),[ng] / [h·ml],"76,897",156064,DB00608,Chloroquine
,18810398,absolute bioavailability,The absolute bioavailability was 72.3 +/- 23.9%.,High absolute bioavailability of methylene blue given as an aqueous oral formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18810398/),%,72.3,156065,DB00608,Chloroquine
,29194347,IC50,"By using standard in vitro antimalarial assays, AM1 showed low nanomolar inhibitory activity against chloroquine-sensitive and resistant P. falciparum strains (range IC50 16-53 nM), matched with a high potency against P. vivax field isolates (Mean IC50 29 nM).",In Vivo and In Vitro Activities and ADME-Tox Profile of a Quinolizidine-Modified 4-Aminoquinoline: A Potent Anti-P. falciparum and Anti-P. vivax Blood-Stage Antimalarial. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29194347/),nM,16-53,156645,DB00608,Chloroquine
,29194347,IC50,"By using standard in vitro antimalarial assays, AM1 showed low nanomolar inhibitory activity against chloroquine-sensitive and resistant P. falciparum strains (range IC50 16-53 nM), matched with a high potency against P. vivax field isolates (Mean IC50 29 nM).",In Vivo and In Vitro Activities and ADME-Tox Profile of a Quinolizidine-Modified 4-Aminoquinoline: A Potent Anti-P. falciparum and Anti-P. vivax Blood-Stage Antimalarial. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29194347/),nM,29,156646,DB00608,Chloroquine
,2239323,peak serum levels,"When the drug was given orally in tablet form to rabbits at doses of 10, 20 and 30 mg/kg, peak serum levels of 0.03, 0.05 and 0.13 micrograms/ml, respectively, were obtained in 1 to 2 h.",[The pharmacokinetics of dihydroqinghasu given orally to rabbits and dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2239323/),[μg] / [ml],0.03,158354,DB00608,Chloroquine
,2239323,peak serum levels,"When the drug was given orally in tablet form to rabbits at doses of 10, 20 and 30 mg/kg, peak serum levels of 0.03, 0.05 and 0.13 micrograms/ml, respectively, were obtained in 1 to 2 h.",[The pharmacokinetics of dihydroqinghasu given orally to rabbits and dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2239323/),[μg] / [ml],0.05,158355,DB00608,Chloroquine
,2239323,peak serum levels,"When the drug was given orally in tablet form to rabbits at doses of 10, 20 and 30 mg/kg, peak serum levels of 0.03, 0.05 and 0.13 micrograms/ml, respectively, were obtained in 1 to 2 h.",[The pharmacokinetics of dihydroqinghasu given orally to rabbits and dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2239323/),[μg] / [ml],0.13,158356,DB00608,Chloroquine
,2239323,T1/2,"The corresponding T1/2 of the drug were found to be 1.19, 1.00 and 1.10 h and the MRTs were 1.73, 1.36 and 1.53 h.",[The pharmacokinetics of dihydroqinghasu given orally to rabbits and dogs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2239323/),h,1.19,158357,DB00608,Chloroquine
,2239323,T1/2,"The corresponding T1/2 of the drug were found to be 1.19, 1.00 and 1.10 h and the MRTs were 1.73, 1.36 and 1.53 h.",[The pharmacokinetics of dihydroqinghasu given orally to rabbits and dogs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2239323/),h,1.00,158358,DB00608,Chloroquine
,2239323,T1/2,"The corresponding T1/2 of the drug were found to be 1.19, 1.00 and 1.10 h and the MRTs were 1.73, 1.36 and 1.53 h.",[The pharmacokinetics of dihydroqinghasu given orally to rabbits and dogs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2239323/),h,1.10,158359,DB00608,Chloroquine
,2239323,MRTs,"The corresponding T1/2 of the drug were found to be 1.19, 1.00 and 1.10 h and the MRTs were 1.73, 1.36 and 1.53 h.",[The pharmacokinetics of dihydroqinghasu given orally to rabbits and dogs]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2239323/),h,1.73,158360,DB00608,Chloroquine
,2239323,MRTs,"The corresponding T1/2 of the drug were found to be 1.19, 1.00 and 1.10 h and the MRTs were 1.73, 1.36 and 1.53 h.",[The pharmacokinetics of dihydroqinghasu given orally to rabbits and dogs]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2239323/),h,1.36,158361,DB00608,Chloroquine
,2239323,MRTs,"The corresponding T1/2 of the drug were found to be 1.19, 1.00 and 1.10 h and the MRTs were 1.73, 1.36 and 1.53 h.",[The pharmacokinetics of dihydroqinghasu given orally to rabbits and dogs]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2239323/),h,1.53,158362,DB00608,Chloroquine
,2239323,peak serum concentration,"When dogs were given DHQHS tablets at the dose of 20 mg/kg, a peak serum concentration of 0.13 micrograms/ml wes reached in about 2 h with a T1/2 of 2.10 h and an MRT of 3.04 h.",[The pharmacokinetics of dihydroqinghasu given orally to rabbits and dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2239323/),[μg] / [ml],0.13,158363,DB00608,Chloroquine
,2239323,T1/2,"When dogs were given DHQHS tablets at the dose of 20 mg/kg, a peak serum concentration of 0.13 micrograms/ml wes reached in about 2 h with a T1/2 of 2.10 h and an MRT of 3.04 h.",[The pharmacokinetics of dihydroqinghasu given orally to rabbits and dogs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2239323/),h,2.10,158364,DB00608,Chloroquine
,2239323,MRT,"When dogs were given DHQHS tablets at the dose of 20 mg/kg, a peak serum concentration of 0.13 micrograms/ml wes reached in about 2 h with a T1/2 of 2.10 h and an MRT of 3.04 h.",[The pharmacokinetics of dihydroqinghasu given orally to rabbits and dogs]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2239323/),h,3.04,158365,DB00608,Chloroquine
,3582422,saliva: plasma concentrations ratio,The saliva: plasma concentrations ratio was found to be 0.53.,Pharmacokinetics of chloroquine: saliva and plasma levels relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582422/),,0.53,159837,DB00608,Chloroquine
,3582422,Cls/F,The saliva clearance rate (Cls/F) of chloroquine was about twice the plasma clearance rate (Cl/F). (Cls/F: 0.46 +/- 0.051/day/kg; 0.27 +/- 0.021/day/kg).,Pharmacokinetics of chloroquine: saliva and plasma levels relationship. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582422/),1/[d·kg],0.46,159838,DB00608,Chloroquine
,3582422,Cls/F,The saliva clearance rate (Cls/F) of chloroquine was about twice the plasma clearance rate (Cl/F). (Cls/F: 0.46 +/- 0.051/day/kg; 0.27 +/- 0.021/day/kg).,Pharmacokinetics of chloroquine: saliva and plasma levels relationship. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582422/),1/[d·kg],0.27,159839,DB00608,Chloroquine
,3582422,Cl/F,"However, the predicted Cl/F (0.27 +/- 0.031/day/kg) from saliva data was in agreement with Cl/F from plasma data.",Pharmacokinetics of chloroquine: saliva and plasma levels relationship. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582422/),1/[d·kg],0.27,159840,DB00608,Chloroquine
,2206787,maximum plasma concentration (Cmax),"2. After the last maintenance dose of Maloprim, the following kinetic parameters (mean values) were determined for DDS and PYR, respectively: maximum plasma concentration (Cmax) = 1,134 and 116 ng ml-1; elimination half-life (t1/2) = 23 and 105 h; plasma clearance (CL) = 37.6 and 15.9 ml h-1 kg-1 and apparent volume of distribution (Vss) = 1.20 and 2.29 l kg-1.",Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206787/),[ng] / [ml],"1,134",163281,DB00608,Chloroquine
,2206787,maximum plasma concentration (Cmax),"2. After the last maintenance dose of Maloprim, the following kinetic parameters (mean values) were determined for DDS and PYR, respectively: maximum plasma concentration (Cmax) = 1,134 and 116 ng ml-1; elimination half-life (t1/2) = 23 and 105 h; plasma clearance (CL) = 37.6 and 15.9 ml h-1 kg-1 and apparent volume of distribution (Vss) = 1.20 and 2.29 l kg-1.",Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206787/),[ng] / [ml],116,163282,DB00608,Chloroquine
,2206787,elimination half-life (t1/2),"2. After the last maintenance dose of Maloprim, the following kinetic parameters (mean values) were determined for DDS and PYR, respectively: maximum plasma concentration (Cmax) = 1,134 and 116 ng ml-1; elimination half-life (t1/2) = 23 and 105 h; plasma clearance (CL) = 37.6 and 15.9 ml h-1 kg-1 and apparent volume of distribution (Vss) = 1.20 and 2.29 l kg-1.",Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206787/),h,23,163283,DB00608,Chloroquine
,2206787,elimination half-life (t1/2),"2. After the last maintenance dose of Maloprim, the following kinetic parameters (mean values) were determined for DDS and PYR, respectively: maximum plasma concentration (Cmax) = 1,134 and 116 ng ml-1; elimination half-life (t1/2) = 23 and 105 h; plasma clearance (CL) = 37.6 and 15.9 ml h-1 kg-1 and apparent volume of distribution (Vss) = 1.20 and 2.29 l kg-1.",Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206787/),h,105,163284,DB00608,Chloroquine
,2206787,plasma clearance (CL),"2. After the last maintenance dose of Maloprim, the following kinetic parameters (mean values) were determined for DDS and PYR, respectively: maximum plasma concentration (Cmax) = 1,134 and 116 ng ml-1; elimination half-life (t1/2) = 23 and 105 h; plasma clearance (CL) = 37.6 and 15.9 ml h-1 kg-1 and apparent volume of distribution (Vss) = 1.20 and 2.29 l kg-1.",Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206787/),[ml] / [h·kg],37.6,163285,DB00608,Chloroquine
,2206787,plasma clearance (CL),"2. After the last maintenance dose of Maloprim, the following kinetic parameters (mean values) were determined for DDS and PYR, respectively: maximum plasma concentration (Cmax) = 1,134 and 116 ng ml-1; elimination half-life (t1/2) = 23 and 105 h; plasma clearance (CL) = 37.6 and 15.9 ml h-1 kg-1 and apparent volume of distribution (Vss) = 1.20 and 2.29 l kg-1.",Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206787/),[ml] / [h·kg],15.9,163286,DB00608,Chloroquine
,2206787,apparent volume of distribution (Vss),"2. After the last maintenance dose of Maloprim, the following kinetic parameters (mean values) were determined for DDS and PYR, respectively: maximum plasma concentration (Cmax) = 1,134 and 116 ng ml-1; elimination half-life (t1/2) = 23 and 105 h; plasma clearance (CL) = 37.6 and 15.9 ml h-1 kg-1 and apparent volume of distribution (Vss) = 1.20 and 2.29 l kg-1.",Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206787/),[l] / [kg],1.20,163287,DB00608,Chloroquine
,2206787,apparent volume of distribution (Vss),"2. After the last maintenance dose of Maloprim, the following kinetic parameters (mean values) were determined for DDS and PYR, respectively: maximum plasma concentration (Cmax) = 1,134 and 116 ng ml-1; elimination half-life (t1/2) = 23 and 105 h; plasma clearance (CL) = 37.6 and 15.9 ml h-1 kg-1 and apparent volume of distribution (Vss) = 1.20 and 2.29 l kg-1.",Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206787/),[l] / [kg],2.29,163288,DB00608,Chloroquine
,2206787,t1/2,The mean t1/2 of MADDS was 22 h.,Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206787/),h,22,163289,DB00608,Chloroquine
,2206787,B/P ratio,MADDS had a B/P ratio of 0.69 and an E/P ratio of 0.33.,Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206787/),,0.69,163290,DB00608,Chloroquine
,2206787,E/P ratio,MADDS had a B/P ratio of 0.69 and an E/P ratio of 0.33.,Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206787/),,0.33,163291,DB00608,Chloroquine
,2206787,B/P,"The B/P and E/P ratios for PYR were 0.98 and 0.54, respectively.",Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206787/),,0.,163292,DB00608,Chloroquine
,2206787,E/P ratios,"The B/P and E/P ratios for PYR were 0.98 and 0.54, respectively.",Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206787/),,0.54,163293,DB00608,Chloroquine
,26149984,50% inhibitory concentrations (IC50s),"For P. falciparum, the median 50% inhibitory concentrations (IC50s) were 23.2 nM for PL69 and 26.6 nM for PL106, compared to 79.4 nM for unmodified CQ (P < 0.001 and P = 0.036, respectively).","Contrasting ex vivo efficacies of ""reversed chloroquine"" compounds in chloroquine-resistant Plasmodium falciparum and P. vivax isolates. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26149984/),nM,23.2,163952,DB00608,Chloroquine
,26149984,50% inhibitory concentrations (IC50s),"For P. falciparum, the median 50% inhibitory concentrations (IC50s) were 23.2 nM for PL69 and 26.6 nM for PL106, compared to 79.4 nM for unmodified CQ (P < 0.001 and P = 0.036, respectively).","Contrasting ex vivo efficacies of ""reversed chloroquine"" compounds in chloroquine-resistant Plasmodium falciparum and P. vivax isolates. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26149984/),nM,26.6,163953,DB00608,Chloroquine
,26149984,50% inhibitory concentrations (IC50s),"For P. falciparum, the median 50% inhibitory concentrations (IC50s) were 23.2 nM for PL69 and 26.6 nM for PL106, compared to 79.4 nM for unmodified CQ (P < 0.001 and P = 0.036, respectively).","Contrasting ex vivo efficacies of ""reversed chloroquine"" compounds in chloroquine-resistant Plasmodium falciparum and P. vivax isolates. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26149984/),nM,79.4,163954,DB00608,Chloroquine
,26149984,IC50s,"Both RCQs were equally active against the ring and trophozoite stages of P. falciparum, but in P. vivax, PL69 and PL106 showed less potent activity against trophozoite stages (median IC50s, 130.2 and 172.5 nM) compared to ring stages (median IC50s, 17.6 and 91.3 nM).","Contrasting ex vivo efficacies of ""reversed chloroquine"" compounds in chloroquine-resistant Plasmodium falciparum and P. vivax isolates. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26149984/),nM,130.2,163955,DB00608,Chloroquine
,26149984,IC50s,"Both RCQs were equally active against the ring and trophozoite stages of P. falciparum, but in P. vivax, PL69 and PL106 showed less potent activity against trophozoite stages (median IC50s, 130.2 and 172.5 nM) compared to ring stages (median IC50s, 17.6 and 91.3 nM).","Contrasting ex vivo efficacies of ""reversed chloroquine"" compounds in chloroquine-resistant Plasmodium falciparum and P. vivax isolates. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26149984/),nM,172.5,163956,DB00608,Chloroquine
,26149984,IC50s,"Both RCQs were equally active against the ring and trophozoite stages of P. falciparum, but in P. vivax, PL69 and PL106 showed less potent activity against trophozoite stages (median IC50s, 130.2 and 172.5 nM) compared to ring stages (median IC50s, 17.6 and 91.3 nM).","Contrasting ex vivo efficacies of ""reversed chloroquine"" compounds in chloroquine-resistant Plasmodium falciparum and P. vivax isolates. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26149984/),nM,17.6,163957,DB00608,Chloroquine
,26149984,IC50s,"Both RCQs were equally active against the ring and trophozoite stages of P. falciparum, but in P. vivax, PL69 and PL106 showed less potent activity against trophozoite stages (median IC50s, 130.2 and 172.5 nM) compared to ring stages (median IC50s, 17.6 and 91.3 nM).","Contrasting ex vivo efficacies of ""reversed chloroquine"" compounds in chloroquine-resistant Plasmodium falciparum and P. vivax isolates. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26149984/),nM,91.3,163958,DB00608,Chloroquine
,1945743,relative bioavailability,The relative bioavailability of chloroquinone in Witepsol H15 suppositories can vary between 10 and 53% of the bioavailability of a tablet formulation in adults.,Comparative bioavailability of rectal and oral formulations of chloroquine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1945743/),%,10 and 53,165284,DB00608,Chloroquine
,2670309,fever clearance time,"The average fever clearance time for A and B groups was 27.0 +/- 14.1 and 30.2 +/- 13.8h respectively (P greater than 0.05), and the clearance time for asexual parasites was 57.2 +/- 10.2 and 57.9 +/- 8.7h.",[Therapeutic effect of pyronaridine in plain tablets and enteric-coated tablets in falciparum malaria patients]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670309/),h,27.0,167366,DB00608,Chloroquine
,2670309,fever clearance time,"The average fever clearance time for A and B groups was 27.0 +/- 14.1 and 30.2 +/- 13.8h respectively (P greater than 0.05), and the clearance time for asexual parasites was 57.2 +/- 10.2 and 57.9 +/- 8.7h.",[Therapeutic effect of pyronaridine in plain tablets and enteric-coated tablets in falciparum malaria patients]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670309/),h,30.2,167367,DB00608,Chloroquine
,2670309,clearance time,"The average fever clearance time for A and B groups was 27.0 +/- 14.1 and 30.2 +/- 13.8h respectively (P greater than 0.05), and the clearance time for asexual parasites was 57.2 +/- 10.2 and 57.9 +/- 8.7h.",[Therapeutic effect of pyronaridine in plain tablets and enteric-coated tablets in falciparum malaria patients]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670309/),h,57.2,167368,DB00608,Chloroquine
,2670309,clearance time,"The average fever clearance time for A and B groups was 27.0 +/- 14.1 and 30.2 +/- 13.8h respectively (P greater than 0.05), and the clearance time for asexual parasites was 57.2 +/- 10.2 and 57.9 +/- 8.7h.",[Therapeutic effect of pyronaridine in plain tablets and enteric-coated tablets in falciparum malaria patients]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670309/),h,57.9,167369,DB00608,Chloroquine
,2670309,cure rates,Upon 28d following-up examination the cure rates were found to be 100% in group A and 93.8% in group B.,[Therapeutic effect of pyronaridine in plain tablets and enteric-coated tablets in falciparum malaria patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670309/),%,100,167370,DB00608,Chloroquine
,2670309,cure rates,Upon 28d following-up examination the cure rates were found to be 100% in group A and 93.8% in group B.,[Therapeutic effect of pyronaridine in plain tablets and enteric-coated tablets in falciparum malaria patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670309/),%,93.8,167371,DB00608,Chloroquine
,12100441,fever clearance times,"Parasite and fever clearance times (PCT and FCT) in Group 1 were 48 and 33.5 h, respectively, and 39 and 24 h in Group 2.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),h,48,168343,DB00608,Chloroquine
,12100441,fever clearance times,"Parasite and fever clearance times (PCT and FCT) in Group 1 were 48 and 33.5 h, respectively, and 39 and 24 h in Group 2.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),h,33.5,168344,DB00608,Chloroquine
,12100441,fever clearance times,"Parasite and fever clearance times (PCT and FCT) in Group 1 were 48 and 33.5 h, respectively, and 39 and 24 h in Group 2.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),h,39,168345,DB00608,Chloroquine
,12100441,fever clearance times,"Parasite and fever clearance times (PCT and FCT) in Group 1 were 48 and 33.5 h, respectively, and 39 and 24 h in Group 2.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),h,24,168346,DB00608,Chloroquine
,12100441,PCT,"Parasite and fever clearance times (PCT and FCT) in Group 1 were 48 and 33.5 h, respectively, and 39 and 24 h in Group 2.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),h,48,168347,DB00608,Chloroquine
,12100441,PCT,"Parasite and fever clearance times (PCT and FCT) in Group 1 were 48 and 33.5 h, respectively, and 39 and 24 h in Group 2.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),h,39,168348,DB00608,Chloroquine
,12100441,FCT,"Parasite and fever clearance times (PCT and FCT) in Group 1 were 48 and 33.5 h, respectively, and 39 and 24 h in Group 2.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),h,33.5,168349,DB00608,Chloroquine
,12100441,FCT,"Parasite and fever clearance times (PCT and FCT) in Group 1 were 48 and 33.5 h, respectively, and 39 and 24 h in Group 2.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),h,39,168350,DB00608,Chloroquine
,12100441,FCT,"Parasite and fever clearance times (PCT and FCT) in Group 1 were 48 and 33.5 h, respectively, and 39 and 24 h in Group 2.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),h,24,168351,DB00608,Chloroquine
,12100441,elimination half-life (pt1/2),"The parasite elimination half-life (pt1/2) in the CQ + SP0 group was 2.5 h, significantly shorter than the CQ + SP4 group of 5.7 h (P=0.006).",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),h,2.5,168352,DB00608,Chloroquine
,12100441,elimination half-life (pt1/2),"The parasite elimination half-life (pt1/2) in the CQ + SP0 group was 2.5 h, significantly shorter than the CQ + SP4 group of 5.7 h (P=0.006).",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),h,5.7,168353,DB00608,Chloroquine
,12100441,maximum concentration (Cmax),"Group 1 pharmacokinetic parameters showed a median maximum concentration (Cmax), area under the curve (AUC) and elimination half-life (t1/2) of 285 ng/ml, 2299 day ng/ml and 5.7 days for CQ, and 89 ng/ml 1845 day ng/ml and 7.3 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[ng] / [ml],285,168354,DB00608,Chloroquine
,12100441,area under the curve (AUC),"Group 1 pharmacokinetic parameters showed a median maximum concentration (Cmax), area under the curve (AUC) and elimination half-life (t1/2) of 285 ng/ml, 2299 day ng/ml and 5.7 days for CQ, and 89 ng/ml 1845 day ng/ml and 7.3 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[d·ng] / [ml],2299,168355,DB00608,Chloroquine
,12100441,area under the curve (AUC),"Group 1 pharmacokinetic parameters showed a median maximum concentration (Cmax), area under the curve (AUC) and elimination half-life (t1/2) of 285 ng/ml, 2299 day ng/ml and 5.7 days for CQ, and 89 ng/ml 1845 day ng/ml and 7.3 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),d,5.7,168356,DB00608,Chloroquine
,12100441,area under the curve (AUC),"Group 1 pharmacokinetic parameters showed a median maximum concentration (Cmax), area under the curve (AUC) and elimination half-life (t1/2) of 285 ng/ml, 2299 day ng/ml and 5.7 days for CQ, and 89 ng/ml 1845 day ng/ml and 7.3 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[ng] / [ml],89,168357,DB00608,Chloroquine
,12100441,area under the curve (AUC),"Group 1 pharmacokinetic parameters showed a median maximum concentration (Cmax), area under the curve (AUC) and elimination half-life (t1/2) of 285 ng/ml, 2299 day ng/ml and 5.7 days for CQ, and 89 ng/ml 1845 day ng/ml and 7.3 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[ng] / [ml],1845,168358,DB00608,Chloroquine
,12100441,elimination half-life (t1/2),"Group 1 pharmacokinetic parameters showed a median maximum concentration (Cmax), area under the curve (AUC) and elimination half-life (t1/2) of 285 ng/ml, 2299 day ng/ml and 5.7 days for CQ, and 89 ng/ml 1845 day ng/ml and 7.3 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),d,5.7,168359,DB00608,Chloroquine
,12100441,elimination half-life (t1/2),"Group 1 pharmacokinetic parameters showed a median maximum concentration (Cmax), area under the curve (AUC) and elimination half-life (t1/2) of 285 ng/ml, 2299 day ng/ml and 5.7 days for CQ, and 89 ng/ml 1845 day ng/ml and 7.3 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[ng] / [ml],1845,168360,DB00608,Chloroquine
,12100441,elimination half-life (t1/2),"Group 1 pharmacokinetic parameters showed a median maximum concentration (Cmax), area under the curve (AUC) and elimination half-life (t1/2) of 285 ng/ml, 2299 day ng/ml and 5.7 days for CQ, and 89 ng/ml 1845 day ng/ml and 7.3 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),d,7.3,168361,DB00608,Chloroquine
,12100441,Cmax,"In Group 2, the median Cmax, AUC and t1/2 for CQ and DCQ were at 283 ng/ml 1980 day ng/ml and 5.9 days for CQ and 220 ng/ml, 2680 day ng/ml and 8.5 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[ng] / [1980·d·ml·ml·ng],283,168362,DB00608,Chloroquine
,12100441,Cmax,"In Group 2, the median Cmax, AUC and t1/2 for CQ and DCQ were at 283 ng/ml 1980 day ng/ml and 5.9 days for CQ and 220 ng/ml, 2680 day ng/ml and 8.5 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[ng] / [ml],220,168363,DB00608,Chloroquine
,12100441,Cmax,"In Group 2, the median Cmax, AUC and t1/2 for CQ and DCQ were at 283 ng/ml 1980 day ng/ml and 5.9 days for CQ and 220 ng/ml, 2680 day ng/ml and 8.5 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[d·ng] / [ml],2680,168364,DB00608,Chloroquine
,12100441,AUC,"In Group 2, the median Cmax, AUC and t1/2 for CQ and DCQ were at 283 ng/ml 1980 day ng/ml and 5.9 days for CQ and 220 ng/ml, 2680 day ng/ml and 8.5 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),d,5.9,168365,DB00608,Chloroquine
,12100441,AUC,"In Group 2, the median Cmax, AUC and t1/2 for CQ and DCQ were at 283 ng/ml 1980 day ng/ml and 5.9 days for CQ and 220 ng/ml, 2680 day ng/ml and 8.5 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[ng] / [ml],220,168366,DB00608,Chloroquine
,12100441,AUC,"In Group 2, the median Cmax, AUC and t1/2 for CQ and DCQ were at 283 ng/ml 1980 day ng/ml and 5.9 days for CQ and 220 ng/ml, 2680 day ng/ml and 8.5 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[d·ng] / [ml],2680,168367,DB00608,Chloroquine
,12100441,t1/2,"In Group 2, the median Cmax, AUC and t1/2 for CQ and DCQ were at 283 ng/ml 1980 day ng/ml and 5.9 days for CQ and 220 ng/ml, 2680 day ng/ml and 8.5 days for DCQ, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),d,8.5,168368,DB00608,Chloroquine
,12100441,Cmax,"For S and P, the median Cmax, AUC and t1/2 were at 169 microg/ml, 2758 day ng/ml and 10.9 days for sulfadoxine, and 591 ng/ml, 3029 day ng/ml and 2.9 days for pyrimethamine, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[μg] / [ml],169,168369,DB00608,Chloroquine
,12100441,AUC,"For S and P, the median Cmax, AUC and t1/2 were at 169 microg/ml, 2758 day ng/ml and 10.9 days for sulfadoxine, and 591 ng/ml, 3029 day ng/ml and 2.9 days for pyrimethamine, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[d·ng] / [ml],2758,168370,DB00608,Chloroquine
,12100441,AUC,"For S and P, the median Cmax, AUC and t1/2 were at 169 microg/ml, 2758 day ng/ml and 10.9 days for sulfadoxine, and 591 ng/ml, 3029 day ng/ml and 2.9 days for pyrimethamine, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[ng] / [ml],591,168371,DB00608,Chloroquine
,12100441,AUC,"For S and P, the median Cmax, AUC and t1/2 were at 169 microg/ml, 2758 day ng/ml and 10.9 days for sulfadoxine, and 591 ng/ml, 3029 day ng/ml and 2.9 days for pyrimethamine, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),[d·ng] / [ml],3029,168372,DB00608,Chloroquine
,12100441,t1/2,"For S and P, the median Cmax, AUC and t1/2 were at 169 microg/ml, 2758 day ng/ml and 10.9 days for sulfadoxine, and 591 ng/ml, 3029 day ng/ml and 2.9 days for pyrimethamine, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),d,10.9,168373,DB00608,Chloroquine
,12100441,t1/2,"For S and P, the median Cmax, AUC and t1/2 were at 169 microg/ml, 2758 day ng/ml and 10.9 days for sulfadoxine, and 591 ng/ml, 3029 day ng/ml and 2.9 days for pyrimethamine, respectively.",Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100441/),d,2.9,168374,DB00608,Chloroquine
,21646487,elimination half-life (t(1/2)),"The elimination half-life (t(1/2)), clearance (CL), and volume of distribution (V) of CQ were 46.6 h, 9.9 liters/h/kg, and 667 liters/kg, respectively, in healthy mice and 99.3 h, 7.9 liters/h/kg, and 1,122 liters/kg, respectively, in malaria-infected mice.","Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21646487/),h,46.6,171158,DB00608,Chloroquine
,21646487,clearance (CL),"The elimination half-life (t(1/2)), clearance (CL), and volume of distribution (V) of CQ were 46.6 h, 9.9 liters/h/kg, and 667 liters/kg, respectively, in healthy mice and 99.3 h, 7.9 liters/h/kg, and 1,122 liters/kg, respectively, in malaria-infected mice.","Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21646487/),[l] / [h·kg],9.9,171159,DB00608,Chloroquine
,21646487,clearance (CL),"The elimination half-life (t(1/2)), clearance (CL), and volume of distribution (V) of CQ were 46.6 h, 9.9 liters/h/kg, and 667 liters/kg, respectively, in healthy mice and 99.3 h, 7.9 liters/h/kg, and 1,122 liters/kg, respectively, in malaria-infected mice.","Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21646487/),h,99.3,171160,DB00608,Chloroquine
,21646487,clearance (CL),"The elimination half-life (t(1/2)), clearance (CL), and volume of distribution (V) of CQ were 46.6 h, 9.9 liters/h/kg, and 667 liters/kg, respectively, in healthy mice and 99.3 h, 7.9 liters/h/kg, and 1,122 liters/kg, respectively, in malaria-infected mice.","Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21646487/),[l] / [h·kg],7.9,171161,DB00608,Chloroquine
,21646487,volume of distribution (V),"The elimination half-life (t(1/2)), clearance (CL), and volume of distribution (V) of CQ were 46.6 h, 9.9 liters/h/kg, and 667 liters/kg, respectively, in healthy mice and 99.3 h, 7.9 liters/h/kg, and 1,122 liters/kg, respectively, in malaria-infected mice.","Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21646487/),[l] / [kg],667,171162,DB00608,Chloroquine
,21646487,volume of distribution (V),"The elimination half-life (t(1/2)), clearance (CL), and volume of distribution (V) of CQ were 46.6 h, 9.9 liters/h/kg, and 667 liters/kg, respectively, in healthy mice and 99.3 h, 7.9 liters/h/kg, and 1,122 liters/kg, respectively, in malaria-infected mice.","Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21646487/),[l] / [kg],"1,122",171163,DB00608,Chloroquine
,24117456,elimination half-life,"However, it has low solubility in water, a long elimination half-life (4 days), and is neurotoxic, which leads to unwanted side effects.",Formulation and evaluation of Pheroid vesicles containing mefloquine for the treatment of malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24117456/),d,4,171514,DB00608,Chloroquine
,18644969,50% inhibitory concentrations (IC(50)s),The range of 50% inhibitory concentrations (IC(50)s) was 0.0005 to >1 microM.,Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18644969/),μM,0.0005 to >1,178743,DB00608,Chloroquine
<,18644969,IC(50)s,"Five analogs exhibited IC(50)s of <3 nM, and three of these exhibited selectivity indices of >600.",Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18644969/),nM,3,178744,DB00608,Chloroquine
>,18644969,selectivity indices,"Five analogs exhibited IC(50)s of <3 nM, and three of these exhibited selectivity indices of >600.",Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18644969/),,600,178745,DB00608,Chloroquine
,18644969,half-life,"The failure of monotherapy in mice may be due to a short half-life, since the compound was rapidly hydrolyzed to an inactive acid metabolite by loss of its hydroxamate group in vitro (half-life of 11 min in mouse microsomes) and in vivo (half-life in mice of 3.5 h after a single oral dose of 50 mg/kg).",Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18644969/),min,11,178746,DB00608,Chloroquine
,18644969,half-life,"The failure of monotherapy in mice may be due to a short half-life, since the compound was rapidly hydrolyzed to an inactive acid metabolite by loss of its hydroxamate group in vitro (half-life of 11 min in mouse microsomes) and in vivo (half-life in mice of 3.5 h after a single oral dose of 50 mg/kg).",Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18644969/),h,3.5,178747,DB00608,Chloroquine
,11286606,total amounts,The total amounts of CQ plus deethylchloroquine excreted with the urine during the 72-h study period were 5% for group A and 6% for group B.,Comparative in vitro and in vivo study of a sugar-coated chloroquine preparation marketed in Tanzania versus an ordinary brand. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286606/),,5,180762,DB00608,Chloroquine
,11286606,total amounts,The total amounts of CQ plus deethylchloroquine excreted with the urine during the 72-h study period were 5% for group A and 6% for group B.,Comparative in vitro and in vivo study of a sugar-coated chloroquine preparation marketed in Tanzania versus an ordinary brand. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286606/),,6,180763,DB00608,Chloroquine
,23425382,Apparent total clearance,Apparent total clearance of HCQ from blood was 316 (± 319) mL/min (mean (± standard deviation).,A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23425382/),[ml] / [min],316,181982,DB00608,Chloroquine
,4030540,% dose excreted,"The mean % dose excreted, maximum peak of excretion and the time of that peak after the administration of ampicillin alone were: 29 +/- 4.1%, 1.73 +/- 0.27 mg/min and 1.75 +/- 0.164 h, respectively.",Reduced ampicillin bioavailability following oral coadministration with chloroquine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030540/),%,29,182069,DB00608,Chloroquine
,4030540,maximum peak of excretion,"The mean % dose excreted, maximum peak of excretion and the time of that peak after the administration of ampicillin alone were: 29 +/- 4.1%, 1.73 +/- 0.27 mg/min and 1.75 +/- 0.164 h, respectively.",Reduced ampicillin bioavailability following oral coadministration with chloroquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030540/),[mg] / [min],1.73,182070,DB00608,Chloroquine
,4030540,time of that peak,"The mean % dose excreted, maximum peak of excretion and the time of that peak after the administration of ampicillin alone were: 29 +/- 4.1%, 1.73 +/- 0.27 mg/min and 1.75 +/- 0.164 h, respectively.",Reduced ampicillin bioavailability following oral coadministration with chloroquine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030540/),h,1.75,182071,DB00608,Chloroquine
,6129306,plasma half-life,"The antimalarial drug, chloroquine, is extensively distributed in tissue and slowly eliminated such that after a single dose, a plasma half-life of 3-5 days has been found (McChesney & McAuliff 1961; McChesney et al 1967).",Tissue and blood concentrations of chloroquine following chronic administration in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129306/),d,3-5,182533,DB00608,Chloroquine
greater,6129306,peak tissue/plasma concentration ratio,A peak tissue/plasma concentration ratio greater than 300 is obtained in many tissues and after a single dose the drug can be found in the liver and urine for up to five years (Gaudette & Coatney 1961; Rubin et al 1963; Zvaifler et al 1963).,Tissue and blood concentrations of chloroquine following chronic administration in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129306/),,300,182534,DB00608,Chloroquine
,8068494,Maximum blood concentrations,"Maximum blood concentrations of (-)-(R)-hydroxychloroquine were higher than (+)-(S)-hydroxychloroquine after oral dosing (121 +/- 56 and 99 +/- 42 ng/ml, respectively, P = 0.009).",Disposition and absorption of hydroxychloroquine enantiomers following a single dose of the racemate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8068494/),[ng] / [ml],121,183178,DB00608,Chloroquine
,8068494,Maximum blood concentrations,"Maximum blood concentrations of (-)-(R)-hydroxychloroquine were higher than (+)-(S)-hydroxychloroquine after oral dosing (121 +/- 56 and 99 +/- 42 ng/ml, respectively, P = 0.009).",Disposition and absorption of hydroxychloroquine enantiomers following a single dose of the racemate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8068494/),[ng] / [ml],99,183179,DB00608,Chloroquine
,3543146,time to peak concentration,"Absorption of im and sc chloroquine was rapid, with a median time to peak concentration of 30 min and a peak plasma concentration five times higher than after oral administration.",Parenteral chloroquine for treating falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3543146/),min,30,185579,DB00608,Chloroquine
,33492492,binding energy,"4-O-(6-galloylglucoside) gave binding energy values of - 8.4, - 6.8, - 8.9, - 9.1, and - 7.5 kcal/mol against Mpro, nsp3, nsp12, nsp13, and nsp15 respectively.",Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33492492/),[kcal] / [mol],-,185697,DB00608,Chloroquine
,33492492,binding energy,"4-O-(6-galloylglucoside) gave binding energy values of - 8.4, - 6.8, - 8.9, - 9.1, and - 7.5 kcal/mol against Mpro, nsp3, nsp12, nsp13, and nsp15 respectively.",Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33492492/),[kcal] / [mol],8.4,185698,DB00608,Chloroquine
,33492492,binding energy,"4-O-(6-galloylglucoside) gave binding energy values of - 8.4, - 6.8, - 8.9, - 9.1, and - 7.5 kcal/mol against Mpro, nsp3, nsp12, nsp13, and nsp15 respectively.",Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33492492/),[kcal] / [mol],6.8,185699,DB00608,Chloroquine
,33492492,binding energy,"4-O-(6-galloylglucoside) gave binding energy values of - 8.4, - 6.8, - 8.9, - 9.1, and - 7.5 kcal/mol against Mpro, nsp3, nsp12, nsp13, and nsp15 respectively.",Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33492492/),[kcal] / [mol],8.9,185700,DB00608,Chloroquine
,33492492,binding energy,"4-O-(6-galloylglucoside) gave binding energy values of - 8.4, - 6.8, - 8.9, - 9.1, and - 7.5 kcal/mol against Mpro, nsp3, nsp12, nsp13, and nsp15 respectively.",Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33492492/),[kcal] / [mol],9.1,185701,DB00608,Chloroquine
,33492492,binding energy,"4-O-(6-galloylglucoside) gave binding energy values of - 8.4, - 6.8, - 8.9, - 9.1, and - 7.5 kcal/mol against Mpro, nsp3, nsp12, nsp13, and nsp15 respectively.",Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33492492/),[kcal] / [mol],7.5,185702,DB00608,Chloroquine
,8882301,protein binding to serum albumin,A mean protein binding to serum albumin of 42 to 57% is usually reported.,Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8882301/),%,42 to 57,186895,DB00608,Chloroquine
,8882301,steady-state volume of distribution,The steady-state volume of distribution is approximately 1 L/kg.,Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8882301/),[l] / [kg],1,186896,DB00608,Chloroquine
,8882301,elimination half-life,"The usually reported mean values for the elimination half-life and the total body clearance of methotrexate are 5 to 8 hours and 4.8 to 7.8 L/h, respectively.",Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8882301/),h,5 to 8,186897,DB00608,Chloroquine
,8882301,total body clearance,"The usually reported mean values for the elimination half-life and the total body clearance of methotrexate are 5 to 8 hours and 4.8 to 7.8 L/h, respectively.",Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8882301/),[l] / [h],4.8 to 7.8,186898,DB00608,Chloroquine
,14638485,peak concentrations,"The peak concentrations in plasma following oral administration were higher in patients with acute illness (median, 1,905 mmol of dihydroartemisinin [DHA] equivalents per liter; range, 955 to 3,358 mmol of DHA equivalents per liter) than in patients in the convalescent phase (median, 955 mmol of DHA equivalents per liter; range, 576 to 1,363 mmol of DHA equivalents per liter), and clearance (CL/F) was lower in patients in the acute phase (1.11 liters/kg/h; range, 0.21 to 3.08 liters/kg/h) than in patients in the convalescent phase (median, 2.76 liters/kg/h; range, 1.56 to 5.74 liters/kg/h) (P< or =0.008).",Artemether bioavailability after oral or intramuscular administration in uncomplicated falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638485/),mM,"1,905",188372,DB00608,Chloroquine
,14638485,peak concentrations,"The peak concentrations in plasma following oral administration were higher in patients with acute illness (median, 1,905 mmol of dihydroartemisinin [DHA] equivalents per liter; range, 955 to 3,358 mmol of DHA equivalents per liter) than in patients in the convalescent phase (median, 955 mmol of DHA equivalents per liter; range, 576 to 1,363 mmol of DHA equivalents per liter), and clearance (CL/F) was lower in patients in the acute phase (1.11 liters/kg/h; range, 0.21 to 3.08 liters/kg/h) than in patients in the convalescent phase (median, 2.76 liters/kg/h; range, 1.56 to 5.74 liters/kg/h) (P< or =0.008).",Artemether bioavailability after oral or intramuscular administration in uncomplicated falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638485/),mM,955,188373,DB00608,Chloroquine
,14638485,clearance (CL/F),"The peak concentrations in plasma following oral administration were higher in patients with acute illness (median, 1,905 mmol of dihydroartemisinin [DHA] equivalents per liter; range, 955 to 3,358 mmol of DHA equivalents per liter) than in patients in the convalescent phase (median, 955 mmol of DHA equivalents per liter; range, 576 to 1,363 mmol of DHA equivalents per liter), and clearance (CL/F) was lower in patients in the acute phase (1.11 liters/kg/h; range, 0.21 to 3.08 liters/kg/h) than in patients in the convalescent phase (median, 2.76 liters/kg/h; range, 1.56 to 5.74 liters/kg/h) (P< or =0.008).",Artemether bioavailability after oral or intramuscular administration in uncomplicated falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638485/),[l] / [h·kg],1.11,188374,DB00608,Chloroquine
,14638485,clearance (CL/F),"The peak concentrations in plasma following oral administration were higher in patients with acute illness (median, 1,905 mmol of dihydroartemisinin [DHA] equivalents per liter; range, 955 to 3,358 mmol of DHA equivalents per liter) than in patients in the convalescent phase (median, 955 mmol of DHA equivalents per liter; range, 576 to 1,363 mmol of DHA equivalents per liter), and clearance (CL/F) was lower in patients in the acute phase (1.11 liters/kg/h; range, 0.21 to 3.08 liters/kg/h) than in patients in the convalescent phase (median, 2.76 liters/kg/h; range, 1.56 to 5.74 liters/kg/h) (P< or =0.008).",Artemether bioavailability after oral or intramuscular administration in uncomplicated falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638485/),[l] / [h·kg],2.76,188375,DB00608,Chloroquine
,14638485,time to Cmax,"In the acute phase, the time to Cmax was significantly shorter after oral administration (median, 1 h; range, 0.5 to 3.0 h) than after intramuscular administration (median, 8 h; range, 4 to 24 h) (P=0.001).",Artemether bioavailability after oral or intramuscular administration in uncomplicated falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638485/),h,1,188376,DB00608,Chloroquine
,14638485,time to Cmax,"In the acute phase, the time to Cmax was significantly shorter after oral administration (median, 1 h; range, 0.5 to 3.0 h) than after intramuscular administration (median, 8 h; range, 4 to 24 h) (P=0.001).",Artemether bioavailability after oral or intramuscular administration in uncomplicated falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14638485/),h,8,188377,DB00608,Chloroquine
,3054558,total cumulative dose,In all regimens the total cumulative dose was 25 mg of chloroquine base per kilogram of body weight.,"Chloroquine treatment of severe malaria in children. Pharmacokinetics, toxicity, and new dosage recommendations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3054558/),mg,25,190536,DB00608,Chloroquine
down,7329771,detection limit,The method is highly selective for the compounds of interest with a detection limit down to 1 ng/ml.,HPLC-analysis and preliminary pharmacokinetic parameter estimations of chloroquine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7329771/),[ng] / [ml],1,190831,DB00608,Chloroquine
,32501511,unbound plasma concentration,Geometric mean-simulated average unbound plasma concentration values among children within different developmental age groups (32-35 ng/mL) were congruent to adults (32 ng/mL).,Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501511/),[ng] / [ml],32-35,191092,DB00608,Chloroquine
,32501511,unbound plasma concentration,Geometric mean-simulated average unbound plasma concentration values among children within different developmental age groups (32-35 ng/mL) were congruent to adults (32 ng/mL).,Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501511/),[ng] / [ml],32,191093,DB00608,Chloroquine
,32501511,plasma area under the time curve 0 to infinity,Geometric mean-simulated plasma area under the time curve 0 to infinity values among children within different developmental age-groups (4315-5027 ng × h/mL) were similar to adults (4398 ng × h/mL).,Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501511/),[h·ng] / [ml],4315-5027,191094,DB00608,Chloroquine
,32501511,plasma area under the time curve 0 to infinity,Geometric mean-simulated plasma area under the time curve 0 to infinity values among children within different developmental age-groups (4315-5027 ng × h/mL) were similar to adults (4398 ng × h/mL).,Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501511/),[h·ng] / [ml],4398,191095,DB00608,Chloroquine
greater,7904547,elimination half-lives,Both drugs have reported elimination half-lives of greater than 1 month.,Clinical pharmacokinetics of slow-acting antirheumatic drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7904547/),month,1,193639,DB00608,Chloroquine
,8644048,initial peak,Plasma chloroquine levels showed an initial peak of 6.7 mumol/l.,[Chloroquine poisoning]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8644048/),[μM] / [l],6.7,194903,DB00608,Chloroquine
,8803904,bioavailability,Hydroxychloroquine (HCQ) and chloroquine (CQ) are well absorbed (0.7-0.8 bioavailability) when given orally.,Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803904/),,0.7-0.8,195382,DB00608,Chloroquine
,8803904,half-lives,"Both HCQ and CQ have prolonged half-lives, between 40 and 50 days, and low blood clearance (e.g. hydroxychloroquine's blood clearance is 96 ml/min).",Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803904/),d,40 and 50,195383,DB00608,Chloroquine
,8803904,blood clearance,"Both HCQ and CQ have prolonged half-lives, between 40 and 50 days, and low blood clearance (e.g. hydroxychloroquine's blood clearance is 96 ml/min).",Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803904/),[ml] / [min],96,195384,DB00608,Chloroquine
,8803904,Protein binding,"Protein binding ranges between 30 and 40% with binding to both albumin and alpha, glycoprotein.",Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803904/),%,30 and 40,195385,DB00608,Chloroquine
,2653061,fever clearance time,"The mean fever clearance time was 44.1 hr, and the mean parasite clearance time was 59.6 hr.","Intravenous quinine therapy of hospitalized children with Plasmodium falciparum malaria in Kinshasa, Zaire. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2653061/),h,44.1,196748,DB00608,Chloroquine
,2653061,parasite clearance time,"The mean fever clearance time was 44.1 hr, and the mean parasite clearance time was 59.6 hr.","Intravenous quinine therapy of hospitalized children with Plasmodium falciparum malaria in Kinshasa, Zaire. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2653061/),h,59.6,196749,DB00608,Chloroquine
,2653061,peak quinine level,"A mean peak quinine level of 9.7 ppm was attained after the second dose of quinine, and the minimum concentration was maintained at 5-7 ppm during the 2nd and 3rd hospital days.","Intravenous quinine therapy of hospitalized children with Plasmodium falciparum malaria in Kinshasa, Zaire. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2653061/),ppm,9.7,196750,DB00608,Chloroquine
,2653061,minimum concentration,"A mean peak quinine level of 9.7 ppm was attained after the second dose of quinine, and the minimum concentration was maintained at 5-7 ppm during the 2nd and 3rd hospital days.","Intravenous quinine therapy of hospitalized children with Plasmodium falciparum malaria in Kinshasa, Zaire. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2653061/),ppm,5-7,196751,DB00608,Chloroquine
,33146311,half-life,"The pharmacokinetic parameters of chloroquine were similar between male and female patients: a half-life of 9.5 days and 10.2 days, maximum concentration (Cmax) of 1295 ng/ml and 1220 ng/ml, area-under-the-curve (AUC 0-28) of 241 µg/mL h and 237 µg/mL h, observed clearance (CL/f) of 5.8 and 5.5 L/h and the volume of distribution (V/f) of 1869 L and 1936 L.",Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33146311/),d,9.5,197054,DB00608,Chloroquine
,33146311,half-life,"The pharmacokinetic parameters of chloroquine were similar between male and female patients: a half-life of 9.5 days and 10.2 days, maximum concentration (Cmax) of 1295 ng/ml and 1220 ng/ml, area-under-the-curve (AUC 0-28) of 241 µg/mL h and 237 µg/mL h, observed clearance (CL/f) of 5.8 and 5.5 L/h and the volume of distribution (V/f) of 1869 L and 1936 L.",Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33146311/),d,10.2,197055,DB00608,Chloroquine
,33146311,maximum concentration (Cmax),"The pharmacokinetic parameters of chloroquine were similar between male and female patients: a half-life of 9.5 days and 10.2 days, maximum concentration (Cmax) of 1295 ng/ml and 1220 ng/ml, area-under-the-curve (AUC 0-28) of 241 µg/mL h and 237 µg/mL h, observed clearance (CL/f) of 5.8 and 5.5 L/h and the volume of distribution (V/f) of 1869 L and 1936 L.",Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33146311/),[ng] / [ml],1295,197056,DB00608,Chloroquine
,33146311,maximum concentration (Cmax),"The pharmacokinetic parameters of chloroquine were similar between male and female patients: a half-life of 9.5 days and 10.2 days, maximum concentration (Cmax) of 1295 ng/ml and 1220 ng/ml, area-under-the-curve (AUC 0-28) of 241 µg/mL h and 237 µg/mL h, observed clearance (CL/f) of 5.8 and 5.5 L/h and the volume of distribution (V/f) of 1869 L and 1936 L.",Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33146311/),[ng] / [ml],1220,197057,DB00608,Chloroquine
,33146311,area-under-the-curve (AUC 0-28),"The pharmacokinetic parameters of chloroquine were similar between male and female patients: a half-life of 9.5 days and 10.2 days, maximum concentration (Cmax) of 1295 ng/ml and 1220 ng/ml, area-under-the-curve (AUC 0-28) of 241 µg/mL h and 237 µg/mL h, observed clearance (CL/f) of 5.8 and 5.5 L/h and the volume of distribution (V/f) of 1869 L and 1936 L.",Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33146311/),[μg] / [h·ml],241,197058,DB00608,Chloroquine
,33146311,area-under-the-curve (AUC 0-28),"The pharmacokinetic parameters of chloroquine were similar between male and female patients: a half-life of 9.5 days and 10.2 days, maximum concentration (Cmax) of 1295 ng/ml and 1220 ng/ml, area-under-the-curve (AUC 0-28) of 241 µg/mL h and 237 µg/mL h, observed clearance (CL/f) of 5.8 and 5.5 L/h and the volume of distribution (V/f) of 1869 L and 1936 L.",Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33146311/),[μg] / [h·ml],237,197059,DB00608,Chloroquine
,33146311,observed clearance (CL/f),"The pharmacokinetic parameters of chloroquine were similar between male and female patients: a half-life of 9.5 days and 10.2 days, maximum concentration (Cmax) of 1295 ng/ml and 1220 ng/ml, area-under-the-curve (AUC 0-28) of 241 µg/mL h and 237 µg/mL h, observed clearance (CL/f) of 5.8 and 5.5 L/h and the volume of distribution (V/f) of 1869 L and 1936 L.",Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33146311/),[l] / [h],5.8,197060,DB00608,Chloroquine
,33146311,observed clearance (CL/f),"The pharmacokinetic parameters of chloroquine were similar between male and female patients: a half-life of 9.5 days and 10.2 days, maximum concentration (Cmax) of 1295 ng/ml and 1220 ng/ml, area-under-the-curve (AUC 0-28) of 241 µg/mL h and 237 µg/mL h, observed clearance (CL/f) of 5.8 and 5.5 L/h and the volume of distribution (V/f) of 1869 L and 1936 L.",Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33146311/),[l] / [h],5.5,197061,DB00608,Chloroquine
,33146311,volume of distribution (V/f),"The pharmacokinetic parameters of chloroquine were similar between male and female patients: a half-life of 9.5 days and 10.2 days, maximum concentration (Cmax) of 1295 ng/ml and 1220 ng/ml, area-under-the-curve (AUC 0-28) of 241 µg/mL h and 237 µg/mL h, observed clearance (CL/f) of 5.8 and 5.5 L/h and the volume of distribution (V/f) of 1869 L and 1936 L.",Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33146311/),l,1869,197062,DB00608,Chloroquine
,33146311,volume of distribution (V/f),"The pharmacokinetic parameters of chloroquine were similar between male and female patients: a half-life of 9.5 days and 10.2 days, maximum concentration (Cmax) of 1295 ng/ml and 1220 ng/ml, area-under-the-curve (AUC 0-28) of 241 µg/mL h and 237 µg/mL h, observed clearance (CL/f) of 5.8 and 5.5 L/h and the volume of distribution (V/f) of 1869 L and 1936 L.",Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33146311/),l,1936,197063,DB00608,Chloroquine
,32959888,IC50,Methnaridine exhibited potent antimalarial activity against P. falciparum (3D7: IC50 = 0.0066 μM; Dd2: IC50 = 0.0056 μM).,"Methnaridine is an orally bioavailable, fast-killing and long-acting antimalarial agent that cures Plasmodium infections in mice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959888/),μM,0.0066,198909,DB00608,Chloroquine
,32959888,IC50,Methnaridine exhibited potent antimalarial activity against P. falciparum (3D7: IC50 = 0.0066 μM; Dd2: IC50 = 0.0056 μM).,"Methnaridine is an orally bioavailable, fast-killing and long-acting antimalarial agent that cures Plasmodium infections in mice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959888/),μM,0.0056,198910,DB00608,Chloroquine
,32959888,ED50,"In P. berghei-infected mice, oral administration effectively suppressed parasitemia (ED50 = 0.52 mg·kg-1 ·day-1 ) and cured the established infection (CD50 = 10.13 mg·kg-1 ·day-1 ).","Methnaridine is an orally bioavailable, fast-killing and long-acting antimalarial agent that cures Plasmodium infections in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959888/),[mg] / [d·kg],0.52,198911,DB00608,Chloroquine
,32959888,CD50,"In P. berghei-infected mice, oral administration effectively suppressed parasitemia (ED50 = 0.52 mg·kg-1 ·day-1 ) and cured the established infection (CD50 = 10.13 mg·kg-1 ·day-1 ).","Methnaridine is an orally bioavailable, fast-killing and long-acting antimalarial agent that cures Plasmodium infections in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959888/),[mg] / [d·kg],10.13,198912,DB00608,Chloroquine
,32959888,PCT99,Methnaridine exhibited a rapid parasiticidal profile (PCT99 = 36.0 h) and showed no cross-resistance to chloroquine.,"Methnaridine is an orally bioavailable, fast-killing and long-acting antimalarial agent that cures Plasmodium infections in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959888/),h,36.0,198913,DB00608,Chloroquine
,32959888,maximum tolerated dose,"The safety profile of methnaridine is also satisfactory (maximum tolerated dose = 1,125 mg·kg-1 ).","Methnaridine is an orally bioavailable, fast-killing and long-acting antimalarial agent that cures Plasmodium infections in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959888/),[mg] / [kg],"1,125",198914,DB00608,Chloroquine
,18294337,failure rates,"The reported day 14 failure rates were 48% and 18%, respectively.",Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294337/),%,48,200770,DB00608,Chloroquine
,18294337,failure rates,"The reported day 14 failure rates were 48% and 18%, respectively.",Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294337/),%,18,200771,DB00608,Chloroquine
,18294337,apparent clearance (CL/F),"For CQ, the typical apparent clearance (CL/F) and volume of distribution (V(C)/F) values were estimated to be 2.84 l h(-1) and 230 l.",Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294337/),[l] / [h],2.84,200772,DB00608,Chloroquine
,18294337,volume of distribution (V(C)/F),"For CQ, the typical apparent clearance (CL/F) and volume of distribution (V(C)/F) values were estimated to be 2.84 l h(-1) and 230 l.",Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294337/),l,230,200773,DB00608,Chloroquine
,18294337,CL/F,"The typical CL/F for SDx was 0.023 l h(-1), while the factor relating its V(C)/F to normalized body weight was 1.6 l kg(-1).",Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294337/),[l] / [h],0.023,200774,DB00608,Chloroquine
,18294337,V(C)/F,"The typical CL/F for SDx was 0.023 l h(-1), while the factor relating its V(C)/F to normalized body weight was 1.6 l kg(-1).",Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294337/),[l] / [kg],1.6,200775,DB00608,Chloroquine
,3288115,terminal half-life,"After a rapid absorption phase, the drug concentrations decreased in the plasma, with a terminal half-life of 14.5 h.",Disposition of amopyroquin in rats and rabbits and in vitro activity against Plasmodium falciparum. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3288115/),h,14.5,204644,DB00608,Chloroquine
,3288115,bioavailability,The similar bioavailability values (0.67 and 0.69) suggested that the drug could be used through i.m. or oral administration.,Disposition of amopyroquin in rats and rabbits and in vitro activity against Plasmodium falciparum. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3288115/),,0.67,204645,DB00608,Chloroquine
,3288115,bioavailability,The similar bioavailability values (0.67 and 0.69) suggested that the drug could be used through i.m. or oral administration.,Disposition of amopyroquin in rats and rabbits and in vitro activity against Plasmodium falciparum. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3288115/),,0.69,204646,DB00608,Chloroquine
,3288115,Clearance,"Clearance and distribution volume did not differ significantly among the three modes of administration, and the terminal half-lives were 18.1 +/- 3.3, 23.9 +/- 6.7, and 25.7 +/- 5.4 h for intravenous, i.m., and oral routes, respectively.",Disposition of amopyroquin in rats and rabbits and in vitro activity against Plasmodium falciparum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3288115/),h,18.1,204647,DB00608,Chloroquine
,3288115,terminal half-lives,"Clearance and distribution volume did not differ significantly among the three modes of administration, and the terminal half-lives were 18.1 +/- 3.3, 23.9 +/- 6.7, and 25.7 +/- 5.4 h for intravenous, i.m., and oral routes, respectively.",Disposition of amopyroquin in rats and rabbits and in vitro activity against Plasmodium falciparum. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3288115/),h,23.9,204648,DB00608,Chloroquine
,3288115,terminal half-lives,"Clearance and distribution volume did not differ significantly among the three modes of administration, and the terminal half-lives were 18.1 +/- 3.3, 23.9 +/- 6.7, and 25.7 +/- 5.4 h for intravenous, i.m., and oral routes, respectively.",Disposition of amopyroquin in rats and rabbits and in vitro activity against Plasmodium falciparum. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3288115/),h,25.7,204649,DB00608,Chloroquine
,3288115,ratio of concentrations,The ratio of concentrations in erythrocytes and plasma was about 5 in rats and rabbits.,Disposition of amopyroquin in rats and rabbits and in vitro activity against Plasmodium falciparum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3288115/),,5,204650,DB00608,Chloroquine
greater,3949918,overall recovery,The mean overall recovery from each biological fluid was greater than 75%.,"Simultaneous determination of chloroquine, amodiaquine and their metabolites in human plasma, red blood cells, whole blood and urine by column liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3949918/),%,75,204869,DB00608,Chloroquine
,15099441,maximum value (C(max)),The uveal tract concentrations reached the maximum value (C(max)) of 26.33 +/- 0.75 microg eq.,"Absorption, distribution and excretion of 14C-levofloxacin after single oral administration in albino and pigmented rats: binding characteristics of levofloxacin-related radioactivity to melanin in vivo. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15099441/),eq·μg,26.33,206672,DB00608,Chloroquine
,15099441,terminal half-life,g(-1) at 24 h after dosing and declined slowly with a terminal half-life of 468.1 h (19.5 days).,"Absorption, distribution and excretion of 14C-levofloxacin after single oral administration in albino and pigmented rats: binding characteristics of levofloxacin-related radioactivity to melanin in vivo. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15099441/),h,468.1,206673,DB00608,Chloroquine
,15099441,uveal tract concentration,"The uveal tract concentration at 12 weeks was 0.73+/- 0.12 microg eq. g(-1), which is c. 1/36 of C(max).","Absorption, distribution and excretion of 14C-levofloxacin after single oral administration in albino and pigmented rats: binding characteristics of levofloxacin-related radioactivity to melanin in vivo. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15099441/),[eq·μg] / [g],0.73,206674,DB00608,Chloroquine
,15099441,AUC(0- infinity ),The AUC(0- infinity ) for the uveal tract was 12.58 mg h(-1) g(-1).,"Absorption, distribution and excretion of 14C-levofloxacin after single oral administration in albino and pigmented rats: binding characteristics of levofloxacin-related radioactivity to melanin in vivo. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15099441/),[mg] / [g·h],12.58,206675,DB00608,Chloroquine
>,9010884,Saliva to plasma concentration ratios,Saliva to plasma concentration ratios obtained after administration of the drug by both routes were high (mean > 11) and exhibited a time-dependent variability.,Time-dependent variability of chloroquine secretion into human saliva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010884/),,11,206685,DB00608,Chloroquine
,12959287,fraction absorbed,The mean (+/- s.d.) fraction absorbed estimated by the four methods was 0.64 +/- 0.14 after the tablet and 0.87 +/- 0.30 after the oral solution.,Absorption and in vivo dissolution of hydroxycholoroquine in fed subjects assessed using deconvolution techniques. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959287/),,0.64,207324,DB00608,Chloroquine
,12959287,fraction absorbed,The mean (+/- s.d.) fraction absorbed estimated by the four methods was 0.64 +/- 0.14 after the tablet and 0.87 +/- 0.30 after the oral solution.,Absorption and in vivo dissolution of hydroxycholoroquine in fed subjects assessed using deconvolution techniques. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959287/),,0.87,207325,DB00608,Chloroquine
,12959287,absorption half-life,"3. The mean (+/- s.d.) absorption half-life was 3.7 +/- 2.0 h for the tablet and 3.3 +/- 1.6 h for the solution, suggesting that absorption following the tablet dose was not rate-limited by dissolution.",Absorption and in vivo dissolution of hydroxycholoroquine in fed subjects assessed using deconvolution techniques. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959287/),h,3.7,207326,DB00608,Chloroquine
,12959287,absorption half-life,"3. The mean (+/- s.d.) absorption half-life was 3.7 +/- 2.0 h for the tablet and 3.3 +/- 1.6 h for the solution, suggesting that absorption following the tablet dose was not rate-limited by dissolution.",Absorption and in vivo dissolution of hydroxycholoroquine in fed subjects assessed using deconvolution techniques. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959287/),h,3.3,207327,DB00608,Chloroquine
,12959287,lag-time before absorption commenced,"The lag-time before absorption commenced in fed subjects (1.65 +/- 0.46 h) showed a significant three-fold increase over that reported previously in fasting subjects (0.63 +/- 0.33 h), but this difference is not likely to be of clinical significance.",Absorption and in vivo dissolution of hydroxycholoroquine in fed subjects assessed using deconvolution techniques. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959287/),h,1.65,207328,DB00608,Chloroquine
,12959287,lag-time before absorption commenced,"The lag-time before absorption commenced in fed subjects (1.65 +/- 0.46 h) showed a significant three-fold increase over that reported previously in fasting subjects (0.63 +/- 0.33 h), but this difference is not likely to be of clinical significance.",Absorption and in vivo dissolution of hydroxycholoroquine in fed subjects assessed using deconvolution techniques. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959287/),h,0.63,207329,DB00608,Chloroquine
,8896943,volume of distribution,"The drug is extensively distributed, with a volume of distribution of 200 to 800 L/kg when calculated from plasma concentrations and 200 L/kg when estimated from whole blood data (concentrations being 5 to 10 times higher).",Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8896943/),[l] / [kg],200 to 800,207330,DB00608,Chloroquine
,8896943,volume of distribution,"The drug is extensively distributed, with a volume of distribution of 200 to 800 L/kg when calculated from plasma concentrations and 200 L/kg when estimated from whole blood data (concentrations being 5 to 10 times higher).",Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8896943/),[l] / [kg],200,207331,DB00608,Chloroquine
,8896943,elimination half-lives,"Desethylchloroquine and bisdesethylchloroquine concentrations reach 40 and 10% of chloroquine concentrations, respectively; both chloroquine and desethylchloroquine concentrations decline slowly, with elimination half-lives of 20 to 60 days.",Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8896943/),d,20 to 60,207332,DB00608,Chloroquine
,2039190,time required,The time required for a 50% decrease in the initial parasitemia was shorter in patients on schedule 2 (14.3 +/- 1.6 h) than it was in patients on schedule 1 (35.5 +/- 5.4 h; P less than 0.01).,Efficacy of a loading dose of oral chloroquine in a 36-hour treatment schedule for uncomplicated plasmodium falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2039190/),h,14.3,208570,DB00608,Chloroquine
,2039190,time required,The time required for a 50% decrease in the initial parasitemia was shorter in patients on schedule 2 (14.3 +/- 1.6 h) than it was in patients on schedule 1 (35.5 +/- 5.4 h; P less than 0.01).,Efficacy of a loading dose of oral chloroquine in a 36-hour treatment schedule for uncomplicated plasmodium falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2039190/),h,35.5,208571,DB00608,Chloroquine
,9278201,areas under the pruritus intensity-time curve,"The areas under the pruritus intensity-time curve were promethazine 105 +/- 28 (units h), niacin 76 +/- 22, prednisolone 28 +/- 24, and prednisolone and niacin 34 +/- 17 (P < 0.001 ANOVA).","Chloroquine-induced pruritus in malaria fever: contribution of malaria parasitaemia and the effects of prednisolone, niacin, and their combination, compared with antihistamine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278201/),h·units,105,209541,DB00608,Chloroquine
,9278201,areas under the pruritus intensity-time curve,"The areas under the pruritus intensity-time curve were promethazine 105 +/- 28 (units h), niacin 76 +/- 22, prednisolone 28 +/- 24, and prednisolone and niacin 34 +/- 17 (P < 0.001 ANOVA).","Chloroquine-induced pruritus in malaria fever: contribution of malaria parasitaemia and the effects of prednisolone, niacin, and their combination, compared with antihistamine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278201/),h·units,76,209542,DB00608,Chloroquine
,9278201,areas under the pruritus intensity-time curve,"The areas under the pruritus intensity-time curve were promethazine 105 +/- 28 (units h), niacin 76 +/- 22, prednisolone 28 +/- 24, and prednisolone and niacin 34 +/- 17 (P < 0.001 ANOVA).","Chloroquine-induced pruritus in malaria fever: contribution of malaria parasitaemia and the effects of prednisolone, niacin, and their combination, compared with antihistamine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278201/),h·units,28,209543,DB00608,Chloroquine
,9278201,areas under the pruritus intensity-time curve,"The areas under the pruritus intensity-time curve were promethazine 105 +/- 28 (units h), niacin 76 +/- 22, prednisolone 28 +/- 24, and prednisolone and niacin 34 +/- 17 (P < 0.001 ANOVA).","Chloroquine-induced pruritus in malaria fever: contribution of malaria parasitaemia and the effects of prednisolone, niacin, and their combination, compared with antihistamine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278201/),h·units,34,209544,DB00608,Chloroquine
,3879657,absorption half-times,"Absorption was rapid with both dose schedules used; mean absorption half-times were 1.5 and 1.8 hr, and plasma mefloquine concentrations exceeded 200 ng/g within 3 hr of completing administration in all but one exceptionally ill patient who died 40 hr later.",Intragastric mefloquine is absorbed rapidly in patients with cerebral malaria. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879657/),h,1.5,211361,DB00608,Chloroquine
,3879657,absorption half-times,"Absorption was rapid with both dose schedules used; mean absorption half-times were 1.5 and 1.8 hr, and plasma mefloquine concentrations exceeded 200 ng/g within 3 hr of completing administration in all but one exceptionally ill patient who died 40 hr later.",Intragastric mefloquine is absorbed rapidly in patients with cerebral malaria. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879657/),h,1.8,211362,DB00608,Chloroquine
,3879657,Steady state plasma concentrations,"Steady state plasma concentrations over 7 days ranged from 300 to 1,050 (mean 561) ng/g.",Intragastric mefloquine is absorbed rapidly in patients with cerebral malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879657/),[ng] / [g],561,211363,DB00608,Chloroquine
,33558079,plasma concentration,HCQ doses ranged from 200 to 800mg/day administered for 1 to 11days and median HCQ plasma concentration was 151ng/mL.,Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33558079/),ng,151,213017,DB00608,Chloroquine
,33558079,CL/F,"CL/F (F for unknown bioavailability) and Vd/F (relative standard-error, %) estimates were 45.9L/h (21.2) and 6690L (16.1).",Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33558079/),[l] / [h],45.9,213018,DB00608,Chloroquine
,33558079,Vd/F,"CL/F (F for unknown bioavailability) and Vd/F (relative standard-error, %) estimates were 45.9L/h (21.2) and 6690L (16.1).",Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33558079/),[l] / [h],45.9,213019,DB00608,Chloroquine
,33558079,Vd/F,"CL/F (F for unknown bioavailability) and Vd/F (relative standard-error, %) estimates were 45.9L/h (21.2) and 6690L (16.1).",Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33558079/),l,6690,213020,DB00608,Chloroquine
,33558079,elimination half-life (t1/2),The derived elimination half-life (t1/2) was 102h.,Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33558079/),h,102,213021,DB00608,Chloroquine
,33558079,CL/F,"These parameters in COVID-19 differed from those reported in patients with lupus, where CL/F, Vd/F and t1/2 are reported to be 68L/h, 2440 L and 19.5h, respectively.",Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33558079/),[l] / [h],68,213022,DB00608,Chloroquine
,33558079,Vd/F,"These parameters in COVID-19 differed from those reported in patients with lupus, where CL/F, Vd/F and t1/2 are reported to be 68L/h, 2440 L and 19.5h, respectively.",Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33558079/),l,2440,213023,DB00608,Chloroquine
,33558079,t1/2,"These parameters in COVID-19 differed from those reported in patients with lupus, where CL/F, Vd/F and t1/2 are reported to be 68L/h, 2440 L and 19.5h, respectively.",Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33558079/),h,19.5,213024,DB00608,Chloroquine
,33558079,half maximal effective concentration,"Within 72h of HCQ initiation, only 16/104 (15.4%) COVID-19 patients had HCQ plasma levels above the in vitro half maximal effective concentration of HCQ against SARS-CoV-2 (240ng/mL).",Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33558079/),[ng] / [ml],240,213025,DB00608,Chloroquine
,33089870,resolution factor,The resolution factor and RSD were 1.62 and 0.35% and in vitro data of both products met the USP requirements.,In Vitro and In Vivo Evaluation of Two Hydroxychloroquine Tablet Formulations: HPLC Assay Development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33089870/),%,1.62,213853,DB00608,Chloroquine
,33089870,RSD,The resolution factor and RSD were 1.62 and 0.35% and in vitro data of both products met the USP requirements.,In Vitro and In Vivo Evaluation of Two Hydroxychloroquine Tablet Formulations: HPLC Assay Development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33089870/),%,0.35,213854,DB00608,Chloroquine
,3543604,t1/2 beta,"In healthy subjects, quinine is rapidly eliminated (t1/2 beta: 6-12 h).","[Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3543604/),h,6-12,215080,DB00608,Chloroquine
,3543604,t1/2 beta,Chloroquine (t1/2 beta: 6-50 days) and mefloquine (t1/2 beta: 6-33 days) have extensive tissue distribution and prolonged activity after a single dose.,"[Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3543604/),d,6-50,215081,DB00608,Chloroquine
,3543604,t1/2 beta,Chloroquine (t1/2 beta: 6-50 days) and mefloquine (t1/2 beta: 6-33 days) have extensive tissue distribution and prolonged activity after a single dose.,"[Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3543604/),d,6-33,215082,DB00608,Chloroquine
,3543604,t1/2 beta,"In healthy subjects, the t1/2 beta of this metabolite is 9 to 18 days in plasma.","[Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3543604/),d,9 to 18,215083,DB00608,Chloroquine
,3543604,elimination half-life,Halofantrine has an elimination half-life of between 1.3 and 6.6 days.,"[Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3543604/),d,1.3 and 6.6,215084,DB00608,Chloroquine
,3543604,elimination half-life,"In rabbits, the elimination half-life in plasma was found to be 40 min.","[Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3543604/),min,40,215085,DB00608,Chloroquine
,14710634,Peak gametocytaemia,"Peak gametocytaemia was 74 +/- 19.9 (se), range 24-198, geometric mean 58 sf (sexual forms)/microliter.",Changes in Plasmodium falciparum gametocytaemia in children with chloroquine-sensitive asexual infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14710634/),se,74,216752,DB00608,Chloroquine
,14710634,Time to peak gamelocytaemia,"Time to peak gamelocytaemia was 43.2 +/- 14.4, range 0-120 h.",Changes in Plasmodium falciparum gametocytaemia in children with chloroquine-sensitive asexual infections. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14710634/),h,43.2,216753,DB00608,Chloroquine
,14710634,half-life of gametocytaemia,"The decline from peak gametocytaemia was exponential with a half-life of gametocytaemia of 43.2 +/- 20.4, range 13.1-206 h.",Changes in Plasmodium falciparum gametocytaemia in children with chloroquine-sensitive asexual infections. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14710634/),h,43.2,216754,DB00608,Chloroquine
higher,12878525,50% lethal dose,"For six mono- and three bis-quaternary ammonium salts, the therapeutic indices (i.e., 50% lethal dose and ED(50)) were higher than 5, and at best, around 20 to 30 for five of them (E6, E8, F4, G5, and G25), which is comparable to that of chloroquine under the same conditions.",In vivo antimalarial activities of mono- and bis quaternary ammonium salts interfering with Plasmodium phospholipid metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878525/),,5,221798,DB00608,Chloroquine
higher,12878525,ED(50),"For six mono- and three bis-quaternary ammonium salts, the therapeutic indices (i.e., 50% lethal dose and ED(50)) were higher than 5, and at best, around 20 to 30 for five of them (E6, E8, F4, G5, and G25), which is comparable to that of chloroquine under the same conditions.",In vivo antimalarial activities of mono- and bis quaternary ammonium salts interfering with Plasmodium phospholipid metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878525/),,5,221799,DB00608,Chloroquine
higher,12878525,ED(50),"For six mono- and three bis-quaternary ammonium salts, the therapeutic indices (i.e., 50% lethal dose and ED(50)) were higher than 5, and at best, around 20 to 30 for five of them (E6, E8, F4, G5, and G25), which is comparable to that of chloroquine under the same conditions.",In vivo antimalarial activities of mono- and bis quaternary ammonium salts interfering with Plasmodium phospholipid metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878525/),,20,221800,DB00608,Chloroquine
,12878525,elimination half-life,"Subcutaneously administered radioactive compounds had a short elimination half-life in mice (3.5 h) with low bioavailability (17.3%), which was likely due to the permanent cationic charge of the molecule.",In vivo antimalarial activities of mono- and bis quaternary ammonium salts interfering with Plasmodium phospholipid metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878525/),h,3.5,221801,DB00608,Chloroquine
,12878525,bioavailability,"Subcutaneously administered radioactive compounds had a short elimination half-life in mice (3.5 h) with low bioavailability (17.3%), which was likely due to the permanent cationic charge of the molecule.",In vivo antimalarial activities of mono- and bis quaternary ammonium salts interfering with Plasmodium phospholipid metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878525/),%,17.3,221802,DB00608,Chloroquine
,27639847,Cmax,"The pharmacokinetic parameters of chloroquine analysed in whole blood dry spot samples showed mean (coefficient of variation) Cmax and AUC0-t values of 374.44 (0.35) and 3700.43 (0.36) ng/mL, respectively.","Safety, efficacy and pharmacokinetic evaluations of a new coated chloroquine tablet in a single-arm open-label non-comparative trial in Brazil: a step towards a user-friendly malaria vivax treatment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27639847/),[ng] / [ml],374.44,223504,DB00608,Chloroquine
,27639847,AUC0-t,"The pharmacokinetic parameters of chloroquine analysed in whole blood dry spot samples showed mean (coefficient of variation) Cmax and AUC0-t values of 374.44 (0.35) and 3700.43 (0.36) ng/mL, respectively.","Safety, efficacy and pharmacokinetic evaluations of a new coated chloroquine tablet in a single-arm open-label non-comparative trial in Brazil: a step towards a user-friendly malaria vivax treatment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27639847/),[ng] / [ml],3700.43,223505,DB00608,Chloroquine
,8866926,Maximum hydroxychloroquine blood concentration (Cmax,"Maximum hydroxychloroquine blood concentration (Cmax; range 135-422 ng ml-1) and time to maximum (tmax; range 1.5-7.0 h) for the three tablet doses showed significant differences between subjects (P < 0.009; between subject coefficients of variation (CVs) 34% and 27%, respectively).",Hydroxychloroquine relative bioavailability: within subject reproducibility. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866926/),[ng] / [ml],135-422,224472,DB00608,Chloroquine
,8866926,time to maximum (tmax,"Maximum hydroxychloroquine blood concentration (Cmax; range 135-422 ng ml-1) and time to maximum (tmax; range 1.5-7.0 h) for the three tablet doses showed significant differences between subjects (P < 0.009; between subject coefficients of variation (CVs) 34% and 27%, respectively).",Hydroxychloroquine relative bioavailability: within subject reproducibility. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866926/),h,1.5-7.0,224473,DB00608,Chloroquine
,16127032,50% efficient dose [ED50],"After intraperitoneal administration, very low doses offer protection in a murine model of malaria (50% efficient dose [ED50] of 0.2 to 0.25 mg/kg).","Pharmacological properties of a new antimalarial bisthiazolium salt, T3, and a corresponding prodrug, TE3. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16127032/),[mg] / [kg],0.2 to 0.25,226938,DB00608,Chloroquine
,16127032,ED50,"After oral administration, the ED50 values were 13 and 5 mg/kg for T3 and TE3, respectively.","Pharmacological properties of a new antimalarial bisthiazolium salt, T3, and a corresponding prodrug, TE3. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16127032/),[mg] / [kg],13,226939,DB00608,Chloroquine
,16127032,ED50,"After oral administration, the ED50 values were 13 and 5 mg/kg for T3 and TE3, respectively.","Pharmacological properties of a new antimalarial bisthiazolium salt, T3, and a corresponding prodrug, TE3. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16127032/),[mg] / [kg],5,226940,DB00608,Chloroquine
,16127032,total clearance,"After TE3 administration, rapid prodrug-drug conversion occurred; the mean values of the pharmacokinetic parameters for T3 were as follows: total clearance, 1 liter/h/kg; steady-state volume of distribution, 14.8 liters/kg; and elimination half-life, 12 h.","Pharmacological properties of a new antimalarial bisthiazolium salt, T3, and a corresponding prodrug, TE3. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16127032/),[l] / [h·kg],1,226941,DB00608,Chloroquine
,16127032,steady-state volume of distribution,"After TE3 administration, rapid prodrug-drug conversion occurred; the mean values of the pharmacokinetic parameters for T3 were as follows: total clearance, 1 liter/h/kg; steady-state volume of distribution, 14.8 liters/kg; and elimination half-life, 12 h.","Pharmacological properties of a new antimalarial bisthiazolium salt, T3, and a corresponding prodrug, TE3. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16127032/),[l] / [kg],14.8,226942,DB00608,Chloroquine
,16127032,elimination half-life,"After TE3 administration, rapid prodrug-drug conversion occurred; the mean values of the pharmacokinetic parameters for T3 were as follows: total clearance, 1 liter/h/kg; steady-state volume of distribution, 14.8 liters/kg; and elimination half-life, 12 h.","Pharmacological properties of a new antimalarial bisthiazolium salt, T3, and a corresponding prodrug, TE3. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16127032/),h,12,226943,DB00608,Chloroquine
,16127032,absolute bioavailability,The absolute bioavailability was 72% after intraperitoneal administration (T3); it was 15% after oral administration (TE3).,"Pharmacological properties of a new antimalarial bisthiazolium salt, T3, and a corresponding prodrug, TE3. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16127032/),%,72,226944,DB00608,Chloroquine
,16127032,absolute bioavailability,The absolute bioavailability was 72% after intraperitoneal administration (T3); it was 15% after oral administration (TE3).,"Pharmacological properties of a new antimalarial bisthiazolium salt, T3, and a corresponding prodrug, TE3. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16127032/),%,15,226945,DB00608,Chloroquine
,16127032,plasma concentrations,T3 plasma concentrations (8 nM) 24 h following oral administration of TE3 were higher than the 50% inhibitory concentrations for the most chloroquine-resistant strains of P. falciparum (6.3 nM).,"Pharmacological properties of a new antimalarial bisthiazolium salt, T3, and a corresponding prodrug, TE3. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16127032/),,8,226946,DB00608,Chloroquine
,16127032,50% inhibitory concentrations,T3 plasma concentrations (8 nM) 24 h following oral administration of TE3 were higher than the 50% inhibitory concentrations for the most chloroquine-resistant strains of P. falciparum (6.3 nM).,"Pharmacological properties of a new antimalarial bisthiazolium salt, T3, and a corresponding prodrug, TE3. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16127032/),nM,6.3,226947,DB00608,Chloroquine
,6849784,volume of distribution,3 After i.v. dosing the volume of distribution ranged from 116 to 285 l/kg and the apparent terminal half-life from 146 to 333 h.,Disposition of chloroquine in man after single intravenous and oral doses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849784/),[l] / [kg],116 to 285,227578,DB00608,Chloroquine
,6849784,apparent terminal half-life,3 After i.v. dosing the volume of distribution ranged from 116 to 285 l/kg and the apparent terminal half-life from 146 to 333 h.,Disposition of chloroquine in man after single intravenous and oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849784/),h,146 to 333,227579,DB00608,Chloroquine
,6849784,Total plasma clearance,Total plasma clearance +/- s.d. was 712 +/- 166 ml/min and renal clearance 412 +/- 139 ml/min.,Disposition of chloroquine in man after single intravenous and oral doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849784/),[ml] / [min],712,227580,DB00608,Chloroquine
,6849784,renal clearance,Total plasma clearance +/- s.d. was 712 +/- 166 ml/min and renal clearance 412 +/- 139 ml/min.,Disposition of chloroquine in man after single intravenous and oral doses. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849784/),[ml] / [min],412,227581,DB00608,Chloroquine
,6849784,urinary recovery,"The mean estimated urinary recovery of chloroquine was 47%, 42% and 46% after i.v., oral solution and tablets indicating nearly complete bioavailability.",Disposition of chloroquine in man after single intravenous and oral doses. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849784/),%,47,227582,DB00608,Chloroquine
,6849784,urinary recovery,"The mean estimated urinary recovery of chloroquine was 47%, 42% and 46% after i.v., oral solution and tablets indicating nearly complete bioavailability.",Disposition of chloroquine in man after single intravenous and oral doses. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849784/),%,42,227583,DB00608,Chloroquine
,6849784,urinary recovery,"The mean estimated urinary recovery of chloroquine was 47%, 42% and 46% after i.v., oral solution and tablets indicating nearly complete bioavailability.",Disposition of chloroquine in man after single intravenous and oral doses. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849784/),%,46,227584,DB00608,Chloroquine
,9647356,systemic clearance (CL),"In arthritic rats, systemic clearance (CL) of HCQ enantiomers was significantly reduced (1.05 +/- 0.15 and 1.3 +/- 0.19 l/h/kg for R- and S-HCQ, respectively) compared to controls (1.69 +/- 0.32 and 1.93 +/- 0.34 l/h/kg for R- and S-HCQ, respectively).",Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9647356/),[l] / [h·kg],1.05,228213,DB00608,Chloroquine
,9647356,systemic clearance (CL),"In arthritic rats, systemic clearance (CL) of HCQ enantiomers was significantly reduced (1.05 +/- 0.15 and 1.3 +/- 0.19 l/h/kg for R- and S-HCQ, respectively) compared to controls (1.69 +/- 0.32 and 1.93 +/- 0.34 l/h/kg for R- and S-HCQ, respectively).",Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9647356/),[l] / [h·kg],1.3,228214,DB00608,Chloroquine
,9647356,systemic clearance (CL),"In arthritic rats, systemic clearance (CL) of HCQ enantiomers was significantly reduced (1.05 +/- 0.15 and 1.3 +/- 0.19 l/h/kg for R- and S-HCQ, respectively) compared to controls (1.69 +/- 0.32 and 1.93 +/- 0.34 l/h/kg for R- and S-HCQ, respectively).",Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9647356/),[l] / [h·kg],1.69,228215,DB00608,Chloroquine
,9647356,systemic clearance (CL),"In arthritic rats, systemic clearance (CL) of HCQ enantiomers was significantly reduced (1.05 +/- 0.15 and 1.3 +/- 0.19 l/h/kg for R- and S-HCQ, respectively) compared to controls (1.69 +/- 0.32 and 1.93 +/- 0.34 l/h/kg for R- and S-HCQ, respectively).",Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9647356/),[l] / [h·kg],1.93,228216,DB00608,Chloroquine
,9647356,fraction unbound,The fraction unbound of the R- and S-HCQ were 49.4% and 50.5% lower in platelet rich plasma of arthritic rats compared to healthy rats.,Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9647356/),%,49,228217,DB00608,Chloroquine
,9647356,fraction unbound,The fraction unbound of the R- and S-HCQ were 49.4% and 50.5% lower in platelet rich plasma of arthritic rats compared to healthy rats.,Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9647356/),%,50,228218,DB00608,Chloroquine
,9120814,Cmax,"At steady state, Cmax values of (-)-MQ were higher than those of (+)-MQ (1.42 +/- 0.19 versus 0.26 +/- 0.05 mg/L; p < 0.001).",Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120814/),[mg] / [l],1.42,230770,DB00608,Chloroquine
,9120814,Cmax,"At steady state, Cmax values of (-)-MQ were higher than those of (+)-MQ (1.42 +/- 0.19 versus 0.26 +/- 0.05 mg/L; p < 0.001).",Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120814/),[mg] / [l],0.26,230771,DB00608,Chloroquine
,9120814,plasma concentrations,"Similarly, the plasma concentrations 7 days after the final dose were higher for (-)-MQ (1.01 +/- 0.26 versus 0.11 +/- 0.04 mg/L; p < 0.001).",Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120814/),[mg] / [l],1.01,230772,DB00608,Chloroquine
,9120814,plasma concentrations,"Similarly, the plasma concentrations 7 days after the final dose were higher for (-)-MQ (1.01 +/- 0.26 versus 0.11 +/- 0.04 mg/L; p < 0.001).",Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120814/),[mg] / [l],0.11,230773,DB00608,Chloroquine
,9120814,AUC,AUC values at steady state were also higher for (-)-MQ (197.3 +/- 36.7 versus 30.1 +/- 8.9 mg/L x h; p < 0.001).,Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120814/),[mg] / [h·l],197.3,230774,DB00608,Chloroquine
,9120814,AUC,AUC values at steady state were also higher for (-)-MQ (197.3 +/- 36.7 versus 30.1 +/- 8.9 mg/L x h; p < 0.001).,Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120814/),[mg] / [h·l],30.1,230775,DB00608,Chloroquine
,9120814,terminal half-life values (T1/2beta),The terminal half-life values (T1/2beta) were longer for (-)-MQ (430.4 +/- 225.2 versus 172.8 +/- 56.5 h; p < 0.001).,Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120814/),h,430.4,230776,DB00608,Chloroquine
,9120814,terminal half-life values (T1/2beta),The terminal half-life values (T1/2beta) were longer for (-)-MQ (430.4 +/- 225.2 versus 172.8 +/- 56.5 h; p < 0.001).,Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120814/),h,172.8,230777,DB00608,Chloroquine
,22878749,overall response rate,"One patient had a partial response to erlotinib/HCQ, for an overall response rate of 5% (95% confidence interval, 1-25).",A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22878749/),%,5,230952,DB00608,Chloroquine
,26774925,IC50,"Among them, compounds 16 and 25 showed potent activity against chloroquine-sensitive (Pf3D7) strain with IC50 of 0.87 and 0.3 μM respectively, while compounds 7 and 13 exhibited better activity in vitro than the reference drug against chloroquine-resistance strain (PfK1) with IC50 of 0.5 μM each.","Identification of β-Amino alcohol grafted 1,4,5 trisubstituted 1,2,3-triazoles as potent antimalarial agents. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26774925/),μM,0.87,233479,DB00608,Chloroquine
,26774925,IC50,"Among them, compounds 16 and 25 showed potent activity against chloroquine-sensitive (Pf3D7) strain with IC50 of 0.87 and 0.3 μM respectively, while compounds 7 and 13 exhibited better activity in vitro than the reference drug against chloroquine-resistance strain (PfK1) with IC50 of 0.5 μM each.","Identification of β-Amino alcohol grafted 1,4,5 trisubstituted 1,2,3-triazoles as potent antimalarial agents. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26774925/),μM,0.3,233480,DB00608,Chloroquine
,26774925,IC50,"Among them, compounds 16 and 25 showed potent activity against chloroquine-sensitive (Pf3D7) strain with IC50 of 0.87 and 0.3 μM respectively, while compounds 7 and 13 exhibited better activity in vitro than the reference drug against chloroquine-resistance strain (PfK1) with IC50 of 0.5 μM each.","Identification of β-Amino alcohol grafted 1,4,5 trisubstituted 1,2,3-triazoles as potent antimalarial agents. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26774925/),μM,0.5,233481,DB00608,Chloroquine
,3209629,Peak chloroquine blood levels,"Peak chloroquine blood levels in children (mean body weight 10 kg, age 21 months) were 0.67 +/- 0.08 micrograms/ml (after 200 mg CP) and 1.06 +/- 0.23 micrograms/ml (after 300 mg CP) following rectal administration of the suppositories.",Chloroquine absorption in children from polyethylene glycol base suppositories. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209629/),[μg] / [ml],0.67,234610,DB00608,Chloroquine
,3209629,Peak chloroquine blood levels,"Peak chloroquine blood levels in children (mean body weight 10 kg, age 21 months) were 0.67 +/- 0.08 micrograms/ml (after 200 mg CP) and 1.06 +/- 0.23 micrograms/ml (after 300 mg CP) following rectal administration of the suppositories.",Chloroquine absorption in children from polyethylene glycol base suppositories. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209629/),[μg] / [ml],1.06,234611,DB00608,Chloroquine
,3209629,Elimination half lives,"Elimination half lives calculated from the rapid phase of log concentration-time curves were 3.3 h (after 200 mg CP) and 2.7 h (after 300 mg CP), respectively.",Chloroquine absorption in children from polyethylene glycol base suppositories. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209629/),h,3.3,234612,DB00608,Chloroquine
,3209629,Elimination half lives,"Elimination half lives calculated from the rapid phase of log concentration-time curves were 3.3 h (after 200 mg CP) and 2.7 h (after 300 mg CP), respectively.",Chloroquine absorption in children from polyethylene glycol base suppositories. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209629/),h,2.7,234613,DB00608,Chloroquine
,6887003,terminal T 1/2,The mean terminal T 1/2 was 12.6 days using i.v. data alone and 14.5 days with simultaneous fitting of oral and i.v. data.,Pharmacokinetics of chloroquine diphosphate in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6887003/),d,12.6,235803,DB00608,Chloroquine
,6887003,terminal T 1/2,The mean terminal T 1/2 was 12.6 days using i.v. data alone and 14.5 days with simultaneous fitting of oral and i.v. data.,Pharmacokinetics of chloroquine diphosphate in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6887003/),d,14.5,235804,DB00608,Chloroquine
,6887003,blood clearance,The model-independent value for blood clearance was 2.67 liters/kg/day.,Pharmacokinetics of chloroquine diphosphate in the dog. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6887003/),[l] / [d·kg],2.67,235805,DB00608,Chloroquine
,6887003,Vdss,A mean Vdss of 53.3 liters/kg indicates that the drug is widely distributed to tissues.,Pharmacokinetics of chloroquine diphosphate in the dog. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6887003/),[l] / [kg],53.3,235806,DB00608,Chloroquine
,2738178,t1/2z,7-chloro-4-aminoquinoline was eliminated more slowly (t1/2z = 126.48 +/- 20.13 h) than the other metabolites and the unchanged drug (t1/2z = 106.43 +/- 10.13 h).,Pharmacokinetics of chloroquine and some of its metabolites in healthy volunteers: a single dose study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2738178/),h,126.48,236027,DB00608,Chloroquine
,2738178,t1/2z,7-chloro-4-aminoquinoline was eliminated more slowly (t1/2z = 126.48 +/- 20.13 h) than the other metabolites and the unchanged drug (t1/2z = 106.43 +/- 10.13 h).,Pharmacokinetics of chloroquine and some of its metabolites in healthy volunteers: a single dose study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2738178/),h,106.43,236028,DB00608,Chloroquine
,33378773,EC50,"The 25 mg BID inhalation dosing was predicted to lead to alveolar HCQ levels of 7 µM (above EC50 of ~1-5 µM), and small plasma levels of 0.18 µM (as compared to plasma levels of 3.22 µM after 200 mg BID oral dosing).",Development of a Physiologically-Based Pharmacokinetic (PBPK) Model of Nebulized Hydroxychloroquine for Pulmonary Delivery to COVID-19 Patients. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33378773/),μM,1-5,240168,DB00608,Chloroquine
>,33378773,average,"However, average contact time (>1 µM) is around 0.5 h in lung parts, suggesting indirect exposure response effect of HCQ.",Development of a Physiologically-Based Pharmacokinetic (PBPK) Model of Nebulized Hydroxychloroquine for Pulmonary Delivery to COVID-19 Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33378773/),μM,1,240169,DB00608,Chloroquine
>,33378773,contact time,"However, average contact time (>1 µM) is around 0.5 h in lung parts, suggesting indirect exposure response effect of HCQ.",Development of a Physiologically-Based Pharmacokinetic (PBPK) Model of Nebulized Hydroxychloroquine for Pulmonary Delivery to COVID-19 Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33378773/),μM,1,240170,DB00608,Chloroquine
,33378773,contact time,"However, average contact time (>1 µM) is around 0.5 h in lung parts, suggesting indirect exposure response effect of HCQ.",Development of a Physiologically-Based Pharmacokinetic (PBPK) Model of Nebulized Hydroxychloroquine for Pulmonary Delivery to COVID-19 Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33378773/),h,0.5,240171,DB00608,Chloroquine
,6849768,binding,The mean binding was 61 +/- 9% in plasma from healthy subjects (range 46-74%) and 64 +/- 7% in plasma from rheumatoid arthritis patients (range 55-79%).,Characterization of chloroquine plasma protein binding in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849768/),%,61,240983,DB00608,Chloroquine
,6849768,binding,The mean binding was 61 +/- 9% in plasma from healthy subjects (range 46-74%) and 64 +/- 7% in plasma from rheumatoid arthritis patients (range 55-79%).,Characterization of chloroquine plasma protein binding in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849768/),%,64,240984,DB00608,Chloroquine
,15619134,area under the chloroquine whole blood concentration-time curve normalized to body weight (AUC(0-24 h)/BW),"During methylene blue exposure, the area under the chloroquine whole blood concentration-time curve normalized to body weight (AUC(0-24 h)/BW) yielded a trend of reduction (249+/-98.2 h mug l(-1) kg(-1) versus 315+/-65.0 h mug l(-1) kg(-1), P=0.06).",Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15619134/),[h·μg] / [kg·l],249,242608,DB00608,Chloroquine
,15619134,area under the chloroquine whole blood concentration-time curve normalized to body weight (AUC(0-24 h)/BW),"During methylene blue exposure, the area under the chloroquine whole blood concentration-time curve normalized to body weight (AUC(0-24 h)/BW) yielded a trend of reduction (249+/-98.2 h mug l(-1) kg(-1) versus 315+/-65.0 h mug l(-1) kg(-1), P=0.06).",Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15619134/),[h·μg] / [kg·l],315,242609,DB00608,Chloroquine
,15619134,AUC(0-24 h)/BW,"The AUC(0-24 h)/BW of desethylchloroquine was reduced by 35% (104+/-40.3 h mug l(-1) kg(-1) versus 159+/-66.6 h mug l(-1) kg(-1), P=0.03), whereas the metabolic ratio between chloroquine and desethylchloroquine remained unchanged (2.25+/-0.49 versus 1.95+/-0.42, P=0.17).",Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15619134/),[h·μg] / [kg·l],104,242610,DB00608,Chloroquine
,15619134,AUC(0-24 h)/BW,"The AUC(0-24 h)/BW of desethylchloroquine was reduced by 35% (104+/-40.3 h mug l(-1) kg(-1) versus 159+/-66.6 h mug l(-1) kg(-1), P=0.03), whereas the metabolic ratio between chloroquine and desethylchloroquine remained unchanged (2.25+/-0.49 versus 1.95+/-0.42, P=0.17).",Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15619134/),[h·μg] / [kg·l],159,242611,DB00608,Chloroquine
,15619134,metabolic ratio,"The AUC(0-24 h)/BW of desethylchloroquine was reduced by 35% (104+/-40.3 h mug l(-1) kg(-1) versus 159+/-66.6 h mug l(-1) kg(-1), P=0.03), whereas the metabolic ratio between chloroquine and desethylchloroquine remained unchanged (2.25+/-0.49 versus 1.95+/-0.42, P=0.17).",Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15619134/),,2.25,242612,DB00608,Chloroquine
,15619134,metabolic ratio,"The AUC(0-24 h)/BW of desethylchloroquine was reduced by 35% (104+/-40.3 h mug l(-1) kg(-1) versus 159+/-66.6 h mug l(-1) kg(-1), P=0.03), whereas the metabolic ratio between chloroquine and desethylchloroquine remained unchanged (2.25+/-0.49 versus 1.95+/-0.42, P=0.17).",Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15619134/),,1.95,242613,DB00608,Chloroquine
,22629364,inhibition concentration 50% (IC(50)),Here we show that FBS0701 has inhibition concentration 50% (IC(50)) of 6 µM for Plasmodium falciparum in contrast to the IC(50) for deferiprone and deferoxamine at 15 and 30 µM respectively.,"Antimalarial iron chelator, FBS0701, shows asexual and gametocyte Plasmodium falciparum activity and single oral dose cure in a murine malaria model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22629364/),μM,6,244824,DB00608,Chloroquine
,22629364,IC(50),Here we show that FBS0701 has inhibition concentration 50% (IC(50)) of 6 µM for Plasmodium falciparum in contrast to the IC(50) for deferiprone and deferoxamine at 15 and 30 µM respectively.,"Antimalarial iron chelator, FBS0701, shows asexual and gametocyte Plasmodium falciparum activity and single oral dose cure in a murine malaria model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22629364/),μM,15,244825,DB00608,Chloroquine
,22629364,IC(50),Here we show that FBS0701 has inhibition concentration 50% (IC(50)) of 6 µM for Plasmodium falciparum in contrast to the IC(50) for deferiprone and deferoxamine at 15 and 30 µM respectively.,"Antimalarial iron chelator, FBS0701, shows asexual and gametocyte Plasmodium falciparum activity and single oral dose cure in a murine malaria model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22629364/),μM,30,244826,DB00608,Chloroquine
,2693504,saliva: total plasma concentrations (S/P) ratio,"The saliva: total plasma concentrations (S/P) ratio was found to be approximately constant in the absorption (0.4 +/- 0.07), distribution (0.47 +/- 0.08), and elimination (0.46 +/- 0.05) phases.",Determination of saliva: total plasma chloroquine levels relationship by high performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2693504/),,0.4,244840,DB00608,Chloroquine
,2693504,saliva: total plasma concentrations (S/P) ratio,"The saliva: total plasma concentrations (S/P) ratio was found to be approximately constant in the absorption (0.4 +/- 0.07), distribution (0.47 +/- 0.08), and elimination (0.46 +/- 0.05) phases.",Determination of saliva: total plasma chloroquine levels relationship by high performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2693504/),,0.47,244841,DB00608,Chloroquine
,2693504,saliva: total plasma concentrations (S/P) ratio,"The saliva: total plasma concentrations (S/P) ratio was found to be approximately constant in the absorption (0.4 +/- 0.07), distribution (0.47 +/- 0.08), and elimination (0.46 +/- 0.05) phases.",Determination of saliva: total plasma chloroquine levels relationship by high performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2693504/),,0.46,244842,DB00608,Chloroquine
,26671222,IC50,"IC50 values of the two compounds for sensitive and resistant strains were 0.064 and 0.047 µM (compound 1), 0.041 and 0.122 µM (compound 2) and 0.505 and 0.463 µM (compound 1), 0.089 and 0.076 µM (compound 2), respectively.","Antiplasmodial activity, in vivo pharmacokinetics and anti-malarial efficacy evaluation of hydroxypyridinone hybrids in a mouse model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26671222/),μM,0.064,245215,DB00608,Chloroquine
,26671222,IC50,"IC50 values of the two compounds for sensitive and resistant strains were 0.064 and 0.047 µM (compound 1), 0.041 and 0.122 µM (compound 2) and 0.505 and 0.463 µM (compound 1), 0.089 and 0.076 µM (compound 2), respectively.","Antiplasmodial activity, in vivo pharmacokinetics and anti-malarial efficacy evaluation of hydroxypyridinone hybrids in a mouse model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26671222/),μM,0.047,245216,DB00608,Chloroquine
,26671222,IC50,"IC50 values of the two compounds for sensitive and resistant strains were 0.064 and 0.047 µM (compound 1), 0.041 and 0.122 µM (compound 2) and 0.505 and 0.463 µM (compound 1), 0.089 and 0.076 µM (compound 2), respectively.","Antiplasmodial activity, in vivo pharmacokinetics and anti-malarial efficacy evaluation of hydroxypyridinone hybrids in a mouse model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26671222/),μM,0.041,245217,DB00608,Chloroquine
,26671222,IC50,"IC50 values of the two compounds for sensitive and resistant strains were 0.064 and 0.047 µM (compound 1), 0.041 and 0.122 µM (compound 2) and 0.505 and 0.463 µM (compound 1), 0.089 and 0.076 µM (compound 2), respectively.","Antiplasmodial activity, in vivo pharmacokinetics and anti-malarial efficacy evaluation of hydroxypyridinone hybrids in a mouse model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26671222/),μM,0.122,245218,DB00608,Chloroquine
,26671222,IC50,"IC50 values of the two compounds for sensitive and resistant strains were 0.064 and 0.047 µM (compound 1), 0.041 and 0.122 µM (compound 2) and 0.505 and 0.463 µM (compound 1), 0.089 and 0.076 µM (compound 2), respectively.","Antiplasmodial activity, in vivo pharmacokinetics and anti-malarial efficacy evaluation of hydroxypyridinone hybrids in a mouse model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26671222/),μM,0.505,245219,DB00608,Chloroquine
,26671222,IC50,"IC50 values of the two compounds for sensitive and resistant strains were 0.064 and 0.047 µM (compound 1), 0.041 and 0.122 µM (compound 2) and 0.505 and 0.463 µM (compound 1), 0.089 and 0.076 µM (compound 2), respectively.","Antiplasmodial activity, in vivo pharmacokinetics and anti-malarial efficacy evaluation of hydroxypyridinone hybrids in a mouse model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26671222/),μM,0.463,245220,DB00608,Chloroquine
,26671222,IC50,"IC50 values of the two compounds for sensitive and resistant strains were 0.064 and 0.047 µM (compound 1), 0.041 and 0.122 µM (compound 2) and 0.505 and 0.463 µM (compound 1), 0.089 and 0.076 µM (compound 2), respectively.","Antiplasmodial activity, in vivo pharmacokinetics and anti-malarial efficacy evaluation of hydroxypyridinone hybrids in a mouse model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26671222/),μM,0.089,245221,DB00608,Chloroquine
,26671222,IC50,"IC50 values of the two compounds for sensitive and resistant strains were 0.064 and 0.047 µM (compound 1), 0.041 and 0.122 µM (compound 2) and 0.505 and 0.463 µM (compound 1), 0.089 and 0.076 µM (compound 2), respectively.","Antiplasmodial activity, in vivo pharmacokinetics and anti-malarial efficacy evaluation of hydroxypyridinone hybrids in a mouse model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26671222/),μM,0.076,245222,DB00608,Chloroquine
,26671222,clearance rate,"However, when dosed intravenously compound 1 showed a clearance rate of 28 ml/min/kg, an apparent volume of distribution of 20 l/kg and a half-life of 4.3 h.","Antiplasmodial activity, in vivo pharmacokinetics and anti-malarial efficacy evaluation of hydroxypyridinone hybrids in a mouse model. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26671222/),[ml] / [kg·min],28,245223,DB00608,Chloroquine
,26671222,apparent volume of distribution,"However, when dosed intravenously compound 1 showed a clearance rate of 28 ml/min/kg, an apparent volume of distribution of 20 l/kg and a half-life of 4.3 h.","Antiplasmodial activity, in vivo pharmacokinetics and anti-malarial efficacy evaluation of hydroxypyridinone hybrids in a mouse model. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26671222/),[l] / [kg],20,245224,DB00608,Chloroquine
,26671222,half-life,"However, when dosed intravenously compound 1 showed a clearance rate of 28 ml/min/kg, an apparent volume of distribution of 20 l/kg and a half-life of 4.3 h.","Antiplasmodial activity, in vivo pharmacokinetics and anti-malarial efficacy evaluation of hydroxypyridinone hybrids in a mouse model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26671222/),h,4.3,245225,DB00608,Chloroquine
,6603979,total body clearance,The total body clearance of chloroquine was 0.35 l/kg/h and that of its metabolites was much higher.,Steady state disposition of chloroquine in patients with rheumatoid disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6603979/),[l] / [h·kg],0.35,245290,DB00608,Chloroquine
,6603979,renal clearance,"The renal clearance was the same for all compounds measured, approximately equal to 0.1 l/kg/h.",Steady state disposition of chloroquine in patients with rheumatoid disease. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6603979/),[l] / [h·kg],0.1,245291,DB00608,Chloroquine
,23896611,IC50,"The most potent compounds, 6b, 6c and 6j, showed IC50 values in the range of 6-77nM against chloroquine-resistant K1- and W2-strains of Plasmodium falciparum.","Tetrazole-based deoxyamodiaquines: synthesis, ADME/PK profiling and pharmacological evaluation as potential antimalarial agents. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23896611/),nM,6-77,246092,DB00608,Chloroquine
,3750371,blood flow rate,"The blood flow rate varied between 200 and 275 ml/min, while the dialysate flow rate was maintained at 500 ml/min.",Hemodialysis clearance of chloroquine in uremic patients. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750371/),[ml] / [min],200 and 275,249125,DB00608,Chloroquine
,3750371,flow rate,"The blood flow rate varied between 200 and 275 ml/min, while the dialysate flow rate was maintained at 500 ml/min.",Hemodialysis clearance of chloroquine in uremic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750371/),[ml] / [min],500,249126,DB00608,Chloroquine
,3750371,extraction ratios,"The mean extraction ratios for chloroquine were 0.238, 0.317, 0.207, and 0.216 in the four patients during the 6-h dialysis period.",Hemodialysis clearance of chloroquine in uremic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750371/),,0.238,249127,DB00608,Chloroquine
,3750371,extraction ratios,"The mean extraction ratios for chloroquine were 0.238, 0.317, 0.207, and 0.216 in the four patients during the 6-h dialysis period.",Hemodialysis clearance of chloroquine in uremic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750371/),,0.317,249128,DB00608,Chloroquine
,3750371,extraction ratios,"The mean extraction ratios for chloroquine were 0.238, 0.317, 0.207, and 0.216 in the four patients during the 6-h dialysis period.",Hemodialysis clearance of chloroquine in uremic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750371/),,0.207,249129,DB00608,Chloroquine
,3750371,extraction ratios,"The mean extraction ratios for chloroquine were 0.238, 0.317, 0.207, and 0.216 in the four patients during the 6-h dialysis period.",Hemodialysis clearance of chloroquine in uremic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750371/),,0.216,249130,DB00608,Chloroquine
,3750371,clearances,"The calculated dialysis clearances were 57.2, 77.0, 56.1, and 48.3 ml/min.",Hemodialysis clearance of chloroquine in uremic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750371/),[ml] / [min],57.2,249131,DB00608,Chloroquine
,3750371,clearances,"The calculated dialysis clearances were 57.2, 77.0, 56.1, and 48.3 ml/min.",Hemodialysis clearance of chloroquine in uremic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750371/),[ml] / [min],77.0,249132,DB00608,Chloroquine
,3750371,clearances,"The calculated dialysis clearances were 57.2, 77.0, 56.1, and 48.3 ml/min.",Hemodialysis clearance of chloroquine in uremic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750371/),[ml] / [min],56.1,249133,DB00608,Chloroquine
,3750371,clearances,"The calculated dialysis clearances were 57.2, 77.0, 56.1, and 48.3 ml/min.",Hemodialysis clearance of chloroquine in uremic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750371/),[ml] / [min],48.3,249134,DB00608,Chloroquine
,9140488,half-time of absorption,The half-time of absorption was around 5 min and almost independent of parasitemia.,The pharmacokinetics of chloroquine in healthy and Plasmodium chabaudi-infected mice: implications for chronotherapy. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9140488/),min,5,254112,DB00608,Chloroquine
,9140488,apparent half-time of drug concentration decay,"The apparent half-time of drug concentration decay was around 40 min in healthy animals, about 90 min at low parasitemia and about 410 min in heavy infection, indicating that the concentration of CQ is a typical spike, that is prolonged by asymptomatic disease, and considerably more by the active accumulation of CQ in infected cells.",The pharmacokinetics of chloroquine in healthy and Plasmodium chabaudi-infected mice: implications for chronotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9140488/),min,40,254113,DB00608,Chloroquine
,9140488,apparent half-time of drug concentration decay,"The apparent half-time of drug concentration decay was around 40 min in healthy animals, about 90 min at low parasitemia and about 410 min in heavy infection, indicating that the concentration of CQ is a typical spike, that is prolonged by asymptomatic disease, and considerably more by the active accumulation of CQ in infected cells.",The pharmacokinetics of chloroquine in healthy and Plasmodium chabaudi-infected mice: implications for chronotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9140488/),min,90,254114,DB00608,Chloroquine
,9140488,apparent half-time of drug concentration decay,"The apparent half-time of drug concentration decay was around 40 min in healthy animals, about 90 min at low parasitemia and about 410 min in heavy infection, indicating that the concentration of CQ is a typical spike, that is prolonged by asymptomatic disease, and considerably more by the active accumulation of CQ in infected cells.",The pharmacokinetics of chloroquine in healthy and Plasmodium chabaudi-infected mice: implications for chronotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9140488/),min,410,254115,DB00608,Chloroquine
,11009001,apparent volume of the central compartment,"The following toxicokinetics data during this severe chloroquine poisoning were calculated: apparent volume of the central compartment 181 L, apparent volume of distribution 1137 L, half-life in the distribution phase 6.4 hrs, half-life in the elimination phase 392.8 hrs, and total body clearance 2.01 L/hour.",Hemoperfusion is ineffectual in severe chloroquine poisoning. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11009001/),l,181,254471,DB00608,Chloroquine
,11009001,apparent volume of distribution,"The following toxicokinetics data during this severe chloroquine poisoning were calculated: apparent volume of the central compartment 181 L, apparent volume of distribution 1137 L, half-life in the distribution phase 6.4 hrs, half-life in the elimination phase 392.8 hrs, and total body clearance 2.01 L/hour.",Hemoperfusion is ineffectual in severe chloroquine poisoning. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11009001/),l,1137,254472,DB00608,Chloroquine
,11009001,half-life in the distribution phase,"The following toxicokinetics data during this severe chloroquine poisoning were calculated: apparent volume of the central compartment 181 L, apparent volume of distribution 1137 L, half-life in the distribution phase 6.4 hrs, half-life in the elimination phase 392.8 hrs, and total body clearance 2.01 L/hour.",Hemoperfusion is ineffectual in severe chloroquine poisoning. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11009001/),h,6.4,254473,DB00608,Chloroquine
,11009001,half-life in the elimination phase,"The following toxicokinetics data during this severe chloroquine poisoning were calculated: apparent volume of the central compartment 181 L, apparent volume of distribution 1137 L, half-life in the distribution phase 6.4 hrs, half-life in the elimination phase 392.8 hrs, and total body clearance 2.01 L/hour.",Hemoperfusion is ineffectual in severe chloroquine poisoning. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11009001/),h,392.8,254474,DB00608,Chloroquine
,11009001,total body clearance,"The following toxicokinetics data during this severe chloroquine poisoning were calculated: apparent volume of the central compartment 181 L, apparent volume of distribution 1137 L, half-life in the distribution phase 6.4 hrs, half-life in the elimination phase 392.8 hrs, and total body clearance 2.01 L/hour.",Hemoperfusion is ineffectual in severe chloroquine poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11009001/),[l] / [h],2.01,254475,DB00608,Chloroquine
,11009001,extraction ratio,"The average extraction ratio during hemoperfusion was 0.07, 0.28, and 0.25, in plasma, erythrocytes and whole blood, respectively.",Hemoperfusion is ineffectual in severe chloroquine poisoning. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11009001/),,0.07,254476,DB00608,Chloroquine
,11009001,extraction ratio,"The average extraction ratio during hemoperfusion was 0.07, 0.28, and 0.25, in plasma, erythrocytes and whole blood, respectively.",Hemoperfusion is ineffectual in severe chloroquine poisoning. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11009001/),,0.28,254477,DB00608,Chloroquine
,11009001,extraction ratio,"The average extraction ratio during hemoperfusion was 0.07, 0.28, and 0.25, in plasma, erythrocytes and whole blood, respectively.",Hemoperfusion is ineffectual in severe chloroquine poisoning. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11009001/),,0.25,254478,DB00608,Chloroquine
,11009001,extraction ratio,"Simulation of a hemoperfusion session over 5 hrs by using a column with an optimal extraction ratio of 1.0 would have removed 1,816 mg chloroquine, only 18.2% of the amount ingested.",Hemoperfusion is ineffectual in severe chloroquine poisoning. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11009001/),,1.0,254479,DB00608,Chloroquine
,26776969,particle size,"The particle size, zeta potential, PDI and entrapment efficiency were found to be 113.6±0.15nm, -27.8±1.21mV, 0.125±0.03 and 93.45±0.43% respectively.",Fabrication and efficacy evaluation of chloroquine nanoparticles in CFA-induced arthritic rats using TNF-α ELISA. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26776969/),nm,113.6,255808,DB00608,Chloroquine
,26776969,PDI,"The particle size, zeta potential, PDI and entrapment efficiency were found to be 113.6±0.15nm, -27.8±1.21mV, 0.125±0.03 and 93.45±0.43% respectively.",Fabrication and efficacy evaluation of chloroquine nanoparticles in CFA-induced arthritic rats using TNF-α ELISA. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26776969/),mv,-,255809,DB00608,Chloroquine
,26776969,PDI,"The particle size, zeta potential, PDI and entrapment efficiency were found to be 113.6±0.15nm, -27.8±1.21mV, 0.125±0.03 and 93.45±0.43% respectively.",Fabrication and efficacy evaluation of chloroquine nanoparticles in CFA-induced arthritic rats using TNF-α ELISA. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26776969/),%,0.125,255810,DB00608,Chloroquine
,26776969,entrapment efficiency,"The particle size, zeta potential, PDI and entrapment efficiency were found to be 113.6±0.15nm, -27.8±1.21mV, 0.125±0.03 and 93.45±0.43% respectively.",Fabrication and efficacy evaluation of chloroquine nanoparticles in CFA-induced arthritic rats using TNF-α ELISA. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26776969/),%,93.45,255811,DB00608,Chloroquine
,10848718,area under the plasma concentration-time curve,"Concomitant administration of HCQ increased the bioavailability of metoprolol, as indicated by significant increases in the area under the plasma concentration-time curve (65 +/- 4.6%) and maximal plasma concentrations (72 +/- 6.9%) of metoprolol.",Influence of hydroxychloroquine on the bioavailability of oral metoprolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10848718/),%,65,256387,DB00608,Chloroquine
,10848718,maximal plasma concentrations,"Concomitant administration of HCQ increased the bioavailability of metoprolol, as indicated by significant increases in the area under the plasma concentration-time curve (65 +/- 4.6%) and maximal plasma concentrations (72 +/- 6.9%) of metoprolol.",Influence of hydroxychloroquine on the bioavailability of oral metoprolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10848718/),%,72,256388,DB00608,Chloroquine
,12659609,maximum serum concentration,Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.,Toxicity related to chloroquine treatment of resistant vivax malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12659609/),[μg] / [l],902,256908,DB00608,Chloroquine
,31200245,Rf,"The Rf values for MTX, SSZ, MK and HCQ were of 0.31 ± 0.03, 0.62 ± 0.02, 0.71 ± 0.02 and 0.83 ± 0.03; respectively.",Innovative HPTLC method for simultaneous determination of ternary mixture of certain DMARDs in real samples of rheumatoid arthritis patients: an application of quality by design approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31200245/),,0.31,259420,DB00608,Chloroquine
,31200245,Rf,"The Rf values for MTX, SSZ, MK and HCQ were of 0.31 ± 0.03, 0.62 ± 0.02, 0.71 ± 0.02 and 0.83 ± 0.03; respectively.",Innovative HPTLC method for simultaneous determination of ternary mixture of certain DMARDs in real samples of rheumatoid arthritis patients: an application of quality by design approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31200245/),,0.62,259421,DB00608,Chloroquine
,31200245,Rf,"The Rf values for MTX, SSZ, MK and HCQ were of 0.31 ± 0.03, 0.62 ± 0.02, 0.71 ± 0.02 and 0.83 ± 0.03; respectively.",Innovative HPTLC method for simultaneous determination of ternary mixture of certain DMARDs in real samples of rheumatoid arthritis patients: an application of quality by design approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31200245/),,0.71,259422,DB00608,Chloroquine
,31200245,Rf,"The Rf values for MTX, SSZ, MK and HCQ were of 0.31 ± 0.03, 0.62 ± 0.02, 0.71 ± 0.02 and 0.83 ± 0.03; respectively.",Innovative HPTLC method for simultaneous determination of ternary mixture of certain DMARDs in real samples of rheumatoid arthritis patients: an application of quality by design approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31200245/),,0.83,259423,DB00608,Chloroquine
,16916298,ka,"Sulfadoxine in Homapak was more rapidly absorbed (ka = 0.55 h(-1)) than in Fansidar + CQ (ka = 0.27 h(-1), p=0.004), but not more than S in Fansidar alone group (ka = 0.32 h(-1), p=0.03).","Pharmacokinetic interactions between chloroquine, sulfadoxine and pyrimethamine and their bioequivalence in a generic fixed-dose combination in healthy volunteers in Uganda. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16916298/),1/[h],0.55,259478,DB00608,Chloroquine
,16916298,ka,"Sulfadoxine in Homapak was more rapidly absorbed (ka = 0.55 h(-1)) than in Fansidar + CQ (ka = 0.27 h(-1), p=0.004), but not more than S in Fansidar alone group (ka = 0.32 h(-1), p=0.03).","Pharmacokinetic interactions between chloroquine, sulfadoxine and pyrimethamine and their bioequivalence in a generic fixed-dose combination in healthy volunteers in Uganda. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16916298/),1/[h],0.27,259479,DB00608,Chloroquine
,16916298,ka,"Sulfadoxine in Homapak was more rapidly absorbed (ka = 0.55 h(-1)) than in Fansidar + CQ (ka = 0.27 h(-1), p=0.004), but not more than S in Fansidar alone group (ka = 0.32 h(-1), p=0.03).","Pharmacokinetic interactions between chloroquine, sulfadoxine and pyrimethamine and their bioequivalence in a generic fixed-dose combination in healthy volunteers in Uganda. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16916298/),1/[h],0.32,259480,DB00608,Chloroquine
,6639836,half-life,"Primaquine (45 mg) given 2 h before antipyrine (300 mg orally), increased antipyrine half-life (calculated from 0-24 h) from 12.7 +/- 3.2 (mean +/- s.d.) to 25.3 +/- 3.9 h and decreased clearance from 3.01 +/- 0.67 to 1.32 +/- 0.32 1 h-1.",Effect of chloroquine and primaquine on antipyrine metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6639836/),h,12.7,259538,DB00608,Chloroquine
,6639836,half-life,"Primaquine (45 mg) given 2 h before antipyrine (300 mg orally), increased antipyrine half-life (calculated from 0-24 h) from 12.7 +/- 3.2 (mean +/- s.d.) to 25.3 +/- 3.9 h and decreased clearance from 3.01 +/- 0.67 to 1.32 +/- 0.32 1 h-1.",Effect of chloroquine and primaquine on antipyrine metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6639836/),h,25.3,259539,DB00608,Chloroquine
,6639836,clearance,"Primaquine (45 mg) given 2 h before antipyrine (300 mg orally), increased antipyrine half-life (calculated from 0-24 h) from 12.7 +/- 3.2 (mean +/- s.d.) to 25.3 +/- 3.9 h and decreased clearance from 3.01 +/- 0.67 to 1.32 +/- 0.32 1 h-1.",Effect of chloroquine and primaquine on antipyrine metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6639836/),[1] / [h],3.01,259540,DB00608,Chloroquine
,6639836,clearance,"Primaquine (45 mg) given 2 h before antipyrine (300 mg orally), increased antipyrine half-life (calculated from 0-24 h) from 12.7 +/- 3.2 (mean +/- s.d.) to 25.3 +/- 3.9 h and decreased clearance from 3.01 +/- 0.67 to 1.32 +/- 0.32 1 h-1.",Effect of chloroquine and primaquine on antipyrine metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6639836/),[1] / [h],1.32,259541,DB00608,Chloroquine
,2058666,Rd,"Total exogenous glucose infusion required to maintain euglycemia significantly increased (1,792.6-2,040.1 mg.kg-1.330 min-1, P less than 0.05) due to an increase in Rd (2,348.0-2,618.9 mg.kg-1.330 min-1, P less than 0.01) without change in Ra.",Mode of action of chloroquine in patients with non-insulin-dependent diabetes mellitus. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058666/),[mg] / [kg·min],"2,348.0-2,618.9",262172,DB00608,Chloroquine
,2058666,Metabolic clearance rate,"Metabolic clearance rate of insulin decreased by 39% from 14.4 +/- 1.3 to 11.0 +/- 0.6 ml.kg-1.min-1 (P less than 0.01) at plasma insulin levels of 150-200 mU/l but not at levels of 2,000-3,000 mU/l.",Mode of action of chloroquine in patients with non-insulin-dependent diabetes mellitus. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058666/),[ml] / [kg·min],14.4,262173,DB00608,Chloroquine
,2058666,Metabolic clearance rate,"Metabolic clearance rate of insulin decreased by 39% from 14.4 +/- 1.3 to 11.0 +/- 0.6 ml.kg-1.min-1 (P less than 0.01) at plasma insulin levels of 150-200 mU/l but not at levels of 2,000-3,000 mU/l.",Mode of action of chloroquine in patients with non-insulin-dependent diabetes mellitus. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058666/),[ml] / [kg·min],11.0,262174,DB00608,Chloroquine
,24900630,half-life,Pharmacokinetic studies on 3d and 3e in mice showed that they had moderate half-life (4-6 h) and low oral bioavailability.,Synthesis and in vitro and in vivo pharmacological evaluation of new 4-aminoquinoline-based compounds. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24900630/),h,4-6,263635,DB00608,Chloroquine
,3207554,slow transfer rate constant,"Chloroquine was found to be excreted into semen with a slow transfer rate constant of 0.0002 min-1, and the semen/plasma ratio based on regression analysis was 0.40 +/- 0.06 (mean +/- s.d.).",Passage of chloroquine into semen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207554/),1/[min],0.0002,264388,DB00608,Chloroquine
,3207554,semen/plasma ratio,"Chloroquine was found to be excreted into semen with a slow transfer rate constant of 0.0002 min-1, and the semen/plasma ratio based on regression analysis was 0.40 +/- 0.06 (mean +/- s.d.).",Passage of chloroquine into semen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207554/),,0.40,264389,DB00608,Chloroquine
,31477360,heart rate,"Vital signs were: BP, 66 mmHg/palpation; heart rate, 115/min; respirations 18/min; oxygen saturation, 100% on room air.",Toxicokinetics of hydroxychloroquine following a massive overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31477360/),1/[min],115,265920,DB00608,Chloroquine
,31477360,respirations,"Vital signs were: BP, 66 mmHg/palpation; heart rate, 115/min; respirations 18/min; oxygen saturation, 100% on room air.",Toxicokinetics of hydroxychloroquine following a massive overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31477360/),1/[min],18,265921,DB00608,Chloroquine
,31477360,half-life,Serial concentrations demonstrated apparent first-order elimination with a half-life of 11.6 h.,Toxicokinetics of hydroxychloroquine following a massive overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31477360/),h,11.6,265922,DB00608,Chloroquine
,31477360,apparent,The apparent 11.6 hour half-life of hydroxychloroquine was shorter than previously described.,Toxicokinetics of hydroxychloroquine following a massive overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31477360/),h,11.6,265923,DB00608,Chloroquine
,25331702,50% inhibitory concentrations (IC50s),"4-(tert-Butyl)-2-((tert-butylamino)methyl)-6-(6-(trifluoromethyl)pyridin-3-yl)-phenol (JPC-2997) is a new aminomethylphenol compound that is highly active in vitro against the chloroquine-sensitive D6, the chloroquine-resistant W2, and the multidrug-resistant TM90-C2B Plasmodium falciparum lines, with 50% inhibitory concentrations (IC50s) ranging from 7 nM to 34 nM.","JPC-2997, a new aminomethylphenol with high in vitro and in vivo antimalarial activities against blood stages of Plasmodium. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25331702/),nM,7,272496,DB00608,Chloroquine
,25331702,50% inhibitory concentrations (IC50s),"4-(tert-Butyl)-2-((tert-butylamino)methyl)-6-(6-(trifluoromethyl)pyridin-3-yl)-phenol (JPC-2997) is a new aminomethylphenol compound that is highly active in vitro against the chloroquine-sensitive D6, the chloroquine-resistant W2, and the multidrug-resistant TM90-C2B Plasmodium falciparum lines, with 50% inhibitory concentrations (IC50s) ranging from 7 nM to 34 nM.","JPC-2997, a new aminomethylphenol with high in vitro and in vivo antimalarial activities against blood stages of Plasmodium. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25331702/),nM,34,272497,DB00608,Chloroquine
>,25331702,IC50s,"JPC-2997 is >2,500 times less cytotoxic (IC50s > 35 μM) to human (HepG2 and HEK293) and rodent (BHK) cell lines than the D6 parasite line.","JPC-2997, a new aminomethylphenol with high in vitro and in vivo antimalarial activities against blood stages of Plasmodium. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25331702/),μM,35,272498,DB00608,Chloroquine
,25331702,50% effective dose (ED50),"The compound possesses potent in vivo suppression activity against Plasmodium berghei, with a 50% effective dose (ED50) of 0.5 mg/kg of body weight/day following oral dosing in the Peters 4-day test.","JPC-2997, a new aminomethylphenol with high in vitro and in vivo antimalarial activities against blood stages of Plasmodium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25331702/),[mg] / [kg],0.5,272499,DB00608,Chloroquine
,25331702,clearance,"Preliminary studies of JPC-2997 in mice show linear pharmacokinetics over the range 2.5 to 40 mg/kg, a low clearance of 0.22 liters/h/kg, a volume of distribution of 15.6 liters/kg, and an elimination half-life of 49.8 h.","JPC-2997, a new aminomethylphenol with high in vitro and in vivo antimalarial activities against blood stages of Plasmodium. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25331702/),[l] / [h·kg],0.22,272500,DB00608,Chloroquine
,25331702,volume of distribution,"Preliminary studies of JPC-2997 in mice show linear pharmacokinetics over the range 2.5 to 40 mg/kg, a low clearance of 0.22 liters/h/kg, a volume of distribution of 15.6 liters/kg, and an elimination half-life of 49.8 h.","JPC-2997, a new aminomethylphenol with high in vitro and in vivo antimalarial activities against blood stages of Plasmodium. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25331702/),[l] / [kg],15.6,272501,DB00608,Chloroquine
,25331702,elimination half-life,"Preliminary studies of JPC-2997 in mice show linear pharmacokinetics over the range 2.5 to 40 mg/kg, a low clearance of 0.22 liters/h/kg, a volume of distribution of 15.6 liters/kg, and an elimination half-life of 49.8 h.","JPC-2997, a new aminomethylphenol with high in vitro and in vivo antimalarial activities against blood stages of Plasmodium. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25331702/),h,49.8,272502,DB00608,Chloroquine
